nci_id,nct_id,official_title,inclusion_indicaInclusionor,description,NCITNCI-2014-01497,NCT02270450,Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction,Inclusion,"Patients must be registered to the study within 3 days after being seen by surgical team for MBO or within 3 days after completion of indicated treatment (e.g. total parenteral nutrition [TPN], anticoagulation reversal) to make them eligible for surgical intervention, whichever is later, and prior to any treatment (surgical or non-surgical) for MBO; treatment is defined as any medication or invasive interventions beyond nasogastric decompression, hydration, pain medications or antiemetic medications; NOTE: somatostatin analogues may be used prior to registration if that use is limited to not more than the two days just prior to registration",N/ANCI-2014-02559,NCT01885455,"Improving Resection Rates Among African Americans with NSCLC (""Southern Lung Cancer Study"")",Exclusion,Status post-surgical resection or definitive radiotherapy for recently diagnosed clinically suspicious or biopsy-proven early stage NSCLC,(C16169 = NO OR (C16169 = YES AND C2926 = NO)) AND (C15477= NO OR (C15477= YES AND C2926 = NO))NCI-2015-00128,NCT02488967,A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer,Exclusion,"EXCLUSIONChemotherapy administered for the currently diagnosed breast cancer prior to randomizationPrevious therapy with anthracyclines or taxanes for any malignancyINCLUSIONThe interval between the last surgery for breast cancer (including re-excision of margins) and randomization must be no more than 60 daysThe patient must have undergone either a mastectomy (total, skin-sparing, or nipple-sparing) or lumpectomy",(C16171 = NO OR (C16171 = YES AND PRIOR TREATMENT OF CURRENT CANCER = NO) AND C16169 = YES AND C15451 = NO AND (C16124 = YES AND C149 = NO)NCI-2016-01844,,A Phase I Study of Tailmogene Laheparepvec (Talimogene Laherparepvec) with Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum,Exclusion,"Patients with a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of therapy, or anticipation of need for major surgical procedure during the course of the study other than that defined by protocol are ineligiblePatients with evidence of clinically significant immunosuppression such as the following are ineligible:* Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid doses > 10 mg/day of prednisone or equivalent within 2 months prior to enrollmentPatients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) except alopecia are ineligible",C16124 = NO OR C16124 = YESNCI-2017-00178,NCT03067181,A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors,Exclusion/INCLUSION,"EXCLUSIONPatients must have had no prior radiation therapy with the exception of CNS irradiation of brain metastases; (this exception only applies to SR1 patients; any patients over age 11 with distant metastases to brain [stage IV disease] would be considered poor risk and therefore not eligible for this trial)Patients must have had no prior systemic therapyINCLUSIONHas experienced prior or ongoing hearing impairment due to chemotherapy or radiotherapy as defined by one of the following: * Society of Pediatric Oncology (SIOP) grade 1 hearing loss* Subjective (patient-reported) hearing difficulties* Subjective (patient-reported) tinnitusHas received prior cisplatin- or carboplatin-based chemotherapy regimen for malignancy including diagnoses other than germ cell tumor",(C15477= NO OR C15477= YES AND C3813 = YES) AND (C16124 = YES AND C15698 = NO) AND (C16171 = NO OR (C16171 = YES AND (C376 = YES OR C1282 = YES)))NCI-2009-00336,NCT00392327,Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients,Inclusion,No previous chemotherapy or radiation therapy,C16171 = NO AND C15477= NONCI-2009-00470,NCT00632853,Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide,Inclusion,"Patients with complete surgical resection of disease are not eligibleNo prior radiotherapy or chemotherapy (except for the chemotherapy described in the bullet above) for small cell lung cancer (SCLC)Patients may have received one and only one cycle of chemotherapy prior to enrolling on Cancer and Leukemia Group B (CALGB) 30610, which must have included carboplatin or cisplatin and etoposide; if a patient has had one cycle of cisplatin (or carboplatin)/etoposide prior to registration, the patient must have had all of the prior to registration tests prior to starting their first cycle of chemotherapy; additionally, these patients also must have met all of the eligibility criteria prior to receiving the first cycle of chemotherapy; registration to CALGB 30610 must take place within 7-21 days after the start of the non-protocol therapy; failing to do all of the above will make the patient NOT eligible for CALGB 30610No prior mediastinal or thoracic radiotherapy",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR (C15477= YES AND C12748 = NO AND C12799 = NO)) AND C16169 = NONCI-2009-00595,NCT00719303,"Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?",Exclusion/Inclusion,"Exclusion:Patients who are currently undergoing treatment (primary or consolidation) for stage II, III or IV ovarian, fallopian tube or primary peritoneal cancer or who completed treatment less than six weeks agoInclusion:Patients must have completed all primary chemotherapy and consolidation therapy (if administered) at least 6 weeks, and no more than 6 months and 2 weeks, prior to enrollment and must be in complete remission; consolidation therapy is defined as any chemotherapy or biological therapy used for a patient who has completed at least four courses of primary chemotherapy and had documented complete remission prior to initiation of such chemotherapy (chemo) or biological therapy",C16171 = YES AND C4870 = YESNCI-2009-00603,NCT00492778,A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus,Exclusion/Inclusion,"Exclusion: Patients who have received previous vaginal, pelvic, or abdominal irradiationPatients who received chemotherapy directed at the present recurrencePatients who have undergone complete surgical resection of the recurrent tumor and have no evidence of residual disease evaluable clinically and by CT or MRI imaging, following resectionInclusion: Primary surgical debulking before protocol therapy is permissible; this would include removal of gross symptomatic disease in the pelvis and/or vagina* Exenterative surgery is not permissible; patients with complete resection of gross recurrent disease are eligibleAll patients must have undergone complete hysterectomy and bilateral salpingo-oophorectomy at the time of original therapy for their uterine carcinomaPatients may have received prior hormone therapy and/or systemic chemotherapy; such therapy must have been completed at least 6 months prior to study entry and the patient has clear evidence of disease subsequent to such therapy; patients must not have received neoadjuvant chemotherapy for the present recurrent disease",(C16171 = YES OR ((C15477= NO OR (C15477= YES AND C12407 = NO AND C12767 = NO AND C12664 = NO)) AND (C16169 = NO OR  (C16169 = YES AND C91837 = NO) OR (C16175 = YES)NCI-2009-00817,NCT00001337,Dose-Adjusted EPOCH Chemotherapy and Rituximab (Cd20+) in Adults and Children with Previously Untreated Aggressive Non-Hodgkin's Lymphoma,Inclusion,"No prior systemic chemotherapy; patients may be entered if they have had prior limited-field radiotherapy, a short course of glucocorticoids and/or cyclophosphamide for an urgent problem at diagnosis (e.g. epidural cord compression, superior vena cava syndrome)",C16171 = NO AND (C15477= NO OR (C15477= YES AND C54225 = YES)) NCI-2009-01057,NCT00576654,"A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients with Advanced Solid Tumors",Exclusion/INclusion,"Patients with known active brain metastases should be excluded from this clinical trial; patients with prior treated brain metastases are allowed, providing that they were not accompanied by seizures and that a baseline brain magnetic resonance imaging (MRI) scan prior to study entry demonstrates no current evidence of brain metastases; all patients with central nervous system (CNS) metastases must be stable for > 3 months after treatment and off steroid treatment prior to study enrollmentPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients who have been administered ABT-888 as part of a single or limited dosing study, such as a phase 0 study, should not necessarily be excluded from participating in this study solely because of receiving prior ABT-888Patients may not have received any other investigational agents within 4 weeks of study entryPatients must not receive any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) while on this study except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (i.e. megestrol acetate, bisphosphonates); these medications must have been started 1 month prior to enrollment on this study; in addition, men receiving treatment for prostate cancer will be maintained at castrate levels of testosterone by continuation of luteinizing-releasing hormone agonistsINCLUSION:Prior chemotherapy is allowed; patients must not have received chemotherapy for 4 weeks prior to the initiation of study treatment and must have full recovery from any acute effects of any prior chemotherapy; patients must not have had nitrosoureas or mitomycin C for 6 weeks prior to the initiation of study treatmentPrior radiation therapy is allowed; patients must not have received minimal radiation therapy (=< 5% of their total marrow volume) within 3 weeks prior to the initiation of study treatment; otherwise, patients must not have received radiation therapy (> 5% of their total marrow volume) within 4 weeks prior to the initiation of study treatment; patients who have received prior radiation to 50% or more of their total marrow volume will be excludedPrior experimental (non-Food and Drug Administration [FDA] approved) therapies and immunotherapies are allowed; patients must not have received these therapies for 4 weeks prior to the initiation of study treatment and must have full recovery from any acute effects of these therapies",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16168 = NO OR C16168 = YES)NCI-2011-00312,NCT01012817,"A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) after Prior Platinum Containing First-Line Chemotherapy",Exclusion/Inclusion,"EXCLUSION: Prior treatment with a PARP inhibitor or topotecanMore than 2 prior chemotherapy regimens for the current malignancy; full dose chemotherapy used in conjunction with concurrent radiation therapy will be included as prior therapy* Note: Prior hormonal therapy (e.g. leuprolide, aromatase inhibitors, tamoxifen) and immunotherapy will be allowed and not included as a prior chemotherapy; if the chemotherapy regimen is altered during the course due to issues with tolerability or safety, the regimen will be counted as one; using the same regimen at recurrence is counted as one regimen; the addition of bevacizumab to a prior regimen is considered one regimenAny of the following prior therapies:* Chemotherapy =< 4 weeks prior to registration* Mitomycin C/nitrosoureas =< 6 weeks prior to registration* Immunotherapy =< 4 weeks prior to registration* Biologic therapy =< 4 weeks prior to registration* Radiation therapy =< 4 weeks prior to registration* Radiation to > 25% of bone marrow * Investigational therapy or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation) =< 4 weeks prior to registration; subjects with prostate cancer will be permitted to continue hormone therapyOther active malignancy, except non-melanotic skin cancer or carcinoma-in-situ of the cervix* Note: If there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancerINCLUSION:Patients must have received < 3 lines of prior therapy and have relapsed less than a year from their last platinum regimen; regimens that are used twice (for example carboplatin and paclitaxel) can be counted as one; if a regimen is changed during the course of treatment due to side effect profile or allergy, the course of therapy is counted as one regimen; (for example, if docetaxel is substituted for paclitaxel due to a reaction during the initial course of adjuvant therapy, this is considered one regimen)","(C16171 = NO OR (C16171 = YES  AND (C16124 = YES AND C62554 = NO AND C1413 = NO))) AND (C15477= NO OR C15477= YES) AND (C16168 = NO OR C16168 = YES) AND (C16124= YES AND (C15187 = NO OR C15187 = YES))"NCI-2011-00878,NCT00956007,A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer,Exclusion,"Prior systemic chemotherapy or anti-EGF therapy for the study cancer; note: prior chemotherapy or anti-EGF therapy for a different cancer is allowablePrior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields","(C16171 = NO OR (C16171 = YES AND PRIOR TREATMENT OF CURRENT CANCER= NO) AND (C16124 = YES AND C2167= NO OR (C2167= YES AND PRIOR TREATMENT OF CURRENT CANCER = NO)) AND ((C15477= NO OR (C15477= YES AND C54225 = YES))  "NCI-2011-01915,NCT00887146,N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma,Exclusion/INCLUSION,"EXCLUSIONHistory of prior radiation therapy or chemotherapy for glioma; note: patients who have a history of prior low grade glioma (with or without a distant history of prior surgery for that glioma), but who have never received prior chemotherapy or radiation therapy for the glioma are eligible for the studyReceiving any other investigational agent that would be considered as a treatment for the primary neoplasmINCUSIONSurgery (partial or gross total resection or biopsy) must be performed >= 2 weeks prior to registration; patient must have recovered adequately from the effects of surgery",(C16171 = NO OR (C16171 = YES AND C4822 = NO)) AND (C15477= NO OR (C15477= YES AND C4822 = NO)) AND (C16169 = NO OR C16169 = YES)NCI-2011-01973,NCT00980954,Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy,Inclusion / EXCLUSION,"INCLUSION:Patients must have undergone radical hysterectomy (open, laparoscopically or robotic) and staging including pelvic node sampling or dissection for cervical carcinoma within 70 days prior to study entry (NOTE: if the patient did not have a para-aortic lymph node sampling/dissection, but had common iliac node dissection that was negative, a positron emission tomography [PET]-computed tomography [CT] is recommended, but not required; a negative pre or post-operative PET scan or PET-CT scan of the paraâ€“aortic nodes is required if the patient did not undergo para-aortic or common iliac nodal sampling/dissection)EXCLUSION:Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)Prior systemic chemotherapy for the current cervical cancer; note that prior chemotherapy for a different cancer is allowablePrior radiation therapy to the pelvis that would result in overlap of radiation therapy fields",C16169 = YES AND (C16171 = NO OR (C16171 = YES AND PRIOR TREATMENT OF CURRENT CANCER= NO)) AND ((C15477= NO OR (C15477= YES AND C12767 = NO)) NCI-2011-01974,NCT00981656,A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy following a Thorough Transurethral Surgical Re-staging,Exclusion,"Prior systemic chemotherapy for bladder cancer; prior chemotherapy for a different cancer is allowablePrior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fieldsA prior or concurrent malignancy of any other site or histology unless the patient has been disease-free for >= 5 years except for non-melanoma skin cancer and/or stage T1a prostate cancer or carcinoma in situ of the uterine cervix or a urothelial carcinoma of the upper urinary tract stage pTa, pTis or pT1 that has not been free of disease after treatment for more than a 2 year period",(C16171 = NO OR C16171 = YES AND C12414 = NO)) AND ((C15477= NO OR (C15477= YES AND C12414 = NO))NCI-2011-01975,NCT00980460,Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment,INCLUSIONS/Exclusion,"INCLUSIONPatients may have had surgical resection of some or all sites of hepatoblastoma prior to enrollmentEXCLUSIONPatients must not have had major surgery within 6 weeks prior to enrollment on the high risk stratum; patients with history of recent minor surgical procedures (vascular catheter placement, bone marrow evaluation, laparoscopic surgery, liver tumor biopsy) will be eligiblePatients who are currently receiving other anticancer agents are not eligiblePatients who are currently receiving another investigational drug are not eligiblePatients who have received any prior chemotherapy are not eligiblePatients that have been previously treated with chemotherapy for hepatoblastoma or other hepatoblastoma-directed therapy (eg, radiation therapy, biologic agents, local therapy [embolization, radiofrequency ablation, laser]) are not eligiblePatients who are currently receiving therapeutic anticoagulants (including aspirin, low molecular weight heparin, warfarin and others) are not eligible",(C16169 = NO OR C16169 = YES) AND C16171 = NO AND C274 = NO AND C15477= NO AND C16299 = NONCI-2011-01987,NCT01013649,A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma,Exclusion,"Previous history of invasive malignancy (except non-melanoma skin cancer) unless the patient has been disease free for at least 2 years prior to study entry (or first day of chemotherapy for patients having started chemotherapy prior to first step registration); patients with a previous history of carcinoma in situ are eligiblePatients entering on the study after pancreaticoduodenectomy, who have not already started chemotherapy must not have had prior systemic chemotherapy for pancreas cancer; note that prior chemotherapy for a different cancer is allowable; for patients entering on the study who have already received up to 3 months of adjuvant chemotherapy as per the treating institution, patients must not have received adjuvant chemotherapy with agents other than gemcitabine, nab-paclitaxel, oxaliplatin, fluoropyrimidine, or irinotecan for the current pancreatic cancer; prior chemotherapy for a different cancer is allowablePrior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields",C16169 = YES AND (C16171 = NO OR (C16171 = YES AND C9005 = NO)) AND (C15477= NO OR (C15477= YES AND C54225 = YES))NCI-2011-01992,NCT02085408,"Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)",Inclusion,"Patients must be > 28 days from the start of induction or re-induction chemotherapy, or from the start of consolidation cycle 1 (if received) and < 90 days following recovery from most recent treatment; and they must have achieved and maintained a response to induction therapy (CR, CRi, or â€œmorphologic disease-free stateâ€)Patients with secondary AML are eligible for enrollment onto the trial; secondary AML is defined as AML that has developed in a person with a history of antecedent blood count abnormalities, or myelodysplastic syndrome (MDS), or a myeloproliferative disorder (excluding chronic myeloid leukemia); or a history of prior chemotherapy or radiation therapy for a disease other than AML* NOTE: Prior therapy of MDS with decitabine, low-dose cytarabine, or azacitidine is excludedPatient must not have a concurrent active malignancy for which they are receiving treatment (other than myelodysplastic syndromes [MDS])Patients who have received previous treatment for antecedent hematological disorders (AHD) with 5-azacitidine, decitabine, or low dose cytarabine will be excludedPatients may not have received prior chemotherapy for AML with the exception of hydroxyurea for increased blast count or leukapheresis for leukocytosis; patients who have received a limited and short-term exposure of ATRA (all trans retinoid acid) while AML-M3 (acute promyelocytic leukemia) was being ruled out, and which has been discontinued, will be eligible Patients must have recovered from the effects of induction, re-induction, or consolidation chemotherapy (all toxicities =< grade I with the exception of reversible electrolyte abnormalities), and have no ongoing active infection requiring treatment",(C16171 = NO OR (C16171 = YES) OR (C16124 = YES AND C15679 = YES))) AND (C16124 = YES AND (C288 = NO AND C981 = NO AND C408 = NO))NCI-2011-02000,NCT01042522,"A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary",Exclusion/ INCLUSION,"EXCLUSIONPatients who have received any prior cytotoxic chemotherapy or biologics for sex cord-stromal tumors (SCSTs)Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five yearsPatients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study; the investigator can consult the study chair or study co-chairs for uncertainty in this regardInclusionPatients with a history of hypersensitivity reactions to prior chemotherapy administered for previous cancer diagnoses are eligible to participate in the study, unless the hypersensitivity reaction consisted of anaphylaxis not amenable to desensitization",((C16171 = NO OR (C16171 = YES AND C3794 = NO)) AND ((C16124 = YES AND (C15187 = NO OR (C15187 = YES AND C3794 = NO))NCI-2011-02029,NCT01096368,Phase III Randomized Trial of Post-radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years,Exclusion,No prior treatment other than surgical intervention and corticosteroids; patients are allowed to have had more than one attempt at resection prior to enrollment,(C16169 = NO OR (C16169 = YES))  AND C16171 = NO AND C15477= NO AND C16175 = NO AND (C16124 = YES AND C15187 = NO)NCI-2011-02034,NCT01118026,Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL),Inclusion,"Patients may have had one cycle only of ABVD prior to enrolling on study; no other prior treatment (chemotherapy or radiation therapy) for Hodgkin lymphoma is allowed; if patient has had one cycle of ABVD, in order to be eligible to enroll on Cancer and Leukemia Group B (CALGB) 50801, the patient must have had all of the following tests prior to starting the first cycle of ABVD:* Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multi gated acquisition (MUGA)* Pulmonary function tests (PFTs) (including diffusing capacity of the lung for carbon monoxide [DLCO]/forced vital capacity [FVC])* CT scan (neck**, chest, abdomen, pelvis)* FDG-PET/CT scan* Chest X-ray, posterior-anterior (PA) & lateral* Complete blood count (CBC), differential, platelets* Erythrocyte sedimentation rate (ESR)* Serum creatinine* Glucose* Aspartate aminotransferase (AST)* Alkaline phosphatase* Bilirubin* Lactate dehydrogenase (LDH)** Patients with a negative FDG-PET/CT scan do not need to have had a dedicated neck CT scan prior to starting the previous cycle of ABVD",(C16171 = NO OR (C16171 = YES = C9509) AND C15477 = NONCI-2011-02037,NCT01101451,"Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy",Exclusion,"Patients with cervix cancer who have received any previous radiation or chemotherapyPatients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy",C16171 = NO  AND C15477= NO NCI-2011-02073,NCT02589938,"A Phase III Prospective Randomized Trial of Acupuncture for Treatmentof Radiation-Induced Xerostomia in Patients with Head and Neck Cancer",Inclusion,"Must have received bilateral radiation therapy, and subsequently developed grade 2 or 3 xerostomia, according to modified Radiation Therapy Oncology Group (RTOG) scale:* Grade 0 â€“ None* Grade 1 â€“ Slight dryness of mouth* Grade 2 â€“ Moderate dryness of mouth* Grade 3 â€“ Complete dryness of mouth* Grade 4 â€“ Fibrosis",C15477= YES  NCI-2011-02515,NCT01051635,A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults with Relapsed Solid Tumors and Lymphomas,Inclusion,"Patients must have recovered to at least a grade =< 1 toxicity eligibility levels due to adverse events (AEs) and/or toxicity of prior chemotherapy or biologic therapy* They must not have had chemotherapy or biologic therapy within 4 weeks (6 weeks for nitrosoureas and mitomycin C, or 2 months for UCN-01), or therapy with tyrosine kinase inhibitors within 5 times the half-life of the inhibitors prior to entering the study* Patients must be >= 2 weeks since any prior administration of study drug in an exploratory Investigational New Drug (IND)/phase 0 study; patients must be >= 1 month since completion of any prior radiation (>= 2 weeks for palliative radiation therapy); however, patients receiving bisphosphonates for any cancer or undergoing androgen deprivation therapy for prostate cancer are eligible for this therapy* Prior therapy with topoisomerase I inhibitors is allowedPatients must have histologically documented (confirmed at the Laboratory of Pathology, National Cancer Institute [NCI]), relapsed solid tumor malignancy or Hodgkin's disease/non-Hodgkin lymphoma that is metastatic or unresectable for which standard curative measures do not exist, or are associated with minimal patient survival benefit ( THIS IS RELATED TO THE DISEASE, NOT PRIOR THERAPY)",C16171 = YES OR (C16124 = YES AND C15187 = YES)NCI-2011-02539,NCT01226940,A Phase I Trial of Lenalidomide and Radiotherapy in Children with Diffuse Intrinsic Pontine Gliomas and High-Grade Gliomas,Exclusion/Inclusion,"EXCLUSIONPatients who have had prior chemotherapy for this tumorINCLUSIONNo prior chemotherapy or radiation therapy for HGG or DIPG is permitted; prior chemotherapy or radiation therapy for treatment of other malignancies is permitted","(C16171 = NO OR C16171 = YES AND C94764 = NO AND C4822= NO)) AND ((C15477= NO OR (C15477= YES AND C94764 = NO AND C4822= NO))"NCI-2011-02592,NCT01386385,"A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)",Inclusion,"Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888, carboplatin, paclitaxel or other agents used in studyNo other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five yearsPatients must not have received any prior systemic therapy (chemotherapy or other biologic therapy) for lung cancerREGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have completed chemoradiotherapy per protocol and at least four weeks but no more than six weeks must have elapsed from the last day of induction therapy (the last day of radiation)Patients must not have received prior chest radiation therapy for NSCLC",(C16171 = NO OR (C16171 = YES AND C12468 = NO)) AND (C16124 = YES AND C15187 = NO OR (C16124 = YES AND C15187 = YES AND C12468 = NO)) AND (C15477= NO OR (C15477= YES AND C25389 = YES AND C2926 = NO) OR (C15477= YES AND C25389 = NO AND C2926= NO))  NCI-2011-02594,NCT01381718,"A Phase II Placebo-Controlled Trial of Modafinil to ImproveNeurocognitive Deficits in Children Treated for a Primary Brain Tumor",Exclusion,"Concurrent treatment with any medications or substances that are potent inhibitors or inducers of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4), hepatic enzyme inducing antiepileptic drugs (EIAEDs), or other drugs known to affect the metabolism of modafinil; examples include, but are not limited to, itraconazole, ketoconazole, doxycycline, rifampin, St. John's wort, phenytoin, phenobarbital, diazepam, and tricyclic antidepressants* If patients were previously taking EIAEDs, they must be off for > 2 weeks prior to study enrollmentTreatment with other stimulant medications within 14 days of registration; however, a diagnosis of attention-deficit hyperactivity disorder (ADHD) does NOT exclude a child from participationHistory of grade 2 depression or anxiety or treatment with antidepressants, antipsychotics or monoamine oxidase inhibitor (MAO) inhibitors within 30 days of registration","NA "NCI-2011-02599,NCT01190930,Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy),Exclusion,"With the exception of steroid pretreatment (defined below) or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for either the current diagnosis of B-ALL or B-LLy or for any cancer diagnosed prior to initiation of protocol therapy on AALL0932* Patients receiving prior steroid therapy may be eligible for AALL0932",C16171 = NO OR (C16171 = YES AND C408 = YES AND C15750 = YES) NCI-2011-02611,NCT01231906,A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma,Inclusion,No prior chemotherapy or radiation therapy is allowed; patients should only have had a biopsy of the primary tumor without an attempt at complete or partial resection; patients will still be eligible if unplanned excision was attempted or accomplished as long as adequate imaging was obtained prior to surgery,C16171 = NO AND C15477= NO NCI-2011-02623,NCT01272037,"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer",Inclusion,"No other prior malignancy is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years (THIS IS DISEASE)Patients must not have received an aromatase inhibitor (AI) or a selective estrogen receptor modulator (SERM) such as tamoxifen or raloxifene within 5 years prior to registrationPatients must not have begun chemotherapy or endocrine therapy for their breast cancer prior to registrationPatients with a prior diagnosis of contralateral ductal carcinoma in situ (DCIS) are eligible if they underwent a mastectomy or lumpectomy with whole breast radiation; prior partial breast irradiation, including brachytherapy, is not allowed; patients with a prior diagnosis of ipsilateral DCIS or invasive breast cancer who received radiation to that breast are not eligible",(C16171 = NO OR (C16171 = YES AND PRIOR TREATMENT OF CURRENT CANCER = NO)) AND (C16175 = NO OR (C16175 = YES AND PRIOR TREATMENT OF CURRENT CANCER = NO)) AND (C16169 = NO OR C16169 = YES) AND ( C15477= NO OR C15477= YES)NCI-2011-02660,NCT01275664,Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated with First Line Post-Operative Intraperitoneal Chemotherapy,Exclusion,"Patients who have received prior chemotherapy for any abdominal or pelvic tumor including neo-adjuvant chemotherapy for their ovarian or primary peritoneal cancer are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic diseasePatients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study; examples of this would be hearing loss or neuropathy which would prevent tolerance to cisplatin, and paclitaxel administration; the investigator should feel free to consult the Study Chair or Study Co-Chairs for uncertainty in this regard",C16171 = NO OR (C16171 = YES AND C12664 = NO AND PEVIS = NO)NCI-2011-02674,NCT01368588,Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial,Exclusion,"Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both LHRH agonist and oral anti-androgen) is =< 45 days prior to the date of registrationPrevious hormonal therapy, such as LHRH agonists (e.g., leuprolide, goserelin, buserelin, triptorelin) or LHRH antagonist (e.g. degarelix), anti-androgens (e.g., flutamide, bicalutamide, cyproterone acetate), estrogens (e.g., diethylstilbestrol [DES]), or surgical castration (orchiectomy)Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomyPrevious radical surgery (prostatectomy) or cryosurgery for prostate cancerPrior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields",C16175 = NO AND (C15477= NO OR (C15477= YES AND C54225 = YES AND C12767 = NO AND C12410 = NO)) AND (C16169= NO OR (C16169 = YES AND C12410 = NO AND C12412= NO))NCI-2011-03458,NCT01434316,Phase 1 Trial of ABT-888 and SCH727965 in Patients with Advanced Solid Tumors,Inclusion,"Prior chemotherapy is allowed; patients must not have received chemotherapy for 3 weeks prior to the initiation of study treatment and must have full recovery from any acute effects of any prior chemotherapy; patients must not have had nitrosoureas or mitomycin C for 6 weeks prior to the initiation of study treatmentPrior exposure to ABT888 or other PARP inhibitors is permitted in all cohorts except the cohort evaluating BRCA-mutated PARP inhibitor naive patients, where prior PARP inhibitor treatment will not be permitted; prior exposure to cyclin-dependent kinase inhibitors other than SCH727965 is permittedPrior experimental (non-Food and Drug Administration [FDA] approved) therapies and immunotherapies are allowed; patients must not have received these therapies for 3 weeks prior to the initiation of study treatment and must have full recovery from any acute effects of these therapiesPrior radiation therapy is allowed; patients must not have received any radiation within 3 weeks prior to the initiation of study treatment; patients may not have areas of irradiated marrow exceeding 40% of bone marrow volumePrior exposure to approved receptor tyrosine kinase inhibitors is permitted; at least 5 half-lives must have elapsed since the completion of the kinase inhibitor and the initiation of study treatment",(C16171 = NO OR C16171 = YES) AND (C16168 = NO OR C16168 = YES) AND (C16124 = YES AND (C41161 = NO OR C41161t= YES)) AND (C15477 = NO OR C15477 = YES) NCI-2011-03797,NCT02883049,A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) including a Stratum Evaluating Dasatinib (NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations,Exclusion,"With the exception of steroid pretreatment or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for either the current diagnosis of B-ALL or any cancer diagnosed prior to the initiation of protocol therapy on AALL1131; patients cannot have secondary B-ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy; patients receiving prior steroid therapy may be eligible for AALL1131",C16171 = NO OR (C16171 = YES AND C408 = YES AND C15750 = YES) NCI-2012-00095,NCT01497444,Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC,Exclusion/INCLUSION,"EXCLUSIONReceived treatment with radiation therapy or investigational therapy =< 28 days prior to registrationRCC patients only: Having received chemotherapy prior to study entry within 5 half-lives of the agent (as described in the package insert), or 4 weeks prior to registration (whichever is shorter) with resolution of side effects from therapy to =< grade 1Receiving any medications or substances that are inducers or strong or moderate inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) =< 7 days prior to registration* Use of CYP3A4 inducers are prohibited =< 7 days prior to registration* Use of CYP3A4 strong or moderate inhibitors are prohibited =< 7 days prior to registrationOther active malignancy =< 3 years prior to registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history or prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancerHistory of lobectomy involving > 50% of lobeINCLUSIONPrior chemoembolization, radioembolization, radiofrequency ablation (RFA) or other local ablative therapies are permissible if >= 6 weeks from procedure with evidence of progression or new metastatic disease, if applicableRCC patients only: Tumor progression after receiving standard/approved chemotherapy and/or targeted agent, where there is no approved therapy or for tumors where sorafenib based therapy would be standard therapy (Phase I)",(C16171 = NO OR C16171 = YES) AND ( C15477= NO OR C15477= YES)NCI-2012-00234,NCT01515787,"A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision",Exclusion,"Chemotherapy within 5 years prior to registration; (hormonal therapy is allowable if the disease free interval is >= 5 years)Any prior pelvic radiation",(C16171 = NO OR (C16171 = YES)) AND (C16175 = NO OR C16175 = YES) AND (C15477= NO OR (C15477= YES AND C12767= NO))NCI-2012-00680,NCT01333046,Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients with Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma,Inclusion,"TREATMENT: Patients should have been off conventional therapy for at least 1 week prior to entry in this study, including rituximabTREATMENT: Patients should have been off other investigational therapy for one month prior to entry in this study",C16124 = NO OR C16124 = YESNCI-2012-00707,NCT01556243,Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC),Exclusion/Inclusion,"EXCLUSIONTreatment including radiation therapy, chemotherapy, biotherapy, or hormonal therapy for this cancer prior to surgery (i.e., any neoadjuvant chemotherapy or endocrine therapy is not allowed); patients who undergo surgical resection with breast conservation and then are treated with adjuvant systemic therapy are eligible to enroll prior to the start of radiotherapySurgical axillary staging procedure prior to first definitive breast operation; Note: fine-needle aspiration (FNA) or core needle biopsy of axillary node is permittedINCLUSIONBilateral mammogram =< 90 days prior to date of surgery; Note: for patients undergoing more than 1 breast operation, this is the date of the first breast surgery for breast cancer treatment",(C16171 = NO OR (C16171 = YES AND PRIOR TREATMENT OF CURRENT CANCER = NO)) AND (C15477= NO OR (C15477= YES AND PRIOR TREATMENT OF CURRENT CANCER = NO)) AND (C16124 = YES AND (C15187 = NO OR (C15187 = YES AND PRIOR TREATMENT OF CURRENT CANCER = NO))) AND (C16175 = NO OR (C16175 =YES AND PRIOR TREATMENT OF CURRENT CANCER = NO)) AND (C16169 = NO OR C16169 = YES)NCI-2012-00719,NCT01573442,Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias,Exclusion,"Prolonged systemic corticosteroid treatment, except for topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airway diseases), eye drops, or local insertion (e.g., intra-articular)* Note: Short duration (< 2 weeks) of systemic corticosteroids is allowed (e.g., for chronic obstructive pulmonary disease), but not within 30 days prior to registration",N/ANCI-2012-00860,NCT01587352,A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma,Exclusion,Patients may have had any number of prior therapies; at least 3 weeks must have elapsed since the last dose of systemic therapy; at least 6 weeks must have elapsed if the last regimen included BCNU or mitomycin C; at least 6 weeks must have elapsed if the last regimen included an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody; patients must have experienced disease progression on their prior therapy in the opinion of the treating investigator,C16124=YES OR C16124= NONCI-2012-00864,NCT01585805,"A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients with  Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)",Exclusion/INCLusion,"EXCLUSION Patients with prior malignancy successfully treated who are currently stable and on no active treatment are eligiblePatients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier* For Part I, prior adjuvant therapy with gemcitabine or a fluoropyrimidine therapy is permitted if completed > 6 months prior to recurrence; no prior PARP inhibitor therapy is allowed* For Part II, no prior PARP inhibitor therapy is permitted; up to two prior treatment regimens are permitted as follows: 1 adjuvant and 1 metastatic; 1 locally advanced and 1 metastatic; or 2 metastatic, or a variation thereofINCLUSIONFor Part II (Arm C): Patients can have either locally advanced or metastatic pancreas adenocarcinoma; up to two prior treatment regimens are permissible (excluding a prior PARP inhibitor) for either localized or metastatic pancreas adenocarcinoma; prior combined chemotherapy and radiotherapy is permissible provided the patient has measurable disease outside the radiation port; prior therapy must have been completed at least 3 weeks prior to starting study therapyFor Part I (Arms A, B): Patients can have either locally advanced or metastatic pancreas adenocarcinoma for which no prior therapy has been administered for either locally advanced or metastatic disease; prior adjuvant therapy is permissible if gemcitabine or a fluoropyrimidine was administered with or without radiation and if disease recurrence has been documented at least 6 months after completion of adjuvant therapy",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND C62554 = NO)NCI-2012-01040,NCT01638533,"A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction",Inclusion/EXCLUSION,"INCLUSIONPatients with biliary obstruction for which a stent has been placed are eligible, provided the shunt has been in place for at least 10 days prior to the first dose of romidepsin and the liver function has stabilized; two measurements at least 2 days apart that put the patient in the same hepatic dysfunction stratum will be accepted as evidence of stable hepatic function; there should be no evidence of biliary sepsisAbility to understand and the willingness to sign a written informed consent documentEXCLUSIONPatients who have had (prior to entering the study): major surgery is not permitted within 4 weeks of romidepsin administration; anti-cancer therapy including chemotherapy, radiotherapy, hormonal (with the exception of hormones for thyroid conditions), and other investigational agents will not be allowed within 14 days or five (5) half-lives (whichever is longer) prior to the first dose of romidepsin (6 weeks for nitrosoureas or mitomycin C); additionally, participants must have recovered to less than grade 2 clinically significant adverse effect(s)/toxicity(ies) of the previous therapy, with the exception of alopecia, unless approved by the principal investigator; biologics or immunotherapy will not be allowed within 28 days prior to, or during, romidepsin administration",(C16169 = NO OR C16169 = YES) AND (C16171 = NO OR C16171 = YES) AND (C16175 = NO OR C16175 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES)) AND (C15477= NO OR C15477= YES)NCI-2012-01695,NCT01775475,"Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy with Concomitant Antiretroviral Therapy in Patients with HIV-Associated Lymphoma in Sub-Saharan Africa",Exclusion,"Participants who received greater than 10 days of corticosteroids in the preceding 30 days prior to enrollment; physiologic dosing of steroid is 4-5 mg/m^2/day prednisone, 0.03-0.15 mg/kg/day dexamethasone, or 0.5-0.75 mg/kg/day hydrocortisone; contact the AMC Protocol Team for physiologic dosing limits for other corticosteroids",N/ANCI-2012-01695,NCT01775475,"Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy with Concomitant Antiretroviral Therapy in Patients with HIV-Associated Lymphoma in Sub-Saharan Africa",Exclusion,Participants who received any lymphoma directed chemotherapy or radiotherapy with the exception of a single dose of intrathecal chemotherapy given at the time of the diagnostic lumbar puncture (spinal tap); patients who received chemotherapy or radiotherapy for Kaposiâ€™s sarcoma > 2 years prior to study enrollment are allowed as long as the prior treatment did not include doxorubicin in its non-liposomal form; prior exposure to liposomal doxorubicin is allowed; prior exposure to intrathecal therapy given as prophylaxis within 30 days is allowed,(C16171 = NO OR (C16171 = YES AND C3208 = NO) OR (C16171 = YES AND C3208 = YES AND C15750 = 1)) AND (C15477= NO OR (C15477= YES AND C3208 = NO))NCI-2012-01712,NCT01695941,A Phase I Study of MLN8237 in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma,Inclusion/EXCLUSION,"INCLUSIONPatients may have received one or more lines of prior chemotherapy with/without rituximab (including high dose therapy plus stem cell transplant which is counted as one regimen); prior bortezomib is allowed; patients must not have received bortezomib in the past 6 monthsEXCLUSIONPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C, 3 weeks for rituximab) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier",C16171 = YES OR C15477= YESNCI-2012-01964,NCT01595061,A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061),Exclusion,Patients who have received prior pelvic radiation or cytotoxic chemotherapy,(C16171 = NO OR C16171 = YES) AND (C15477= NO OR (C15477= YES AND C12767 = NO))NCI-2012-01967,NCT01602666,Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT),Exclusion,Patients must not have received any prior tumor-directed therapy other than surgical intervention and corticosteroids,(C16171 = NO AND C15477= NO AND C16168 = NO AND (C16124= YES AND C15187 = NO)) AND (C16169 = YES OR C16169 = NO)NCI-2012-01977,NCT01622868,Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG,Inclusion/EXCLUSION,"INCLUSIONPrior lapatinib is allowed as long as the last dose received was > 21 days prior to study entry and provided the patient has not received it at any time after the diagnosis of brain metastasisAt least 1 measurable and no more than 10 unirradiated parenchymal brain metastasis within 21 days prior to study entry; the minimum size as measured on T1-weighted gadolinium-enhanced MRI must be as follows according to the number of brain metastases:* For a single solitary lesion the size must be >= 10 mm* For 2 or more lesions, the size of at least 2 of the lesions must be >= 5 mm* Patients may also have the following provided the size requirements above are met:** Progressive parenchymal brain metastasis following stereotactic radiosurgery for 1-3 brain metastases, with at least 1 new measurable brain lesion** Progressive parenchymal brain metastasis following surgical resection of 1-3 brain metastases, with at least 1 measurable brain lesionEXCLUSIONPrior radiation therapy (RT) (any site) with concurrent lapatinib defined as 1 or more days on which the patient received both radiation therapy and lapatinib on the same dayPrior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields except patients who have progressed following stereotactic radiosurgery for 1-3 brain metastases, with at least one new lesion",(C16169 = NO OR C16169 = YES) AND (C15477= NO OR (C15477= YES AND (C16124 = YES AND (C26653 = NO OR (C26653 = YES AND C25456 = NO))))NCI-2012-01990,NCT01649089,Evaluation of Physical Function and Quality of Life (QOL) before and after Non-radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (â‰¤ 2CM) Cervical Cancer,Exclusion,"Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy",C16124 = YES AND C50646 = NONCI-2012-01995,NCT01674140,"Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy.",Inclusion,"Patients must not be receiving or planning to receive trastuzumab; concurrent bisphosphonate therapy is allowed; patients must not have prior exposure to mechanistic target of rapamycin (serine/threonine kinase) (mTOR) inhibitors (rapamycin, everolimus, temsirolimus, deforolimus); patients must not have prior treatment with any investigational drug within the preceding 28 days and must not be planning to receive any other investigational drug for the duration of the studyPatients must have completed standard neoadjuvant or adjuvant taxane and/or anthracycline based chemotherapy prior to randomization; completion of chemotherapy will be determined by the treating oncologist, but should include a minimum of 4 cycles (a cycle of weekly paclitaxel is considered 3 doses); patients must be registered within 42 weeks after the last dose of chemotherapy; patients may have started endocrine therapy at any time after the diagnosis of the current breast cancerPatients must not have an organ allograft or other history of immune compromise; patients must not be receiving chronic, systemic treatment with corticosteroids or other immunosuppressive agent; topical or inhaled corticosteroids are allowedPatients must not have taken within 14 days prior to registration, be taking, nor plan to take while on protocol treatment, strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors and/or CYP3A4 inducers",(C16124 = YES AND C2201= NO AND (C49135 = NO OR C49135 = YES)) (C16171 = NO OR C16171 = YES) AND C60701 = NONCI-2012-01998,NCT01668719,"A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)",Inclusion,"Patients on the Phase I portion may not have received ANY prior chemotherapy; patients on the Phase II portion may have received one prior cycle of any non-investigational chemotherapy; prior chemotherapy must have been completed within 56 days prior to registration and all toxicities must have resolved to =< grade 1; patients on either portion may have received prior treatment with dexamethasone, providing total number of days of treatment was =< 14 days and total treatment dose was =< 360 mgPatients may have received prior radiotherapy for symptomatic localized bone lesions or impending spinal cord compression only; radiotherapy must be completed at least 14 days prior to registration and all toxicities must have resolved to =< grade 1",C16171 = NO AND (C15477= NO OR (C15477= YES AND (C43260 = YES OR C3380 = YES)))NCI-2012-02009,NCT01711541,Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck,Inclusion,"Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent are not eligible to participate in this study; topical or inhaled corticosteroids are allowed",N/ANCI-2012-02011,NCT01711554,A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma,Inclusion,"Patients with prior progressive disease who do not meet criteria above, are eligible as long as they have not been off treatment for > 3 months prior to enrollment on NANT 2011-04Stem Cell Transplant (SCT): * Patients are eligible 6 weeks after date of autologous stem cell infusion following myeloablative therapy (timed from first day of protocol therapy)* Patients are not eligible post allogeneic stem cell transplant* Patients who have received an autologous stem cell infusion to support non-myeloablative therapy (such as 131 iodine [I]-MIBG) are eligible at any time as long as they meet the other criteria for eligibilityPatients with other ongoing serious medical issues must be approved by the study chair prior to registrationPrior anti-disialoganglioside (GD2) antibody, isotretinoin, or lenalidomide therapy:* Patients who have received prior anti-GD2 antibody therapy are eligible if they did not have tumor relapse/progression while receiving this therapy* Patients who have received either isotretinoin or lenalidomide are eligible, but not if they have received the two agents concomitantlyRadiation: * Patients must not have received radiation (small port) for a minimum of two weeks prior to protocol therapy* Except for patients with a history of progressive disease, patients whose only site(s) of disease have been radiated are eligible if at least one lesion meets at least one of the criteria listed in sites of disease above* A minimum of 12 weeks prior to start of protocol therapy is required following large field radiation therapy (i.e. total body irradiation, craniospinal, whole abdominal, total lung, > 50% marrow space)* A minimum of 6 weeks must have elapsed prior to start of protocol therapy for other substantial bone marrow radiationPatients must not have received the therapies indicated below for the specified time period prior to the first day of administration of protocol therapy on this study* Myelosuppressive chemotherapy: must have received last dose at least 2 weeks prior to protocol therapy; this includes cytotoxic agents given on a low dose metronomic regimen* Biologic (anti-neoplastic agent) (includes retinoids): must have received last dose at least 7 days prior to protocol therapy* Monoclonal antibodies: must have received last dose at least 7 days or 3 half-lives, whichever is longer, prior to protocol therapy",C15477= YES OR C16171 = YES OR (C16124 = YES AND C15187 = YES) OR C16168 = YESNCI-2012-02020,NCT01781468,"A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (NuvigilÂ®) toReduce Cancer-Related Fatigue in Patients with High Grade Glioma",Exclusion/INCLUSION,"EXCLUSIONCurrently using any other pharmacologic agents or nonpharmacologic interventions to specifically treat fatigue, including psychostimulants, antidepressants, acupuncture, etc. will be excluded; Note: antidepressants used to treat items other than fatigue (such as hot flashes or depression) are allowed if the patient has been on a stable dose for >= 30 days prior to registration and plans to continue for the duration of the trial; erythropoietin agents to treat anemia are allowed; exercise is allowedINCLUSIONUndergone surgery (gross total or subtotal resection) or biopsy and will have been treated with concurrent radiation therapy and chemotherapy as standard of care for glioblastoma, gliosarcoma, small cell or large cell glioblastoma, glioblastoma with oligo features, glioblastoma with primitive neuroectodermal tumor-like components (GBM-PNET) features, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma patients; Note: radiation must be completed, but chemotherapy is allowed; patients who are currently using Optune device will be eligible to participate in this trial",C16169 = YES OR C15477= YES OR C16171 = YES NCI-2012-02057,NCT01730937,Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma,Exclusion/Inclusion,"EXCLUSIONPrior liver transplantPrior radiotherapy to the region of the liver that would result in excessive doses to normal tissues due to overlap of radiation therapy fieldsINCLUSIONPatients treated with prior surgery are eligible for this study if they otherwise meet eligibility criteria",(C16169 = NO OR (C16169 = YES AND C15271 = NO)) AND (C15477= NO OR (C15477= YES AND C54225 = YES))NCI-2012-02067,NCT01349881,"A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)",Inclusion,"Patients must have a history of stage 0, I, II or III colon or rectal adenocarcinoma that has been treated per standard care with resection alone or in combination with radiation or chemotherapy; adjuvant chemotherapy and radiation therapy (RT) treatment must have been completed at least 30 days prior to registrationPatients must be registered between 180 days and 465 days (inclusive) of primary resection; patients must show no evidence of disease (NED) based on post-operative colonoscopy (performed at least 180 days after the colon resection date or at least 120 days after the rectal resection date and prior to registration) and computed tomography (CT) scans* of chest, abdomen and pelvis (performed at least 180 days after the colon resection date or at least 120 days after the rectal resection date and prior to registration); patients with adenomas detected at the one-year postoperative colonoscopy are eligible if all adenomas have been completely removed* CT scan is for high risk patients, as per National Comprehensive Cancer Network (NCCN) guidelines and at the discretion of the treating physician* NOTE: magnetic resonance imaging (MRI) evaluation is an acceptable alternative to CT scans for eligibility purposes",C16169 = YES OR C16171 = YES OR C15477= YESNCI-2012-02608,NCT01863550,"Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)",Inclusion,"STEP I: Patients with a history of prior malignancy are eligible provided they were treated with curative intent and do not require active therapy (currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma â€œin situâ€ of the cervix or breast are not excluded)STEP I: Patients must have received no more than one cycle (4 weeks or less) of prior chemotherapy and no more than 160 mg of prior dexamethasone (or equivalent dose of prednisone) for treatment of symptomatic myeloma; they should not have been exposed to lenalidomide, bortezomib or carfilzomib for treatment of symptomatic myeloma; prior radiation therapy to symptomatic lesions is allowed provided there are no residual toxicity related to radiation and blood counts that meet the study requirementsSTEP I: Prior systemic glucocorticoid use for the treatment of non-malignant disorders is permitted; prior or concurrent topical or localized glucocorticoid therapy to treat non-malignant comorbid disorders is permitted",(C16171 = NO OR C16171 = YES) AND (C15477 = NO OR C15477 = YES) AND (C16124 = YES AND (C2668 = NO OR (C2668 = YES AND C3242 = NO)) AND (C1851 = NO OR (C1851 = YES  AND C3242 = NO)) AND (C52196 = NO OR (C52196 = YES AND C3242 = NO)))NCI-2012-02767,NCT01749397,"A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 with Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers",Exclusion,"Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatmentAny of the following prior therapies:* Chemotherapy =< 28 days prior to registration* Mitomycin C/nitrosoureas =< 42 days prior to registration* Immunotherapy =< 28 days prior to registration* Biologic therapy =< 28 days prior to registration* Radiation therapy =< 28 days prior to registration* Investigational therapy or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA] approved indication and in the context of a research investigation) =< 28 days prior to registration* Prior poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor therapyMore than 4 prior chemotherapy regimens; note: repeat use of regimens count as 1 prior regimen; switching front-line therapy regimens (for example, from intraperitoneal to intravenous therapy) for reasons other than progression will count as 1 prior therapy; bevacizumab and other â€˜targetedâ€™ agents will count in the total number of prior regimens; vaccine therapies will not count in the total of prior therapiesKnown standard therapy for the patientâ€™s disease that is potentially curative or definitely capable of extending life expectancy; note: patients with recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube will be allowed, if the investigator believes the study treatment is a better alternative to initiation platinum-based chemotherapy, such as patients with a prior platinum allergy or low volume disease for whom platinum-based therapy is deferred until a later date",(C16171 = NO OR C16171 = YES) AND (C16168 = NO OR C16168 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES)) AND (C15477= NO OR C15477= YES) AND ( C16124 = YES AND C62554 = NO)NCI-2012-02869,NCT01806129,EROS: Engendering Reproductive Health within Oncologic Survivorship,Inclusion,Patients must not have initiated chemotherapy or radiation prior to registration to this study,C16171 = NO AND C15477= NONCI-2012-02875,NCT01586403,Transfer of Genetically Engineered Lymphocytes in Melanoma Patients: A Phase 1 Dose Escalation Study,Inclusion,Patients treated with prior Interleukin-2 will be allowed to be in this study,N/ANCI-2012-03124,NCT01755195,"A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients with Metastatic Refractory Soft Tissue Sarcoma",Exclusion,"Patients who have had anticancer therapy, including kinase inhibitors or any investigational agent within 4 weeks or 5 half-lives (whichever is shorter) (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered to baseline from adverse events (except alopecia and other non-clinically significant adverse events [AEs]); patients who have received prior cabozantinib or inhibitors of c-MET or HGF are ineligiblePatients are allowed prior VEGFR-tyrosine kinase inhibitor (TKI); patients will be stratified based on prior VEGFR-TKI therapy",(C16171 = YES OR C15477= YES OR C16168 = YES OR (C16124 = YES AND C15187 = YES) AND (C16124 = YES AND C52200 = NO AND C143099 = NO AND HGF Inhibitor = NO) OR (C93259= YES)) NCI-2012-03125,NCT01767194,"A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children with Refractory, Relapsed or Progressive Neuroblastoma",Inclusion/EXCLUSION,"No interim time prior to study entry is required following prior radiation therapy (RT) for non-target lesions; however, patients must not have received radiation for a minimum of 4 weeks prior to study entry at the site of any lesion that will be identified as a target lesion to measure tumor response; lesions that have been previously radiated cannot be used as target lesions unless there is radiographic evidence of progression at the site following radiation or a biopsy done following radiation shows viable neuroblastoma; palliative radiation is allowed to sites that will not be used to measure response during this studySubjects who have previously received anti-GD2 monoclonal antibodies for biologic therapy or for tumor imaging are eligible unless they have had progressive disease while receiving prior anti-GD2 therapy; subjects who have received autologous marrow infusions or autologous stem cell infusions that were purged using monoclonal antibody linked to beads, but no other form of anti-GD2 monoclonal antibody, are eligibleEXCLUSIONPatients must have been off pharmacologic doses of systemic steroids for at least 7 days prior to enrollment; patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study are ineligible; the only exception is for patients known to require 2 mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product administration in order to avoid allergic transfusion reactions; the use of conventional doses of inhaled steroids for the treatment of asthma is permitted, as is the use of physiologic doses of steroids for patients with known adrenal insufficiencyPatients must not have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, valproic acid, or carbamazepine for at least 7 days prior to study enrollment; patients receiving non-enzyme inducing anticonvulsants such as gabapentin or levetiracetam will be eligible",C15477= YES OR (C16124 = YES AND C15187 = YES)NCI-2012-03173,NCT01089101,A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma,Inclusion/EXCLUSION,"INCLUSONPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, biologic therapy or radiotherapy prior to study entry* Myelosuppressive chemotherapy: Patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three weeks prior to registration on the Re-treatment Study or at least six weeks if a nitrosourea* Biologic agent: Patient must have received their last dose of the biologic agent >= 7 days prior to study registration; for biologic agents and monoclonal antibody treatment, at least three half-lives must have elapsed prior to registration* Other investigational agents (not fitting into one of the above specified categories): patients must have received their last dose of any other investigational agent greater than 28 days prior to enrollment* Radiation: Patients must have:** Had their last fraction of local irradiation to the primary tumor >= 12 months prior to registration; investigators are reminded to review potentially eligible cases to avoid confusion with pseudo-progression;** Had their last fraction of craniospinal irradiation (> 24Gy) > 3 months prior to registration* Corticosteroids: Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration* Growth factors: Patients must be off all colony-forming growth factor(s) for at least 1 week prior to registration (filgrastim, sargramostim, erythropoietin) and at least 2 weeks for long-acting formulationsPatients must have received prior therapy other than surgery and must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, biologic therapy or radiotherapy prior to study entryPatients must have received treatment on PBTC-029 or PBTC-029B for a minimum of 12 courses with at least stable disease, or had a sustained response (partial response [PR]/ complete response [CR]) but remained on treatment < 12 coursesPatients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three weeks prior to study registration or at least six weeks if nitrosoureaPatient must have received their last dose of the biologic agent >= 7 days prior to study registration* For biologic agents that have a prolonged half-life, at least three half-lives must have elapsed prior to registrationMonoclonal antibody treatment: at least three half-lives must have elapsed prior to registrationRadiation: patients must have:* Had their last fraction of local irradiation to primary tumor >= 12 months prior to registration; investigators are reminded to review potentially eligible cases to avoid confusion with pseudo-progression* Had their last fraction of craniospinal irradiation (> 24 Gy) > 3 months prior to registrationPatients must be off all colony-forming growth factor(s) for at least 1 week prior to registration (filgrastim, sargramostim, erythropoietin) and at least 2 weeks for long-acting formulationsCorticosteroids: patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registrationEXCLUSIONPrior treatment with a BRAF inhibitor such as vemurafenib or dabrafenib (previous treatment with sorafenib is allowed)",(C16171 = YES OR C16168 = YES OR (C16124 = YES AND C15187 = YES) OR C15477= YES) AND (C16124 = YES AND (C61948 = NO OR C61948 = YES) AND C64768 = NO AND C82386 = NO)NCI-2012-03198,NCT01872975,A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy,Exclusion,"Any prior history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy; (patients with synchronous or previous ipsilateral LCIS are eligible)Any radiation therapy for the currently diagnosed breast cancer prior to randomizationAny continued use of sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy; patients are eligible if these medications are discontinued prior to randomizationPrior breast or thoracic radiation therapy (RT) for any condition","(C16175 = NO OR C16175 = YES) AND (C15477= NO OR (C15477= YES AND C12971 = NO AND C25389 = NO))"NCI-2013-00046,NCT01771107,A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma,Inclusion/EXCLUSION,"Participants must discontinue use of the following agents within 7 days prior to therapy* Strong CYP3A4 inhibitors that treat HIV* Other strong CYP3A inhibitors* Moderate CYP3A4 inhibitors should be used with caution but are not excluded; if 2 moderate CYP3A4 inhibitors are used concurrently, one must be discontinued at least 7 days (1 week) prior to the initiation of chemotherapy* P-glycoprotein inhibitors* If patients are taking any of these excluded medications, they must be discontinued at least 7 days (1 week) prior to the initiation of chemotherapyAll concomitant medications must be reviewed by the study chair or co-chair prior to enrollment by email; because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use ofEXCLUSIONPatients with prior anthracycline therapy will be excluded",C16171 NO OR C16171 = YES) C15451 = NONCI-2013-00370,NCT01220583,A Randomized Phase II / Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors,Inclusion/EXCLUSION,"INCLUSIONSurgical resection with curative intent within 8 weeks prior to registrationEXCLUSIONPrior systemic chemotherapy or radiation therapy for salivary gland malignancy; note that prior chemotherapy for a different cancer is allowablePrior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields",(C16169 = YES) AND (C16171 = NO OR (C16171 = YES AND C12426 = NO)) AND (C15477= NO OR (C15477= YES AND C54225))NCI-2013-00426,NCT01824836,A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS),Inclusion,"Patients must be disease-free of other prior invasive malignancies for >= 5 years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix; prior early stage breast cancers are also allowed as long as prior treatment did not include aromatase inhibitorsPatients must be post-menopausal; post-menopausal will be defined as women meeting any of the following criteria:* >= 60 years of age; or* < 60 years of age and amenorrheic for >= 12 months prior to day 1 if uterus/ovaries are intact; or* < 60 years of age, and the last menstrual period 6-12 months prior to day 1, if intact uterus/ovaries and meets biochemical criteria for menopause (follicle-stimulating hormone [FSH] and estradiol within institutional standard for postmenopausal status); or* < 60 years of age, without a uterus, and meets biochemical criteria for menopause (FSH and estradiol within institutional standards for postmenopausal status); or* < 60 years of age and history of bilateral oophorectomy; surgery must have been completed at least 4 weeks prior to day 1; or* Prior radiation castration with amenorrhea for at least 6 monthsPatients must have completed planned local therapy (i.e., definitive surgery and radiation therapy) and adjuvant chemotherapy for breast cancer prior to registration; in addition, any prior local therapy and adjuvant chemotherapy should be completed prior to participant completion of baseline Patient Reported Outcomes (PRO) instruments (i.e., Health Assessment Questionnaire [HAQ], PROMIS Physical Function, Functional Assessment of Cancer Therapy [FACT] Breast and Endocrine Symptoms [ES], etc.) and collection of optional blood for banking for future researchPatients must not have received prior AI therapy with exemestane, letrozole, or anastrozole as preoperative/adjuvant therapy or for prevention of breast cancer; prior tamoxifen is allowed",((C16124 = YES AND C1740= NO) AND (C15477= NO OR C15477= YES) AND (C16169 = NO OR C16169 = YES) AND (C16171 = NO OR C16171 = YES)) OR (C16124 = YES AND C62078 = YES)NCI-2013-00500,NCT01810913,Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck,Exclusion,"Prior systemic chemotherapy or anti-epidermal growth factor (EGF) therapy for the study cancer; note that prior chemotherapy for a different cancer is allowablePrior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields",(C16171 = NO OR (C16171 = YES AND C34447 = NO)) AND (C2167 = NO OR (C2167= YES AND C34447 = NO)) AND (C15477= NO OR (C15477= YES AND C54225))NCI-2013-00716,NCT00978250,Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine (FdCyd + THU),Inclusion,"Any prior therapy must have been completed >= 4 weeks prior to enrollment on protocol and the participant must have recovered to eligibility levels from prior toxicity; patients should be at least six weeks out from nitrosoureas and mitomycin C; prior radiation should have been completed >= 4 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (also referred to as an â€œearly phase I studyâ€ or â€œpre-phase I studyâ€ where a sub-therapeutic dose of drug is administered) at the PIâ€™s discretion, and should have recovered to eligibility levels from any toxicities",C16124 = NO OR C16124 = YESNCI-2013-00737,NCT01822496,A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC),Exclusion,"Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowablePrior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields",(C16171 = NO OR (C16171 = YES AND PRIOR TREATMENT OF CURRENT CANCER= NO)) AND (C15477= NO OR (C15477= YES  AND C54225 = YES))NCI-2013-00739,NCT01822509,A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation,Exclusion,"Participants who have had anti-tumor therapy or other investigational agents within 4 weeks prior to registration (6 weeks for nitrosoureas or mitomycin C), or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to registrationPatients with a history of prior treatment with ipilimumab, anti-programmed cell death protein 1 (PD 1) antibody, or cluster of differentiation (CD)137 agonist therapy are ineligible for the ipilimumab arm, but are eligible for the nivolumab arm",C16124 = YESNCI-2013-00740,NCT01822522,Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection,Inclusion/EXCLUSION,"INCLUSIONParticipants must have known HIV infection and histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; any number of prior cancer therapies will be permitted; at least 4 weeks must have elapsed since prior chemotherapy or biological therapy, 6 weeks if the regimen included carmustine (BCNU) or mitomycin C; prior radiation therapy to the thoracic cavity, abdomen, or pelvis must be completed at least 3 months prior to registration; radiotherapy to any other site (including bone or brain metastases) must be completed at least 28 days prior to registrationEXCLUSIONPrior treatment with cabozantinib (XL184)The participant has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 4 weeks or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment; note: participants with prostate cancer currently receiving luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agentsThe participant has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)",(C16171 = NO OR C16171 = YES) AND (C16124= YES AND (C15187 = NO OR C15187 = YES)) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND C52200 = NO)NCI-2013-00805,NCT01244737,A Phase II Study of [18F] FLT for PET Imaging of Brain Tumors in Children,Inclusion,"Subjects may be enrolled at one of three time points in the clinical course of disease:* Study 1 (New Diagnosis): ** Pediatric patients with newly diagnosed primary central nervous system tumors undergoing surgical resection/biopsy within 21 days or who, within the prior 21 days, have undergone resection/biopsy with substantial residual (greater than half as assessed by the surgeon) tumor* Study 2 (Possible Tumor Recurrence): ** Pediatric patients with a history of treated primary central nervous system tumor, in whom standard imaging has raised concern for tumor recurrence; tumor tissue for histological analysis must be available from a biopsy/resection planned within the next 21 days or from a prior resection/biopsy if no current biopsy material is available* Study 3 (Response to Therapy): ** Pediatric patients with a primary central nervous system tumor who will be starting a new regimen (standard or experimental) of chemotherapy within 21 days, have not received radiation therapy during the past six months, and who will not be receiving radiation therapy during the first two cycles of chemotherapy",(C16169 = NO OR C16169 = YES) AND (C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES)NCI-2013-00826,NCT01841723,A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia,Exclusion,"Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopeciaChemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatmentPrior exposure to a Bruton's tyrosine kinase (BTK) inhibitor",(C16171 = YES OR C16168 = YES) AND (C16124 = YES AND C124801 = NO)NCI-2013-00858,NCT01849146,Phase I Study of AZD1775 (MK-1775) with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma,Inclusion/EXCLUSION,"EXCLUSIONPatients going on Arm 1 or combination dose cohort must not have received prior radiation therapy, chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, tumor infiltrating lymphocytes [TIL], lymphokine-activated killer [LAK] or gene therapy), or hormonal therapy for their brain tumor; glucocorticoid therapy is allowedPatients going on Arm 2 must have received planned treatment with radiation therapy and concomitant temozolomide at least 28 days but no more than 49 days prior to starting treatment on this study; patients must have received at least 80% of planned temozolomide and radiation therapy with no grade 3 or grade 4 toxicity (except lymphopenia) attributed to the temozolomide; Arm 2 patients may not have received any other prior chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor; prior Gliadel wafers are allowed; glucocorticoid therapy is allowedPatients may have an unlimited number of prior therapy regimensPatients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:* 12 weeks from the completion of radiation * 6 weeks from a nitrosourea chemotherapy* 3 weeks from a non-nitrosourea chemotherapy* 4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents * 2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., Tarceva, hydroxychloroquine, bevacizumab, etc.)EXCLUSIONPatients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs; patients previously treated with EIAED may be enrolled if they have been off the EIAED for 10 days or more prior to the first dose of AZD1775 (MK-1775)",C15477= YES OR C16171 = YES OR C16168 = YES OR (C16124 = YES AND C15187 = YES)NCI-2013-00875,NCT01901094,A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy,Inclusion,"Patients must have completed all chemotherapy prior to surgery; sandwich chemotherapy is not allowed (i.e. chemotherapy planned to be given after surgery); patients must have completed at least 4 cycles of neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen without evidence of disease progression in the breast or the lymph nodes* Note: Delays/dose modifications due to toxicities/adverse events are allowed as long as a minimum of 4 cycles of neoadjuvant chemotherapy is administered; more than 4 cycles of neoadjuvant chemotherapy (NAC) may be administered at the discretion of the treating medical oncologistNo prior ipsilateral axillary surgery, such as excisional biopsy of lymph node(s) or treatment of hidradenitisNo SLN surgery/excisional biopsy for pathological confirmation of axillary status prior to or during neoadjuvant chemotherapyNo more than 8 weeks of neoadjuvant endocrine therapy prior to the start of neoadjuvant chemotherapy",(C16171 = YES AND (C149 = YES OR C15451 = YES)) AND (C16175 = NO OR C16175 = YES)NCI-2013-00877,NCT01851369,A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas,Inclusion,"Patients must have completed any chemotherapy, radiation therapy, or biologic therapy >= 4 weeks (or 5 half-lives, whichever is shorter) prior to entering the study (6 weeks for nitrosoureas or mitomycin C); patients must be >= 2 weeks since any prior administration of a study drug in a phase 0 or equivalent study and >= 1 week from palliative radiation therapy; patients must have recovered to eligibility levels from prior toxicity or adverse events; treatment with bisphosphonates is permitted",C16171 = YES OR C15477= YES OR (C16124=YES AND C15187 = YES)NCI-2013-00890,NCT01935934,A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer,Exclusion/INCLUSION,"EXCLUSIONOther clinically significant disorders such as:* Active uncontrolled infection requiring intravenous systemic treatment within 14 days before the first dose of study treatment* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment* History of organ transplant* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment* History of major surgery as follows:** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications*** In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgeryPrior treatment with cabozantinibThe subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatmentThe subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from related toxicity to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)InclusionPrior therapy: Eligible subjects must have had 1 line of systemic cytotoxic treatment; this may be adjuvant therapy with documented progression within 12 months of completion, or 1 line of cytotoxic therapy for metastatic disease; NOTE: eligible patients are allowed up to 2 lines of systemic cytotoxic treatment, of whiMFPch only 1 line is allowed for metastatic disease; the acceptance of progression within 12 months of adjuvant is part inclusion to not require patient to re-challenge with chemotherapy (chemo) if they progressed soon after adjuvant therapy; prior hormonal therapy for metastatic/recurrent disease is also allowed; prior targeted therapy not directed against cMET or vascular endothelial growth factor (VEGF) pathways is allowed",(C16169 = NO OR C16169 = YES) AND (C16171= YES) AND (C16175 = NO OR C16175 = YES) AND (C16124 = YES AND (C143099= NO AND C93259= NO AND C52200 = NO)NCI-2013-00998,NCT01881867,A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved Therapy with Sipuleucel-T (ProvengeÂ®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC),Inclusion/EXCLUSION,"INCLUSIONPrior orchiectomy or must be on ongoing luteinizing hormone-releasing hormone (LHRH) agonist or antagonist (e.g., degarelix) therapyPatients receiving any other hormonal therapy, including any dose of megestrol acetate (Megace), Proscar (finasteride), any herbal product known to decrease prostate specific antigen (PSA) levels (e.g. saw palmetto, PC-SPES), or any systemic corticosteroid, must discontinue the agent for at least 30 days prior to study treatmentPrior local radiation therapy must be completed at least 30 days prior to enrollment and the patient must have recovered from all toxicityPrior â€œsystemicâ€ radiopharmaceuticals (strontium, samarium, radium 223 dichloride) must be completed >= 8 weeks prior to enrollmentEXCLUSION:Prior chemotherapy for castration resistant prostate cancer; neoadjuvant chemotherapy and chemotherapy given for hormone sensitive prostate cancer are allowedPrior investigational immunotherapyCurrent treatment with systemic steroid therapy (inhaled/topical steroids are acceptable); systemic corticosteroids must be discontinued for at least 30 days prior to first CYT107 injectionPatients who have received prior immunosuppressive therapy within 30 days prior to enrollmentPatients who have received hepatotoxic drugs less than 7 days prior to enrollmentPatients who have received prior biologic agents less than 30 days prior to enrollment",((C16124 = YES AND C15288 = YES) OR C15445 = YES) AND (C16175 = NO OR C16175= YES) AND (C15477= NO OR C15477= YES) AND (C16171 = NO OR C16171 = YES) AND (C16168 = NO OR C16168 = YES AND (C16124 = YES AND C49135 = NO))) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES))NCI-2013-01132,NCT01534598,Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid Tumors,Inclusion,"Patients must have completed any chemotherapy, radiation therapy, biologic therapy, or major surgery >= 4 weeks prior to enrollment (6 weeks for nitrosoureas or mitomycin C); patients must be >= 2 weeks since any prior administration of a study drug in a phase 0 or equivalent study, at the discretion of the principal investigator; patients must have recovered to eligibility levels from prior toxicity or adverse events; patients with bone metastases or hypercalcemia on intravenous (IV) bisphosphonate treatment prior to study entry may continue this treatment",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16169 = NO OR  C16169 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES))NCI-2013-01272,NCT01897012,A Phase 1 Trial of MLN8237 plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas,Exclusion,"Patients who have had chemotherapy, radiation therapy, or other investigational agents within 3 weeks prior to entering study, 6 weeks for nitrosoureas or mitomycin",C16171 = YES OR C15477= YES OR (C16124 = YES AND C49135 = YES)NCI-2013-01275,NCT01896999,"A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma",Inclusion,"PHASE I: Patients may have received prior brentuximab vedotin, but must not have received brentuximab vedotin within 6 months prior to registration, and must not have relapsed within 6 months of receiving previous brentuximab vedotin; patients may not have received prior nivolumab or programmed cell death protein 1 (PD1)/programmed cell death ligand 1 (PDL1) axis agents; patients in the nivolumab/brentuximab cohorts ONLY (D, E, F, Y) may have received prior ipilimumabPHASE I: Patients may have received other prior activating immunotherapies (i.e. checkpoint inhibitors), but must not have received them within 6 months prior to registration, and there must be no serious unresolved complication of therapy at the time of registration; for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)PHASE II: Patients must have relapsed after first line chemotherapy; may have relapsed after autologous or allogeneic stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; if status post allogeneic stem cell transplant, no active graft versus host disease and not on immunosuppressive therapyPHASE II: Patients may have received prior brentuximab vedotin, but must not have received brentuximab vedotin within 6 months prior to registration, and must not have relapsed within 6 months of receiving previous brentuximab vedotin; patients may not have received prior nivolumab or PD1/PDL1 axis agents; patients may not have received prior ipilimumabPHASE II: Patients may have received other prior activating immunotherapies, but must not have received them within 6 months prior to registration, and there must be no serious unresolved complication of therapy at the time of registration; for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)PHASE I: All prior therapy must have been completed at least 21 days prior to enrollment; no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowedPHASE I: No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma or any surgically- or radiation-cured malignancy continuously disease free for >= 5 years so as not to interfere with interpretation of radiographic responsePHASE II: No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma or any surgically- or radiation-cured malignancy continuously disease free for >= 5 years so as not to interfere with interpretation of radiographic responsePHASE II: All prior therapy must have been completed at least 21 days prior to enrollment; no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowedPHASE II: Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least 2 weeks prior to randomization are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study",(C16168 = NO OR (C16168 = YES AND (C16124 = YES AND (C68814 = NO AND C124946 = NO AND PD-L1 INHIBITOR = NO)))) OR C16171 = YES OR C16169 = YES OR C15477= YESNCI-2013-01320,NCT01902173,Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer,Inclusion,"Patients may have received prior radiation therapy; all adverse events associated with prior radiation therapy must have resolved to =< grade 1 prior to registrationPatients may have received prior surgery (for both the primary and stage IV disease); all adverse events associated with prior surgery must have resolved to =< grade 1 prior to registrationPatients progressing on a prior BRAF inhibitor-based therapy will be eligible, as are patients nave to BRAF inhibitor therapy; resistance to BRAF inhibitor-based therapy will be defined as progressive disease by RECIST 1.1 criteria while receiving therapy with a BRAF inhibitor (vemurafenib or dabrafenib, alone or in combination with a mitogen-activated protein kinase [MEK] inhibitor); this may be innate resistance (patients who never achieved a tumor response while on BRAF inhibitor therapy) or acquired resistance (progression after having a tumor response to BRAF inhibitor therapy); there will not be a period of break between progression on the prior BRAF inhibitor-based therapy and the start of dabrafenib, trametinib and GSK2141795Patients may have received prior systemic therapy (chemotherapy, immunotherapy, biologic therapy, or combination regimens); all adverse events associated with prior treatment must have resolved to =< grade 1 prior to registrationPatients must have received prior BRAF inhibitor therapy (e.g. dabrafenib, vemurafenib) within 56 days prior to registration; prior trametinib therapy is permitted; patients are not required to interrupt BRAF or MEK inhibitor therapy prior to the initiation of three agent combination therapy on study",(C15477= NO OR C15477= YES) AND (C16169 = NO OR C16169 = YES) AND (C16171 = NO OR C16171 = YES) AND (C16168 = NO OR C16168 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES))NCI-2013-01340,NCT01953588,ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study,Exclusion,"Treatment for this cancer including surgery, radiation therapy, chemotherapy, biotherapy, hormonal therapy or investigational agent prior to study entrySurgical axillary staging procedure prior to study entry; Note: fine needle aspiration (FNA) or core needle biopsy of axillary node is permittedHormone replacement therapy of any type, megestrol acetate, or raloxifene within one week prior to registration",(C16169 = NO OR (C16169 = YES AND C4872 = NO)) AND (C15477= NO OR (C15477= YES AND C4872 = NO)) AND (C16175 = NO OR (C16175 = YES AND C4872 = NO)) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES)) OR (C16124 = YES AND C15599 = YES)NCI-2013-01357,NCT01912625,A Phase 1 Study of Trametinib in Combination with Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer,Inclusion/EXCLUSION,"Prior thoracic radiation allowed only if there is minimal to no overlap with the treatment area estimated at the time of consultation, and there is no cumulative esophageal dose that exceeds more than 50% of the maximal acceptable dose toleranceEXCLUSIONAny major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to enrollmentCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:* Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if used as an appetite stimulant is allowed)* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis* Concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. Johnâ€™s wort, kava, ephedra [ma huang], gingko biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)","(C15477= NO OR (C15477= YES AND C25389 = NO)) AND (C16169 = NO OR C16169 = YES) AND (C16171 = NO OR C16171 = YES)"NCI-2013-01368,NCT01925131,"A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (including B-ALL, Mixed Phenotypic Leukemia and Burkitt's Leukemia)",Inclusion,"Patients must not have received prior treatment with inotuzumab ozogamicin; previous treatment with other anti-CD22 antibodies must have been completed at least 90 days prior to registrationPrior malignancy other than acute leukemia is allowed, provided it is in remission and there is no plan to treat the malignancy at the time of registrationPatients must be refractory or have relapsed following prior induction therapy; a standard induction regimen is defined as any program of treatment that includes vincristine and prednisone or dexamethasone, cytarabine/anthracycline, or high dose cytarabinePatients may have received prior allogeneic transplant or autologous transplant; however, patients with prior allogeneic bone marrow transplant will be eligible only if both of the following conditions are met:* The transplant must have been performed >= 90 days prior to registration* The patient must not have >= grade 2 acute graft versus host disease (GvHD) or either moderate or severe limited chronic GvHD within 14 days prior to registrationPatients must not have received any chemotherapy, investigational agents, or undergone major surgery within 14 days prior to registration with the following exceptions:* Monoclonal antibodies must not have been received for 1 week prior to registration* Chimeric antigen receptor (CAR) T-cells must not have been received for 28 days prior to registration* Steroids, hydroxyurea, vincristine, 6-mercaptopurine, methotrexate, thioguanine and intrathecal chemotherapy are permitted within any time frame prior to registration; Food and Drug Administration (FDA)-approved tyrosine kinase inhibitors may also be administered until 1 day prior to start of study therapy (cycle 1 [C1], day 1 [D1])* All drug-related toxicities must have resolved to =< grade 2",C16124 = YES AND (C71542 = NO AND C15746 = YES) AND (C16171 = YES OR (C16124 = YES AND C49135 = YES) OR C16169 = YES OR C60701 = YES)NCI-2013-01452,NCT00942877,Phase II Study of Cediranib (AZD2171) in Patients with Alveolar Soft Part Sarcoma,Inclusion,"Any prior therapy must have been completed >= 4 weeks prior to enrollment on protocol and the participant must have recovered to eligibility levels from prior toxicity; patients should be at least 6 weeks out from nitrosoureas and mitomycin C; prior radiation should have been completed >= 4 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (also referred to as an â€œearly phase I studyâ€ or â€œpre-phase I studyâ€ where a sub-therapeutic dose of drug is administered) at the principal investigator's (PIâ€™s) discretion, and should have recovered to eligibility levels from any toxicitiesAny degree of prior treatment is allowed, including other anti-angiogenic treatments (e.g., vascular endothelial growth factor receptor 2 [VEGFR2] inhibitors or bevacizumab); patients with no prior therapy are eligible, provided they have metastatic disease that is not curable by surgeryPrior therapy with anti-angiogenic agents is permitted",C16124 = YES OR C16124 = NO NCI-2013-01474,NCT01273155,Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction,Exclusion/INCLUSION,"EXCLUSIONPrior therapy with belinostatPatients with significant cardiovascular disease (New York Heart Association class III or IV cardiac disease), symptomatic congestive heart failure, myocardial infarction within the past 6 months, unstable angina, unstable arrhythmia or a need for anti-arrhythmic therapy (use of frequency adjusting medication for atrial fibrillation is allowed, if stable medication for at least last month prior to initiation of belinostat treatment and medication not listed as causing Torsades de Pointes), or evidence of acute ischemia on electrocardiogram (ECG); marked baseline prolongation of QT/corrected QT (QTc) interval, e.g., repeated demonstration of a QTc interval > 450 msec; long QT syndrome; concomitant use of drugs known to prolong the QT interval and/or cause Torsades de Pointes is not allowed during the study or within 2 weeks of study entry; these drugs should also be avoided for up to 4 weeks following discontinuation of study treatment; drugs that may be associated with Torsades de Pointes but lack substantial evidence will be allowed at the discretion of the PI (although it is preferable to substitute an alternate medication), and patients will be closely monitoredINCLUSIONNo radiation, major surgery, chemotherapy or biologic therapy within 4 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin C); >= 2 weeks since any prior administration of study drug in an exploratory investigational new drug (IND)/phase 0 study (also referred to as an â€œearly phase I studyâ€ or â€œpre-phase I studyâ€ where a subtherapeutic dose of drug is administered) at the principal investigator (PI)â€™s discretion; patients must have recovered to at least eligibility levels due to adverse events and/or toxicity of prior chemotherapy or biologic therapy",(C16124 = YES AND C48812 = NO) AND (C15477= NO OR C15477= YES) AND (C16169 = NO OR C16169 = YES) AND (C16171 = NO OR C16171 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES)) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES))NCI-2013-01475,NCT01273168,"Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors",Exclusion/INCLUSION,"EXCLUSIONPatients with a history of deep vein thrombosis must be on anti-coagulation therapy prior to enrollment; patients requiring prophylactic anti-coagulation are eligibleINCLUSIONPatients with breast cancer must have had at least one prior chemotherapy regimen for metastatic disease; additionally, patients with breast cancer must have received prior tamoxifen and/or aromatase inhibitor therapy (if post-menopausal) with at least one hormonal regimen in the metastatic setting; patients with human epidermal growth factor receptor 2 (HER2)+ breast cancer must have progressed after at least one prior HER2-directed regimen (trastuzumab, lapatinib) for metastatic disease* All other patients must have disease that has progressed following at least one line of standard therapy; prior therapy with tamoxifen is allowedPatients must have recovered to at least eligibility levels following any display of adverse events and/or toxicity due to prior chemotherapy or biologic therapy; they must not have had hormonal therapy, chemotherapy or biologic therapy within 4 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin C, or 7-hydroxystaurosporin [UCN-01]); patients must be >= 2 weeks since any prior administration of study drug in a phase 0 study (also referred to as an â€œearly phase I studyâ€ or â€œpre-phase I studyâ€ where a sub-therapeutic dose of drug is administered) at the principal investigator's (PIâ€™s) discretion; patients must be >= 4 weeks since any prior radiation or major surgery; however, patients receiving bisphosphonates or therapeutic anticoagulation are eligible for this trial",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES)) AND (C16175 = NO OR C16175 = YES) AND (C16169 = NO OR C16169 = YES)NCI-2013-01491,NCT01362803,A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; HYD Sulfate) in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN),Exclusion/INCLUSION,"EXCLUSIONPrior treatment with selumetinib or another specific mitogen-activated protein kinase (MEK)1/2 inhibitor (unless the subject meets criteria for re-treatment)Recent major surgery within a minimum of 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular accessINCLUSIONPatients with NF1 will only be eligible if complete tumor resection is not considered to be feasible without substantial risk or morbidity* Patients may be treated on this trial without having received prior medical therapy directed at their PN* There will be no limit to number of prior myelosuppressive regimen for PN or other tumor manifestations associated with NF1 such as optic glioma* Patients who have received previous investigational agents or biologic therapy, such as tipifarnib, pirfenidone, peginterferon alfa-2b (Peg-Intron), sorafenib, imatinib, or other targeted therapies are eligible for enrollment; at least 4 weeks must have elapsed since receiving medical therapy directed at the PN; patients who received prior medical therapy for their PN must have recovered from the acute toxic effects of all prior therapy to =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v)4 before entering this study* Growth factors that support platelet or white cell number or function must not have been administered within the 7 days prior to enrollment* At least 6 weeks must have elapsed prior to enrollment since the patient received any prior radiation therapy* At least 4 weeks must have elapsed since any surgeries, with evidence of good wound healing",(C16171 = NO OR C16171 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES)) AND (C15477= NO OR C15477= YES) AND (C16169 = NO OR C16169 = YES)NCI-2013-01496,NCT01391962,"A Phase II Trial in Which Patients with Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, with Cross-Over at Disease Progression",Inclusion/EXCLUSION,"INCLUSIONAny prior therapy must have been completed >= 4 weeks prior to enrollment on protocol and the participant must have recovered to eligibility levels from prior toxicity; patients should be at least 6 weeks out from nitrosoureas and mitomycin C; prior radiation should have been completed >= 4 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients who have had prior monoclonal antibody therapy must have completed that therapy at least 3 half-lives of the antibody or 6 weeks ago; patients who have received more than a cumulative dose of 350 mg/m^2 of doxorubicin may be enrolled at the discretion of the coordinating center principal investigator (PI) after consultation with a cardiologist and if screening echocardiogram is normalPatients with no prior therapy are eligible, provided they have metastatic disease that is not curable by surgeryThe following groups of patients are eligible after consultation with a cardiologist and at the coordinating center PIâ€™s discretion, provided they have New York Heart Association class II (NYHA) cardiac function on baseline echocardiogram (ECHO)/multigated acquisition scan (MUGA):* Those with a history of class II heart failure who are asymptomatic on treatment* Those with prior anthracycline exposure greater than a cumulative dose of 350 mg/m^2* Those who have received central thoracic radiation that included the heart in the radiotherapy portEXCLUSIONPatients must not have received prior treatment with any vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (e.g., cediranib, sunitinib, pazopanib, sorafenib); however, prior treatment with bevacizumab is allowed",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477=YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES)) AND (C16169 = NO OR C16169 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES))NCI-2013-01520,NCT01572493,A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human IL-15 (rhIL-15) in Adults with Metastatic Cancers,Inclusion/EXCLUSION,"INCLUSIONPatients must have recovered to =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4 from toxicity of prior chemotherapy or biologic therapy and must not have had prior chemotherapy or biologic therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C, 8 weeks for 7-hydroxystaurosporine [UCN-01])EXCLUSIONPatients who have received any systemic corticosteroid therapy within 3 weeks prior to the start of therapy with the exception of physiological replacement doses of cortisone acetate or equivalentPatients who have received any cytotoxic therapy, immunotherapy, antitumor vaccines, monoclonal antibodies or major surgery in the 4 weeks prior to the start of the studyHistory of autoimmune disease, with the exception of an autoimmune event associated with prior ipilimumab (anti-cytotoxic T-lymphocyte antigen 4 [CTLA-4]) therapy that has been completely resolved for more than 4 weeks",C16171 = NO OR C16171 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES)) AND (C16168 = NO OR C16168 = YES)NCI-2013-01568,NCT01748825,"A Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients with Advanced Refractory Solid Tumors",Inclusion,"Patients must have measurable disease or evaluable disease for the escalation phase; for the 6 additional patients enrolled at maximum tolerated dose (MTD) for further evaluation of pharmacokinetic (PK) and pharmacodynamic (PD) endpoints (Expansion Cohort A), for the 6-patient breast cancer gene (BRCA)-mutation expansion cohort, patients must have measurable disease; however, tumor biopsies are optional; for Expansion Cohort B, patients must have tumor amenable to biopsy (excisional or incision biopsies of skin or head and neck (H & N) lesions under visualization) and willingness to undergo a tumor biopsy or patient will be undergoing a procedure due to medical necessity during which the tissue may be collected, or tumor biopsy tissue from a previous research study or medical care is available for submission at registration; criteria for the submission of tissue are:* Tissue must have been collected within 3 months prior to registration* Patient has not received any intervening therapy for their cancer since the collection of the tumor sample* Tumor tissue must meet the minimum requirements outlinedPatients must have completed any chemotherapy, radiation therapy, surgery, or biologic therapy >= 3 weeks (or >= 5 half-lives, whichever is shorter) prior to entering the study; patients must be >= 2 weeks since any prior administration of a study drug in an exploratory investigational new drug (IND)/phase 0 study or >= 1 week from palliative radiation therapy; patients must have recovered to eligibility levels from prior toxicity or adverse events",C16171 = YES OR C15477= YES OR C16169 = YES OR (C16124 = YES AND C15187 = YES)  OR (C16124 = YES AND C49135 = YES)NCI-2013-01588,NCT01827384,Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors,Inclusion,"TREATMENT: Any prior therapy, radiotherapy, or major surgery must have been completed >= 3 weeks (> 6 weeks for nitrosoureas or mitomycin C) prior to enrollment on protocol, and the participant must have recovered to eligibility levels from prior toxicity; radiofrequency ablation (RFA) of localized lesions should have been performed >= 2 weeks prior to treatmentTREATMENT: Patients who have had prior treatment with any of the other investigational agents or combinations on this protocol are eligible but will not receive the same investigational agent (everolimus or trametinib) or combination (AZD1775/combination or veliparib/temozolomide); instead, patients will receive an investigational agent or combination prospectively identified to work on a different target in their tumorâ€™s mutation/aberrant pathwayTREATMENT: Patients who have received prior carboplatin or AZD1775 (MK-1775) (WEE1 inhibitor MK-1775) would not be excluded unless the two drugs were administered in combination; patients who have received prior carboplatin in combination with AZD1775 (MK-1775) would still be eligible to receive other study treatment regimens based on identified genetic mutation(s), other than carboplatin plus AZD1775 (MK-1775)TREATMENT: Patients who have had prior treatment with any PARP inhibitor in combination with temozolomide are ineligible to receive treatment with veliparib on this study; patients who have received prior temozolomide or PARP inhibitor with or without other chemotherapy/targeted agent aside from temozolomide should not be excluded solely because of receiving prior PARP inhibitor or temozolomide, unless it was in combination; patients who have received temozolomide with a PARP inhibitor in the past are eligible to participate but will not receive veliparib with temozolomide on study; such patients are eligible to receive other treatment regimens on study based on identified genetic mutationsTREATMENT: Patients who have received prior everolimus or other mechanistic target of rapamycin (mTOR) inhibitors or those with known intolerance or hypersensitivity to other rapamycin analogs (e.g., sirolimus, temsirolimus) would not be eligible to receive everolimus on study; if these patients have mutations of interest in pathways other than the phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (pI3K) pathway, they will be eligible to receive agents based on that mutationTREATMENT: Patients who have received prior mitogen-activated protein kinase kinase (MEK) inhibitors would not be eligible to receive trametinib DMSO on study; if these patients have mutations of interest in pathways other than the rat sarcoma (RAS) pathway, they will be eligible to receive agents based on that mutation",(C15477= NO OR C15477= YES) AND (C16169 = NO OR C16169 = YES) AND (C16171 = NO OR C16171 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES))NCI-2013-01602,NCT01922076,"A Phase 1 Study of AZD1775 (MK-1775, IND# 116495) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas",Inclusion/EXCLUSION,"INCLUSIONPatients must not have received any prior chemotherapy, radiation therapy, immunotherapy or bone marrow transplant for the treatment of DIPG; prior dexamethasone and/or surgery are allowedEXCLUSIONPatients must not receive metformin for at least 5 days prior to enrollment and for the duration of study treatmentPatients who have received a prior solid organ transplantation are not eligible",(C16171 = NO OR (C16171 = YES AND C94764 = NO)) AND (C15477= NO OR (C15477= YES AND C94764 = NO)) AND (C16168 = NO OR (C16168 = YES AND C94764 = NO)) AND (C16124 = YES AND (C15194 = NO OR (C15194 = YES AND C94764 = NO))) AND (C16169 = NO OR C16169 =YES) AND C130200 = NONCI-2013-01639,NCT01964300,Phase II Study of Peginterferon Alfa-2b (SYLATRON) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma,Inclusion/EXCLUSION,"INCLUSIONSubjects must have recovered from the acute toxicities of all prior therapy before entering this study; for those acute baseline adverse events attributable to prior therapy, recovery is defined as a toxicity grade =< 2, using Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.0, unless otherwise specified in the inclusion and exclusion criteriaMyelosuppressive chemotherapy:* Subjects must have received their last dose of known myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration or at least six (6) weeks if nitrosoureaSubjects must have received their last dose of investigational or biologic agent >= 7 days prior to study registration* In the event that a subject has received an investigational or biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to registration* If the investigational or biologic agent has a prolonged half-life (>= 7 days) then at least three (3) weeks must have elapsed prior to registrationSubjects must have completed at least 3 half-life periods from the last dose of monoclonal antibody prior to registration * Note: a list of half-lives of commonly used monoclonal antibodies is available on the Pediatric Brain Tumor Consortium (PBTC) website under Generic Forms and TemplatesEXCLUSIONPatients may not have received prior interferon, either systemic or intra-cystic",(C16171 = NO OR C16171 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES)) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES)) AND (C16168 = NO OR C16168 = YES) AND (C16124 = YES AND C20493 = NO)NCI-2013-01702,NCT02004275,"A Phase I/II Study of Pomalidomide, Dexamethasone, and Ixazomib vs.Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy",Inclusion,"No other chemotherapy or radiation therapy within 14 days prior to registrationPomalidomide naive and pomalidomide sensitive disease are allowed during phase I and phase II* Please note: Sensitivity to pomalidomide is defined as an MR or better to prior pomalidomide-based therapy that is maintained for >= 60 days from the last dose of therapyAt least 2 or more prior lines of systemic therapy for multiple myeloma* Please note: a line of therapy for myeloma is defined as 1 or more planned cycles of single agent or combination therapy, as well as a planned series of treatment regimens administered in a sequential manner (e.g. lenalidomide, bortezomib and dexamethasone induction therapy for 4 cycles followed by autologous stem cell transplantation and then lenalidomide maintenance therapy would be considered 1 line of prior therapy); a new line of therapy begins when a planned therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, disease relapse or treatment-related toxicity (e.g. a patient is progressing in the face of lenalidomide maintenance therapy and has bortezomib and dexamethasone added into their regimen); a new line of therapy also begins when a planned treatment-free interval is interrupted by the need to start treatment due to disease relapse/progression (e.g. a patient with relapsed myeloma achieves a partial response after a planned 8 cycles of cyclophosphamide, bortezomib and dexamethasone, enjoys an 8-month period off therapy but then experiences disease progression requiring re-initiation of therapy)",(C16171 = YES OR C15477= YES) AND (C16124 >= 2 AND C3242 = YES)NCI-2013-01703,NCT01940809,A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of Combined CTLA-4 Blockade and PD-1 Blockade for BRAF Mutant Melanoma,Exclusion/INCLUSION,"EXCLUSIONStudy participants who had prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathwaysStudy participants with a history of prior treatment with BRAF or MEK inhibitorsPrior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last 3 weeks; chemotherapy regimens without delayed toxicity within the last 2 weeks preceding the first dose of study treatmentINCLUSIONStudy participants must have completed any prior treatment at least 3 weeks prior to treatment on this protocol; prior treatments may have included chemotherapy however may not have included BRAF or MEK inhibitors or immunotherapies (interleukin-2, ipilimumab, anti-programmed death [PD]1 antibodies etc.) excluding vaccine therapy; prior treatment with interferon in the adjuvant setting is allowed, though prior treatment with ipilimumab in the adjuvant setting is not; prior radiation therapy is allowed though must have included no more than 3000 centigray (cGy) to fields including substantial marrow",(C16124 = YES AND T-CELL CO-STMULATOR = NO AND C143250 = NO AND  BRAF INHIBITOR= NO AND C69145= NO) AND (C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16168 = NO OR  C16168 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES))NCI-2013-01748,NCT01947023,A Phase 1 Study of Dabrafenib in Combination with Lapatinib in BRAF Mutant Thyroid Cancer,Exclusion/INCLUSION,"Prior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last 3 weeks; chemotherapy regimens without delayed toxicity within the last 2 weeks preceding the first dose of study treatmentINCLUSIONNo recent treatment for thyroid cancer as defined as:* No radioactive iodine therapy is allowed if given < 3 months prior to initiation of this protocol therapy; a diagnostic study using < 10 mCi of radioactive iodine (RAI) is not considered radioactive iodine therapy* No external beam radiation therapy < 4 weeks prior to initiation of therapy on this protocol* No chemotherapy or targeted therapy (e.g., tyrosine kinase inhibitor) is allowed < 4 weeks prior to the initiation of therapy",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16168 = NO OR C16168 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES))NCI-2013-01760,NCT01988571,Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT),Inclusion,Prior administration of anthracyclines is acceptable if therapy was completed > 6 months prior to study registration,N/ANCI-2013-01850,NCT01993810,Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC,Exclusion,"Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowablePrior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields",(C16171 = NO OR (C16171 = YES AND C2926 = NO)) AND (C15477 = NO OR (C15477= YES) AND C2926 = NO))NCI-2013-01999,NCT01946789,"A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Sarcoma, Colon, Non-Hodgkin Lymphoma, Non-small Cell Lung, Squamous Cell Head and Neck Cancer and Cutaneous Squamous Cell Cancer",Exclusion/INCLUSION,"EXCLUSIONPatients who have had chemotherapy, targeted therapy, or radiotherapy, and have not recovered from acute toxicity to their pretreatment baseline or to a grade 1 level within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study * Note: patients with chronic residual prior therapy-related toxicity (e.g. vitiligo, alopecia, low grade neuropathy), or in the consensus opinion of the Cancer Immunotherapy Trials Network (CITN)/Cancer Therapy Evaluation Program (CTEP) investigators would not impact the safety of the patient or the integrity of the study, are not excluded* Note: for resolution of autoimmune toxicity from prior immune therapy, patients must be off steroids for at least 30 days without relapse of autoimmune toxicity, or it must be at least 30 days from their last dose of infliximab or related immunosuppressive therapy without relapse of autoimmune toxicityImmunosuppressive therapy within 30 days prior to initiation of protocol therapyINCLUSIONPrior therapy requirements:* At least one prior therapy using an agent with the potential for prolonged remission (generally includes interleukin-2, checkpoint-blocking antibodies, or adoptive cell therapy)* At least 4 weeks from last dose of prior chemotherapy or immunomodulator therapy with resolution of the acute toxicities; for patients coming off molecularly-targeted therapy, at least 2 weeks since last dose and recovery from laboratory and constitutional toxicities; patients must meet entry eligibility criteria* At least 2 weeks from completion of prior radiation therapy with no residual radiation toxicities* At least 4 weeks from last dose of prior investigational therapy with recovery to meet baseline eligibility criteria* Not receiving any current anticancer therapy* Note: any patient whose tumors carry a B-Raf proto-oncogene, serine/threonine kinase (BRAF) v600 mutation should either be excluded, or may be included after experiencing progression following treatment with BRAF inhibitor regimen or if they consent and agree to forgo Food and Drug Administration (FDA)-approved therapies that increase median survival",(C16168 = NO OR C16168 = YES) AND (C16171 = NO OR C16171 = YES) AND (C15477 = NO OR C15477= YES) AND (C16124 = YES AND (C41161 = NO OR C41161 = YES))NCI-2013-02103,NCT01989585,"Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors",Exclusion/INCLUSION,"EXCLUSIONIn the phase I portion of the study, patients must not have received prior navitoclax, unless the patient received < 7 days of navitoclax lead-in on this or another study and had to stop for reasons other than toxicity or disease progression; in the phase II portion of the study, prior navitoclax, BRAF inhibitor and MEK inhibitor will be prohibitedPatients who have had immunotherapy, chemotherapy or radiotherapy within 14 days prior to the first dose of navitoclax, or prior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last 3 weeks prior to first dose of dabrafenib and/or trametinib; chemotherapy regimens without delayed toxicity within the last 2 weeks preceding the first dose of study treatment; biologics will not be allowed within 30 days prior to, or during, navitoclax administrationINCLUSIONPrior therapy is allowed:* Phase I: for patients enrolled in the phase I portion of the study, patients may have received any number of prior lines of therapy including treatment with a BRAF and/or mitogen-activated protein kinase kinase (MEK) inhibitor; prior navitoclax use will not be allowed, unless the patient received < 7 days of navitoclax lead-in on this or another study and had to stop for reasons other than toxicity or disease progression* Phase II: for patients enrolled in the phase II portion of the study, patients may have received prior immunotherapy (including high-dose interleukin [IL]-2, ipilimumab, nivolumab, and other anti-programmed cell death 1 [PD1]/programmed cell death 1 ligand 1 [PDL1] antibodies) or chemotherapy, however prior navitoclax, BRAF inhibitor and/or MEK inhibitor therapy will not be allowed",(C16124 = YES AND C64776 = NO) AND (C16171 = NO OR C16171 = YES) AND (C16168 = NO OR C16168 = YES) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES))NCI-2013-02167,NCT01979536,"A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)",Exclusion,"Intrathecal chemotherapy prior to enrollment is allowed for the current diagnosis of ALCL as long as adequate cerebrospinal fluid (CSF) is obtained prior to administration of the intrathecal chemotherapy and subsequently demonstrated to be negative for ALCLPatients who have received any prior cytotoxic chemotherapy for the current diagnosis of ALCL or any cancer diagnosed previously are not eligible",(C16124 = YES AND C15750 = YES AND C3720 = YES) OR C16171 = NONCI-2013-02238,NCT01896869,"A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination with Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer",Exclusion,"Patients who have been off of FOLFIRINOX more than 70 days prior to treatment on studyPatients who have had prior chemotherapy for metastatic pancreatic cancer (other than FOLFIRINOX); prior radiation is allowed; chemotherapy for non-metastatic disease is allowedPatients with a history of prior treatment with ipilimumab, anti-programmed cell death 1 (PD1) antibody, cluster of differentiation (CD)137 agonist or anti-CD 40 antibody",(C16171 = NO OR (C16171 = YES AND C9005 = YES AND C19151 = NO) OR (C16171 = YES AND C9005 = YES AND C19151 = YES AND C11764 = YES) OR (C16171 = YES AND C9005 = NO))  AND (C15477= NO OR C15477= YES)NCI-2013-02284,NCT02065687,"A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer",Inclusion,"Patients must NOT have received prior chemotherapy or targeted therapy, including chemotherapy used for radiation sensitization for treatment of endometrial carcinomaPatients may have received prior radiation therapy for treatment of endometrial carcinoma; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy; all radiation therapy must be completed at least 4 weeks prior to the first date of study therapyPatients may have received prior hormonal therapy for treatment of endometrial carcinoma; all hormonal therapy must be discontinued at least one week prior to the first date of study therapy",(C16171 = NO OR (C16171 = YES AND C7558 = NO)) AND (C15477= NO OR C15477= YES) AND (C16175 = NO OR C16175 = YES)NCI-2013-02288,NCT02059499,"A Randomized, Phase III Study of Intra-anal Imiquimod 2.5 % vs. Topical 5-Fluorouracil 5% vs. Observation for the Treatment of High-Grade Anal Squamous Intraepithelial Lesions in HIV-Positive Men and Women",Inclusion,"HSIL comprising 2 or more lesions, or anal HSIL in at least 2 octants, or anal HSIL that has recurred or is persistent after prior ablative treatmentNote: HSIL should be in the anal canal at either the squamocolumnar junction or distal anus on HRA at screening or randomization; the extent of HSIL should be based on available biopsy results and visual appearance",C16124 = NO OR C16124 = YESNCI-2014-00416,NCT02070549,A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction,Inclusion,"INCLUSIONPatients must have a histologically or cytologically confirmed solid malignancy that is metastatic or unresectable for which standard curative or palliative treatments do not exist or are no longer effective* Hepatocellular carcinoma (HCC) patients are not required to have histologically or cytologically confirmed malignancy, patients are considered eligible based on tumor markers and/or imaging assessment* Patients with the following tumor types will be excluded from the normal and mild cohorts:** Pancreatic cancer patients** Colorectal cancer patients ** BRAF V600E melanoma patients who have failed BRAF inhibitors*** Note: Patients with pancreatic cancer, colorectal cancer, and BRAF V600E melanoma patients who have failed BRAF inhibitors are allowed to enroll in the moderate and severe cohorts provided the patients: 1) sign a separate consent form which outlines the extremely limited activity observed in prior studies, and 2) are consented to the study by a protocol-specified designee who is not their longitudinal oncologistAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4 (CTCAE v4) grade =< 1 (except alopecia) at the time of enrollmentEXCLUSIONCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:* Other anti-cancer therapy while on study treatment; (Note: megestrol [Megace] if used as an appetite stimulant is allowed)* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis* The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. Johnâ€™s wort, kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)",C16124 = YES OR C16124 = NO NCI-2014-00461,NCT02079740,"An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects with KRAS or NRAS Mutation-Positive Advanced Solid Tumors",Inclusion/EXCLUSION,"INCLUSIONAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4 (CTCAE v 4) grade =< 1 (except alopecia) at the time of enrollment; this requirement to return to =< grade 1 does not apply to immune checkpoint inhibitor related endocrinopathies (e.g. thyroiditis, hypophysitis, etc.) that necessitate hormone replacement therapy including, but not limited to levothyroxine, cortisol, and testosteroneEXCLUSIONAny major surgery, extensive radiotherapy (> 15 days of treatment), chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to first dose of study treatment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to first dose of study treatmentCurrent use of a prohibited medication; the following medications or non-drug therapies are prohibited:* Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if used as an appetite stimulant is allowed)* Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy; prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis* The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. Johnâ€™s wort, kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)* The following concomitant medications are not allowed during navitoclax administration: warfarin, clopidogrel (Plavix), ibuprofen, tirofiban (Aggrastat), and other anticoagulants, drugs, or herbal supplements that affect platelet function are excluded, with the exception of low-dose anticoagulation medications (such as heparin) that are used to maintain the patency of a central intravenous catheter; aspirin will not be allowed within 7 days prior to the first dose of navitoclax or during navitoclax administration; however, subjects who have previously received aspirin therapy for thrombosis prevention may resume a low dose (i.e., maximum 100 mg QD) of aspirin if platelet counts are stable (>= 50,000/mm^3) through 6 weeks of navitoclax administration; all decisions regarding treatment with aspirin therapy will be determined by the investigator in conjunction with the medical monitor",(C16168 = NO OR C16168 = YES) AND (C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16169 = NO OR C16169 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES))NCI-2014-00615,NCT02097225,Phase I Study of AT13387 in Combination with Dabrafenib and Trametinib in Patients with BRAF-Mutant Melanoma and Other Solid Tumors,Inclusion,"Prior therapy is allowed; patients may have received any number of prior lines of therapy, including treatment with a BRAF and/or MEK inhibitor; all prior anti-cancer treatment-related toxicities must be less than or equal to grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.0; National Cancer Institute [NCI], 2009) at the time of enrollment",C16124 = YESNCI-2014-00616,NCT02152982,A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation,Inclusion,"Prior treatment:* Must have completed standard radiotherapy and concomitant TMZ therapy as defined and determined by the study oncologist* Besides concomitant TMZ with radiation, no other therapy (neo-adjuvant or adjuvant) can be given prior to study registration, including chemotherapy (also including Gliadel/carmustine [BCNU] wafers), biologics, immunotherapy, radiation therapy; the only exception is the Optune device (NovoTTF-100A), which may be started any time after end of radiation therapy up through the initiation of Cycle 1; intent to use Optune must be declared at registration for stratification",(C15477= NO OR (C15477= YES AND C1244 = YES)) AND (C16171 = NO AND (C16124 = YES AND C15187 = NO) AND C16168 = NO) OR (C16124= YES AND C125103 = YES)NCI-2014-00620,NCT02101775,"A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination with AZD 1775 (MK 1775) in Women with Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers",Inclusion/EXCLUSION,"INCLUSIONPatients must have completed any prior chemotherapy, radiotherapy or major surgery at least 4 weeks before receiving study treatment; ongoing toxicities related to treatment must be =< grade 1 and patients with grade 2 alopecia or peripheral neuropathy can also be included; palliative radiation to < 10% of bone marrow is permissible if completed within one week of commencing study treatment as long as the toxicities secondary to palliative radiotherapy are limited to grade 1; the lesions that have received radiation treatment immediately before will be excluded as target lesions; previously irradiated lesions can be considered as targeted lesions, as long as there is prove of radiological progressionEXCLUSIONPatients who previously received gemcitabine for the treatment of recurrent disease",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16169 = NO OR  C16169 = YES) AND (C16124 = YES AND (C66876 = NO OR (C66876 = YES AND C38155 = NO))NCI-2014-00623,NCT02143726,Randomized Phase II Study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer,Inclusion,"Radioactive iodine (RAI)-refractory disease defined as 1 or more of the following:* Patients who have received greater than 600 mCi of radioactive iodine in their lifetime OR* RAI-avid metastatic lesion which remained stable in size or progressed despite RAI treatment within 9 months of RAI treatment OR* 10% or more increase in serum thyroglobulin (on thyroid-stimulating hormone [TSH]-suppression) within 9 months of RAI treatment OR* Index metastatic lesion non-RAI avid on a diagnostic RAI scan OR* Presence of fluorodeoxyglucose (FDG) avid metastatic lesions on positron emission tomography (PET)/CT scan (standardized uptake values [SUV]max > 5 of any single lesion)Prior treatment:* Patients may have received prior radiation therapy to index lesions >= 28 days prior to registration on this protocol if there has been documented progression by RECIST criteria; prior radiation therapy to the non-index lesions is allowed if >= 28 days prior to registration on this protocol* Prior RAI therapy is allowed if >= 90 days prior to registration on this protocol and evidence of progression (as defined above) has been documented in the interim (a diagnostic study using < 10 mCi of RAI is not considered RAI therapy)* Prior chemotherapy is allowed if >= 28 days prior to registration on this protocol* Patient may have received any number of prior lines of therapy* No prior use of sorafenib or an mammalian target of rapamycin (mTOR) (including phosphoinositide 3-kinase [PI3k] or protein kinase B [AKT]) inhibitor for the treatment of thyroid cancerConcomitant medications:* Chronic concomitant treatment with strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) is not allowed on this study; patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study* Chronic concomitant treatment with strong CYP3A4 inducers is not allowed; patients must discontinue the drug 14 days prior to the start of study treatment* Patients requiring anticoagulation must be on stable dose of medication prior to registration",(C15477= YES OR C16171 = YES) AND (C16124 = YES AND (C2201 = NO OR (C2201 = YES AND C4815 = NO)))NCI-2014-00627,NCT02154490,A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map),Inclusion,"Patients must either be eligible to be screened at progression on prior treatment or to be pre-screened prior to progression on current treatment; patients will either consent to the screening consent or the pre-screening consent, not both; these criteria are:* Screening at progression on prior treatment: to be eligible for screening at progression, patients must have received at least one line of systemic therapy for any stage of disease (stages I-IV) and must have progressed during or following their most recent line of therapy; for patients whose prior systemic therapy was for stage I-III disease only (i.e. patient has not received any treatment for stage IV or recurrent disease), the prior systemic therapy must have been a platinum-based chemotherapy regimen and disease progression on the platinum-based chemotherapy must have occurred within one year from the last date that patient received that therapy; for patients whose prior therapy was for stage IV or recurrent disease, the patient must have received at least one line of a platinum-based chemotherapy regimen or checkpoint inhibitor therapy (e.g. nivolumab or pembrolizumab)* Pre-screening prior to progression on current treatment: to be eligible for pre-screening, current treatment must be for stage IV or recurrent disease and patient must have received at least one dose of the current regimen; patients must have previously received or currently be receiving a platinum-based chemotherapy regimen or checkpoint inhibitor therapy (e.g. nivolumab or pembrolizumab); patients on first-line platinum-based treatment are eligible upon receiving cycle 1, day 1 infusion; Note: patients will not receive their sub-study assignment until they progress and the S1400 Notice of Progression is submittedPatients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable",C16124= YES NCI-2014-00629,NCT02101788,A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer,Inclusion,All prior treatment-related toxicities must be CTCAE v4 grade =< 1 (except alopecia) at the time of randomization,C16124 = YESNCI-2014-00631,NCT02101853,Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL),Inclusion,"With the exception of intrathecal chemotherapy (methotrexate strongly preferred; cytarabine is permissible) administered at the time of the required diagnostic lumbar puncture to establish baseline CNS status, patient has not received prior relapse-directed therapy (i.e., this protocol is intended as the INITIAL treatment of first relapse)Patient has not had prior treatment with blinatumomab",(C16171 = YES AND C38155 = NO) AND (C16124= YES AND C62528 = NO)NCI-2014-00634,NCT02101905,Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma,Inclusion/EXCLUSION,"INCLUSIONPatients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:* 12 weeks from the completion of radiation * 6 weeks from a nitrosourea chemotherapy* 3 weeks from a non-nitrosourea chemotherapy* 4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents* 4 weeks from the last treatment with bevacizumab* 2 weeks from administration of a non-cytotoxic, FDA-approved agent other than bevacizumab (e.g., hydroxychloroquine, etc.)EXCLUSIONPatients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs; patients previously treated with EIAED may be enrolled if they have been off the EIAED for 10 days or more prior to the first dose of lapatinibPatients with prior therapy with EGFR inhibitors are ineligible; patients with prior EGFRvIII vaccine are eligible if recurrent tumor is positive for EGFR gene amplification",(C15477= YES OR C16171 = YES OR (C16124 = YES AND C49135 = YES)) AND (C16124 = YES AND C2167= NO)NCI-2014-00636,NCT02135419,ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study,Exclusion,History of prior treatment or removal of anal HSIL,(C16124 = NO OR (C16124 = YES AND C8336 = YES AND C43362 = NO) OR (C16124 = YES AND C8336 = NO AND C43362 = NO) OR (C16124 = YES AND C8336 = NO AND C43362 = YES)NCI-2014-00643,NCT02101944,Pilot Trial Evaluating Viral Protein Production from the Combination of Reolysin and Carfilzomib in Multiple Myeloma,Exclusion,"Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study; patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids (e.g., prednisone up to but no more than 10 mg by mouth daily or its equivalent) for symptom management and comorbid conditions; doses of corticosteroid should be stable for at least 7 days prior to study treatment",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES)NCI-2014-00644,NCT02032823,"A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy",Inclusion/EXCLUSION,"INCLUSIONCompleted at least 6 cycles of neoadjuvant or adjuvant chemotherapy containing anthracyclines, taxanes or the combination of both; prior platinum as potentially curative treatment for prior cancer (e.g. ovarian) or as adjuvant or neoadjuvant treatment for breast cancer is allowed; (for neoadjuvant patients all chemotherapy should be delivered prior to surgery; no further cycles of chemotherapy post-surgery are allowed)EXCLUSIONAny previous treatment with a PARP inhibitor, including olaparib and/or known hypersensitivity to any of the excipients of study treatment",C16171 = YES AND (C16124 = YES AND C62554 = NO)NCI-2014-00686,NCT02152137,"A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination with Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer",Inclusion,"There is no limit to the number of prior lines of treatment a patient has receivedNo treatment with chemotherapy, radiation therapy, immunotherapy, biological therapy, hormonal therapy, or other thiazolidinediones (TZDs) =< 21 days before study registration",C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16168 = NO OR C16168 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES) AND (C16175 = NO OR C16175 = YES)NCI-2014-00688,NCT02379416,Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults with Refractory Solid Tumors,Inclusion,"Patients must have histologically confirmed solid tumors that have progressed on standard therapy known to prolong survival or for which no standard treatment options existPatients must have completed radiation therapy or major surgery >= 3 weeks, or biologic therapy or chemotherapy >= 5 half-lives or 3 weeks, whichever is shorter (6 weeks for nitrosoureas and mitomycin C) prior to entering the study; patients must be >= 2 weeks since any prior administration of a study drug in a phase 0 or equivalent study and be >= 1 week from palliative radiation therapy; patients must have recovered to eligibility levels from prior toxicity or adverse events; treatment with bisphosphonates is permitted",C15477= YES OR C16169 = YES OR (C16124 = YES AND C15187 = YES) OR (PRIOR = YES AND C49135 = YES)NCI-2014-00712,NCT02112916,A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy),Exclusion,"Patients must not have received any cytotoxic chemotherapy for either the current diagnosis of T-ALL, T-L-Ly or for any cancer diagnosis prior to the initiation of protocol therapy on AALL1231, with the exception of:* Steroid pretreatment: prednisone or methylprednisolone for =< 120 hours (5 days) in the 7 days prior to initiating induction chemotherapy or for =< 336 hours (14 days) in the 28 days prior to initiating induction chemotherapy; prior exposure to ANY steroids that occurred > 28 days before the initiation of protocol therapy does not affect eligibility; the dose of prednisone or methylprednisolone does not affect eligibility* Intrathecal cytarabine (the CNS status must be determined based on a sample obtained prior to administration of any systemic or intrathecal chemotherapy, except for steroid pretreatment) system chemotherapy must begin with 72 hours of this IT therapy; or* 600 cGy of chest irradiation, if medically necessary** Pre-treatment with dexamethasone in the 28 days prior to initiation of protocol therapy is not allowed with the exception of a single dose of dexamethasone use during sedation to prevent or treat airway edema; inhalation steroids and topical steroids are not considered pretreatment",(C16171 = NO OR (C16171 = YES AND C408 = YES AND C15750 = YES)) AND (C15477= NO OR (C15477= YES AND C25389 = YES))NCI-2014-00746,NCT02115282,A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer,Inclusion,"Patients must have adequate hematologic, liver and renal function =< 28 days prior to randomization* NOTE: It is preferred that laboratory values for eligibility be assessed after the last dose of prior treatment, especially in cases where most-recent treatment prior to study entry is chemotherapyPatients must NOT be receiving valproic acid, an histone deacetylase (HDAC) inhibitor, and may not have previously received any HDAC inhibitor prior to enrollment (e.g. valproic acid, entinostat, vorinostat) unless discussed with the study chair; patients must not have received prior HDAC therapy for the treatment of their malignancyPatients may be treated with bone modifying agents such as bisphosphonates or RANK-ligand agents (e.g. denosumab) per American Society of Clinical Oncology (ASCO) guidelines; whenever possible, patients requiring bone modifying agents should start treatment >= 7 days prior to study therapy and should continue the same agent throughout study unless clinically compelled to changePatients may have received only one prior chemotherapy regimen for metastatic disease provided treatment was completed >= 3 weeks prior to randomizationPatients must meet at least one of the following criteria:* Disease progression any time after non-steroidal aromatase inhibitor (AI) use in the advanced disease setting* Relapse while on or within =< 12 months of end of adjuvant non-steroidal AI therapy with or without prior endocrine therapy for advanced disease* NOTE: In either setting, treatment with any prior endocrine therapy must be completed >= 2 weeks prior to course 1 day 1 (C1D1) of study treatment with the exception of exemestane which is permitted in the advanced disease setting within =< 4 weeks immediately prior to C1D1; prior adjuvant exemestane is allowed if the disease free interval is > 12 months from the discontinuation of exemestane; prior faslodex, everolimus, palbociclib or other cyclin-dependent kinase (CDK) inhibitor (e.g. ribociclib, abemaciclib) use are allowed and must have been completed >= 2 weeks prior to C1D1; failure to adhere to this washout guideline will result in a protocol violation",(C16124 = YES AND (C1946 = NO OR (C1946 = YES AND C4872 = NO))) AND (C16175 = NO OR C16175 = YES) AND (C16171 = NO OR C16171 = YES)NCI-2014-00816,NCT02211755,Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors,Inclusion,"Patients must have completed any chemotherapy, radiation therapy, or biologic therapy >= 3 weeks prior to entering the study; patients must be >= 2 weeks since any prior administration of a study drug in a phase 0 or equivalent study; patients must have recovered to eligibility levels from prior toxicity or adverse events; treatment with bisphosphonates is permittedPatients must have histologically confirmed solid tumors that have progressed on standard therapy known to prolong survival or for which no standard treatment options exist",C16171 = YES OR C15477= YES OR (C16124 = YES AND C15187 = YES) OR (C16124 = YES AND C49135 = YES)NCI-2014-00907,NCT02133183,Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients,Inclusion/EXCLUSION,"INCLUSIONPatients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:* 12 weeks from the completion of radiation * 6 weeks from a nitrosourea chemotherapy or mitomycin C* 3 weeks from a non-nitrosourea chemotherapy* 4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents * 2 weeks from administration of a non-cytotoxic, FDA-approved agent except bevacizumab/vascular endothelial growth factor receptor (VEGFR) inhibitors (e.g., erlotinib, hydroxychloroquine, etc.)* 6 weeks from bevacizumab/VEGFR inhibitorsEXCLUSIONPatients may not have had prior treatment with mTOR, peptidase inhibitor 3, skin-derived (PI3) kinase or Akt inhibitorsPatients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs; patients previously treated with EIAED may be enrolled if they have been off the EIAED for 10 days or more prior to the first dose of MLN0128 (TAK-228)Patients who have initiated treatment with bisphosphonates less than 30 days prior to the first administration of MLN0128 (TAK-228) are ineligible; concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least 30 days prior to the first administration of MLN0128 (TAK-228)Subjects taking strong CYP3A4 and CYP2C19 inhibitors and/or inducers should be considered with caution; alternative treatments that are less likely to affect MLN0128 (TAK-228) metabolism, if available, should be considered; if a subject requires treatment with 1 or more of the strong CYP3A4 and CYP2C19 inhibitors and/or inducers, the study doctor should be consulted",(C15477= YES OR C16171 = YES OR (C16124 = YES AND C49135 = YES)) AND (C16124 = YES AND (C2201= NO AND C105391 = NO AND skin-derived (PI3) kinase or Akt inhibitors =NO))NCI-2014-01028,NCT02249949,"A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients with Previously Treated, Unrespecatble Myxoid Liposarcoma",Inclusion,"Progression on at least one prior systemic chemotherapy for advanced, unresectable or metastatic disease; prior adjuvant or neoadjuvant therapy is not included as prior systemic chemotherapy unless treatment occurred within the 6 months prior to study enrollment* There is no limit to the number of prior lines of treatment a patient has received* No treatment with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation =< 28 days before study registration; no treatment with nitrosourea or mitomycin =< 42 days before study registration* Patients should have resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, grade 1 or lessPatients with diabetes mellitus requiring concurrent treatment with insulin or thiazolidinedione (TZD) oral agents are not eligible",C16171 = YES OR C16168 = YES OR C15477= YES OR (C16124 = YES AND C49135 = YES) OR (C16124 = YES AND C15187 = YES)NCI-2014-01047,NCT02143414,"A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Postive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL with Known or Presumed Activating Dastinib-Sensitive Mutations or Kinase Fusions (DSMKF)",Inclusion,"In the event that the patientâ€™s bone marrow blast count is >= 50% blasts, patients may be registered but should receive steroids for 3-5 days in order to reduce tumor burden prior to blinatumomab administration, as follows* Prephase treatment with dexamethasone (10-20 mg/m^2) for 3-5 days is required for patients with bone marrow blasts >= 50%, peripheral blood blasts 15,000/uL or higher, or elevated lactate dehydrogenase (LDH) suggesting rapidly progressive disease per investigator opinion** Pre-treatment should conclude at least 24 hours prior to the first dose of blinatumomab (although additional dexamethasone is automatically given as a pre-med prior to the first dose); at the time of first infusion of blinatumomab, the absolute peripheral blast count should be < 25,000/uL** Note: For the purposes of the study, day 1 of the cycle will be the first day of blinatumomab administrationPatients must not have received any prior chemotherapy, radiation therapy, or other therapy for the treatment of ALL (other than those noted below) and must not be receiving any immunosuppressive therapy; patients may not have received any prior investigational therapy within 28 days prior to registration; patients must not have received any monoclonal antibody therapy within 42 days of registration; patients may have received the following within any time prior to registration: low dose chemotherapy-including: cyclophosphamide 1 g/m^2, oral 6-mercaptopurine, or oral methotrexate (other low dose chemotherapy may be allowable, however any other options not listed here should be confirmed with the study chairs), TKI therapy, steroids, hydroxyurea, leukapheresis, intrathecal chemotherapy or vincristine (vincristine sulfate)Patients must not have systemic fungal, bacterial, viral or other infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)",(C16171 = NO OR C16171 = YES) AND (C16168 = NO OR C16168 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES))NCI-2014-01072,NCT02179086,Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma,Exclusion,Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted,C16124 = YES AND (C2487 = NO AND C62722= NO AND C38231 = NO)NCI-2014-01106,NCT02152995,"A Phase 2 Study of Trametinib in Combination with Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers",Inclusion,"All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v 4.0) grade =< 1 (except alopecia); grade 2 prior treatment related toxicities may be allowed after discussion with the principal investigatorNo recent treatment for thyroid cancer as defined as:* No prior RAI therapy is allowed < 6 months prior to initiation of therapy on this protocol; a diagnostic study using < 10 millicurie (mCi) of RAI is not considered RAI therapy* No external beam radiation therapy < 4 weeks prior to initiation of therapy on this protocol; (previous treatment with radiation for any indication is allowed if the investigator judges that the previous radiation does not significantly compromise patient safety on this protocol)* No chemotherapy or targeted therapy (e.g., tyrosine kinase inhibitor) is allowed < 4 weeks prior to the initiation of therapy on this protocol",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES)NCI-2014-01107,NCT02159989,Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination with Ziv-Aflibercept (NSC# 724770) in Patients with Advanced Cancers,Exclusion/INCLUSION,"EXCLUSIONHave initiated treatment with bisphosphonates less than 30 days prior to the first administration of MLN0128 (TAK-228); concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least 30 days prior to the first administration of MLN0128 (TAK-228)INCLUSIONPatients must be >= 4 weeks beyond treatment of any chemotherapy, other investigational therapy, hormonal, biological, targeted agents or radiotherapy, and must have recovered to =< grade 1 toxicity or previous baseline for each toxicity; exception: patients may have received palliative low dose radiotherapy to the limbs 1-4 weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field",(C16171 = NO OR C16171 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES) AND (C16175 = NO OR  C16175 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES)) AND (C15477= NO OR C15477= YES)NCI-2014-01118,NCT02142803,A Phase 1 Study of MLN0128 and Bevacizumab in Patients with Recurrent Glioblastoma and Other Solid Tumors,Inclusion/EXCLUSION,"INCLUSIONSolid tumor patients must be off corticosteroids prior to registration; if GBM patient is receiving corticosteroids, patient must be on a stable or decreasing dose of corticosteroids for at least 5 days prior to baseline magnetic resonance imaging (MRI) or computed tomography (CT); if steroids are added or the steroids dose is increased between the date of the screening MRI or CT and the start of treatment, a new baseline MRI or CT is requiredFor stage 1 (all patients) and dose expansion (stage 2) endometrial and ovarian cancer cohorts, participants are allowed following unlimited prior therapy; for stage 2 GBM participants, no more than 2 prior relapses are allowed; for these patients, relapse is defined as progression following initial therapy (i.e. radiation +/- chemo if that was used as initial therapy) or a subsequent therapy; the intent therefore is that GBM patients enrolling onto stage 2 had no more than 3 prior therapies (initial and treatment for 2 relapses); if the patient had a surgical resection for relapsed disease and no anti-cancer therapy was instituted for up to 12 weeks, and the patient undergoes another surgical resection, this is considered to constitute 1 relapse* NOTE: for participants who had prior therapy for a low-grade glioma, the surgical diagnosis of glioblastoma will be considered the first relapse; therefore, these participants may have had more than 3 prior therapiesPatients must have recovered from clinically significant toxicity of prior therapy to grade =< 1 or pre-treatment baseline; the following intervals from previous treatments are required prior to day 1 of study therapy:* 12 weeks from the completion of radiation for recurrent GBM unless there is surgical diagnosis of recurrence or a new lesion that was not previously radiated* 6 weeks from a nitrosourea chemotherapy* 3 weeks from a non-nitrosourea chemotherapy* 4 weeks from an investigational agent (not Food and Drug Administration [FDA] approved) (or 5 half lives, whichever is shorter)* 2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., erlotinib, hydroxychloroquine, etc.) (or 5 half lives, whichever is shorter)EXCLUSIONSubjects taking strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) and cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) inhibitors and/or inducers should be considered with caution; alternative treatments that are less likely to affect MLN0128 metabolism, if available, should be considered; if a subject requires treatment with 1 or more of the strong CYP3A4 and CYP2C19 inhibitors and/or inducers, the principal investigator should be consultedFor stage 2 GBM participants, no prior treatment with bevacizumab/vascular endothelial growth factor receptor (VEGFR) inhibitors; prior treatment with bevacizumab/VEGFR inhibitors is allowed in stage 1 for all participants, as well as stage 2 endometrial and ovarian cancer participantsFor all stage 2 participants, no prior treatment with mTOR, PI3 kinase or Akt inhibitors; prior treatment with mTOR, PI3 kinase or Akt inhibitors allowed in stage 1 only",((C16124 = YES AND C15370 = NO) OR (16124 = YES AND C15370 = YES AND C3058= YES)) AND (C16171 = YES OR C15477 = YES OR C16169 = YES OR (C16124 = YES AND C49135 = YES))NCI-2014-01507,NCT02201992,A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein,Inclusion,"Patients must have completed any prior adjuvant chemotherapy or radiation therapy 2 or more weeks (6 or more weeks for mitomycin and nitrosoureas) prior to randomization and be adequately recovered at the time of randomization* NOTE: Patients taking low dose methotrexate for non-malignant conditions and other cytotoxic agents for non-malignant conditions are allowed to continue treatment while on study* NOTE: Neo-adjuvant chemotherapy or radiation therapy for the resected lung cancer is not permittedNo prior treatment with crizotinib or another ALK inhibitor",(C16171 = NO OR (C16171 = YES AND C4878 = NO)) AND (C15477= NO OR (C15477= YES AND C4878 = NO)) AND (C16124 = YES AND (C74061 = NO AND C141136 = NO))NCI-2014-01696,NCT02375204,"A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors",Inclusion,"No prior treatment with high-dose chemotherapy (defined as treatment utilizing stem cell rescue)No more than one prior line of chemotherapy for GCT (other than the 1 cycle of salvage chemotherapy)* Definition of one line of chemotherapy: One line of therapy can in some cases consist of 2 different cisplatin-based treatment combinations, provided there is no disease progression between these two regimens; for example, a patient could have received 2 cycles of bleomycin, etoposide, and cisplatin (BEP) followed by 2 cycles of cisplatin, ifosfamide, and etoposide (VIP) if the switch from BEP to VIP was made due to pulmonary toxicity rather than disease progression; this would be considered 1 line of prior therapy; in addition, if a patient received 4 cycles of BEP and then underwent post-chemotherapy resection of residual tumor with findings of residual viable non-teratomatous GCT, and subsequently received 2 additional cycles of adjuvant chemotherapy (etoposide, cisplatin [EP] or an alternate regimen such as VIP) in the absence of disease progression, this would also be considered 1 regimen; however, if any change in therapy is prompted by tumor progression including rising tumor markers, this is considered to represent 2 lines of prior treatment* Prior treatment with carboplatin as adjuvant therapy is allowed, provided patients meet other eligibility criteria (e.g., the patient has also received 3-4 cycles of cisplatin-based chemotherapy)* Prior treatment with 1-2 cycles of BEP or EP as adjuvant chemotherapy for early stage GCT is allowed, provided the patient also received 3-4 cycles of BEP or EP again at relapse; patients treated with 3-4 cycles of VIP at relapse following 1-2 cycles of BEP/EP are not eligible as this would be considered more than 1 line of prior therapyMust have received 3-6 cycles of cisplatin-based chemotherapy as part of first-line (initial) chemotherapy; prior cisplatin, vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide, etoposide (POMBACE), carboplatin, bleomycin, vincristine, and cisplatin-bleomycin, etoposide, and cisplatin (CBOP-BEP), or methotrexate, actinomycin-D, etoposide, cisplatin, peg filgrastim (GAMEC) are allowed; Note: for patients requiring immediate treatment, 1 cycle of conventional-dose salvage chemotherapy is allowed; therefore, these patients may have received 7 prior cycles of chemotherapy; 6 cycles as part of first-line chemotherapy and 1 cycle of salvage conventional chemotherapyNo concurrent treatment with other cytotoxic drugs or targeted therapies","(C16171 = YES AND C376 = YES) AND (C15477= NO OR C15477= YES)"NCI-2014-01747,NCT02224781,A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma,Inclusion,"Patients must have discontinued chemotherapy, immunotherapy or other investigational agents used in the adjuvant setting >= 4 weeks prior to entering the study and recovered from adverse events due to those agents; mitomycin and nitrosoureas must have been discontinued at least 6 weeks prior to entering the study; patients must have discontinued radiation therapy >= 2 weeks prior to entering the study and recovered from any adverse events associated with treatment; prior surgery must be >= 4 weeks from registration and patients must be fully recovered from post-surgical complicationsPatients may have had prior systemic therapy in the adjuvant setting; however this adjuvant treatment must not have included a CTLA4 or PD1 pathway blocking antibody or a BRAF/MEK inhibitor; also, patients may not have had any prior systemic treatment for advanced (measurable metastatic) diseasePatients must have discontinued radiation therapy >= 2 weeks prior to registering to Step 2 of the study and recovered from any adverse events associated with treatment; prior surgery must be >= 2 weeks from registration to Step 2 and patients must be fully recovered from post-surgical complications",(C16171 = NO OR (C16171 = YES AND C19151 = NO)) AND (C16168 = NO OR (C16168 = YES AND C19151 = NO)) AND (C16124 = YES AND (C49135 = NO OR (C49135 = YES AND C19151 = NO))) AND (C15477=NO OR C15477= YES) AND (C16169 = NO OR C16169 = YES) AND (C16124 = YES AND (C128036 = NO AND C124946 = NO AND BRAF INHIBITOR= NO AND C69145= NO)NCI-2014-01810,NCT02364557,A Phase IIR/III Trial of  Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer,Exclusion,Prior palliative radiation treatment for metastatic disease to be treated on the protocol (including radiopharmaceuticals),C15477= NO OR (C15477= YES AND C3995= NO)NCI-2014-01820,NCT02445391,A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy,Inclusion,"ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Patients must have completed treatment with any investigational agent >= 30 days prior to randomization for protocol therapy, if applicableMust have completed definitive resection of primary tumor* Negative margins for both invasive and ductal carcinoma in situ (DCIS) are desirable, however patients with positive margins may enroll if the treatment team believes no further surgery is possible and patient has received radiotherapy; patients with margins positive for lobular carcinoma in situ (LCIS) are eligible* Either mastectomy or breast conserving surgery (including lumpectomy or partial mastectomy) is acceptable* Sentinel node biopsy either pre or post neoadjuvant chemotherapy (i.e. at the time of definitive surgery) are allowed; axillary dissection is encouraged in patients with lymph node involvement, but is not mandatoryRadiotherapy may be given before or after protocol treatment per standard of care guidelines; when radiotherapy is planned prior to protocol treatment administration, patients may be registered and screened while receiving radiation* Post-mastectomy radiotherapy is required for all patients with the following:** Primary tumor >= 5 cm (prior to neoadjuvant chemotherapy [clinically] or at the time of definitive surgery) or involvement of 4 or more lymph nodes at the time of definitive surgery** For patients with primary tumors < 5 cm or with < 4 involved lymph nodes prior to neoadjuvant chemotherapy and at the time of definitive surgery, provision of post-mastectomy radiotherapy is at the discretion of the treating physician** Radiation of regional nodal basins is at the discretion of the treating radiation oncologist* NOTE: Breast radiotherapy (whole breast or partial) is required for patients who underwent breast-conserving therapy, including lumpectomy or partial mastectomyELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Radiotherapy may be given before or after protocol treatment. when radiotherapy is planned prior to protocol treatment administration, patients must have completed adjuvant radiotherapy >= 2 weeks prior to randomization for protocol therapy, if applicable",(C16169 = YES AND C16171 = YES) OR C15477= YES NCI-2014-01927,NCT02243605,A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients with Relapsed Osteosarcomas and Ewing Sarcomas,Exclusion,"The subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatmentThe subject requires chronic concomitant treatment of strong cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. Johnâ€™s wort)* it is important to regularly consult a frequently-updated list; medical reference texts such as the Physiciansâ€™ Desk Reference may also provide this information; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal productThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedThe subject has received any other type of investigational agent within 28 days before the first dose of study treatmentReceipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 14 days before the first dose of study treatment; note: subjects with prostate cancer currently receiving luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agentsRadiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before the first dose of study treatment; systemic treatment with radionuclides within 6 weeks before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior radiation therapy are not eligiblePrior treatment with cabozantinibThe subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 3 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatment",((C16124 = YES AND C49135 = YES) OR C16171 = YES OR C15477= YES OR (C16124 = YES AND C15187 = YES)) AND (C16124 = YES AND C52200 = NO)NCI-2014-01984,NCT02298959,A Phase 1 Trial of MK-3475 plus Ziv-Aflibercept in Patients with Advanced Solid Tumors,Exclusion,"Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatmentPatients who are currently participating in or have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatmentHas received a live vaccine within 30 days prior to the first dose of trial treatmentHas received prior therapy with an anti-programmed cell death-1 (PD-1), anti-programmed death-ligand 1 (PD-L1), anti-programmed cell death 1 ligand 2 (PD-L2), anti-cluster of differentiation 137 (CD137), ziv-aflibercept or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)(prior treatment with bevacizumab is not an exclusion criteria)",(C16124 = YES AND (C41161 = NO OR C41161 = YES)) AND (C16168 = NO OR C16168 = YES) AND (PRIOR = YES AND (Anti CD137 = NO AND C2682 = NO AND C143250 = NO AND  T-cell co-stimulator = NO)NCI-2014-02020,NCT02575794,Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma,Inclusion,"Patients may have had treatment for an unlimited number of prior relapsesPatients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:* 12 weeks from the completion of radiation* 6 weeks from a nitrosourea chemotherapy* 3 weeks from a non-nitrosourea chemotherapy* 4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents * 2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., erlotinib, hydroxychloroquine, etc.)* 4 weeks from prior antiangiogenesis therapy (approved or investigational) (e.g., bevacizumab, aflibercept, ramucirumab, cediranib, cabozantinib, etc.)Patients must have histologically confirmed supratentorial high grade glioma (grade III or IV glioma) that is progressive or recurrent following radiation therapy and chemotherapy; patients with grade IV glioma must have progressed or recurred after initial treatment with radiation and temozolomide; patients with grade III glioma must have received at least radiation and one regimen of chemotherapy (temozolomide or procarbazine, lomustine, vincristine [PCV] regimen)",C15477= YES OR C16171 = YES OR (C16124 = YES AND C49135 = YES)NCI-2014-02056,NCT02437851,A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons,Exclusion,"Ongoing use of anticoagulant therapy other than aspirin or non-steroidal anti-inflammatory drugs (NSAIDS) that cannot be stopped for surgical proceduresPatients who are receiving any other chronic (defined as more than 50% of the time in the last 6 months) systemic immunomodulatory agents or investigational agents within 4 weeks before randomization enrollment, other than investigational antiretroviral agents for HIV and investigational agents for hepatitis CPrior pelvic radiation therapy that would preclude radiation therapy if anal cancer develops",(C16168 = NO OR C16168 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES)) AND (C15477= NO OR (C15477= YES AND C12767 = NO))NCI-2014-02167,NCT02275533,Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (Remain Trial),Exclusion,"Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than 4 weeks earlierPatients should be excluded if they have had prior treatment with an anti-programmed cell death protein 1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathwaysPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND (C143250 = NO AND  T-cell co-stimulator = NO)NCI-2014-02197,NCT02281760,A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients with BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease,Exclusion,"Prior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last 3 weeks; chemotherapy regimens without delayed toxicity within the last 2 weeks preceding the first dose of study treatmentUse of other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of study treatment and during the study; patients that have used other BRAF or mitogen-activated protein kinase kinase (MEK) inhibitor are excludedPrior treatment, involving interferon, anakinra, imatinib, steroids, chemotherapy with, but not limited to cladribine, vinblastine, 6-mercaptopurine and etoposide, or other medications used empirically for the treatment of ECD, will be acceptable; these therapies should have been completed and discontinued 4 weeks or more prior to enrollment in this study",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16168 = NO OR C16168 = YES) AND (C16124 = YES AND (C15370 = NO OR C15370 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES)) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES)) AND (C16124 = YES AND (BRAF INHIBITOR = NO OR (BRAF INHIBITOR = YES AND C82386= YES)) AND (C69145= NO OR (C69145= YES AND C77908=YES)))NCI-2014-02266,NCT02339740,A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid,Inclusion,"INCLUSIONTreatment with hydroxyurea, corticosteroids (any route) and intrathecal cytarabine prior to beginning protocol directed therapy is allowed; however, it should be noted that lumbar puncture and intrathecal therapy at initial diagnosis of APL is not recommendedPatients may receive up to a maximum of 5 days of pre-treatment with ATRA prior to administration of protocol therapyEXCLUSIONPatients who have received treatment with any other cytotoxic chemotherapy prior to beginning protocol therapy (other than allowed in above criteria) are excluded",C16171 = NO OR (C16171 = YES AND (C560 = YES OR (C408 = YES AND C15750 = YES))) OR (C16124 = YES AND C900 = YES)NCI-2014-02267,NCT02412670,A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma,Inclusion,Patients must have no prior radiation therapy to >= 25% of the bone marrow for prior systemic anthracycline therapy; prior intravesical anthracycline therapy for non-muscle invasive urothelial carcinoma of the bladder is permitted,(C15477= NO OR C15477= YES) AND (C16171 = NO OR C16171 = YES)NCI-2014-02379,NCT02496208,A Phase 1 Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,Exclusion/INCLUSION,"EXCLUSIONPatients are excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedPatients who have been previously treated with met MET or vascular endothelial growth factor receptor (VEGFR) inhibitors (except for patients on renal cell cancer [RCC] cohort) are not eligible for the expansion cohorts but can enroll in the phase I portionOther clinically significant disorders such as:* Severe active infection requiring systemic treatment within 28 days before the first dose of study treatment* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment* History of organ transplant* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid stimulating hormone [TSH], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment)* History of major surgery as follows:** Major surgery within 3 months of the first dose of cabozantinib; however, if there were no wound healing complications, patients with rapidly growing aggressive cancers, may start as soon as 6 weeks if wound has completely healed post-surgery** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications excluding core biopsies and Mediport placement* In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgeryThe subject requires chronic concomitant treatment of strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. Johnâ€™s wort)The subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, thrombin or factor Xa inhibitors; aspirin (up to 325 mg/day), low-dose warfarin (=< 1 mg/day), prophylactic and therapeutic low molecular weight heparin (LMWH) are permittedThe subject has received prior treatment with a small molecule kinase inhibitor within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatmentThe subject has received radionuclide treatment within 6 weeks of the first dose of study treatmentThe subject has received radiation therapy:* To the thoracic cavity or abdomen within 3 months before the first dose of study treatment, or has ongoing complications, or is without complete recovery and healing from prior radiation therapy* To bone or brain metastasis within 3 weeks before the first dose of study treatment* To any other site(s) within 28 days before the first dose of study treatmentPrior treatment with any therapy on the programmed cell death 1 (PD-1)/PD-L1 axis or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors unless enrolling the urothelial carcinoma with previous checkpoint inhibition therapy expansion cohortThe subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 3 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatmentINCLUSIONPatients must have failed at least one standard therapy or no standard treatment exists that has been shown to prolong survival; patients may have received any number of prior cytotoxic agents",(C16171 = NO OR C16171 = YES) AND (C16169 = NO OR C16169 = YES) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES)) AND (C16124 = YES AND ((C49135 = NO OR C49135 = YES) AND C130200 = NO))NCI-2014-02380,NCT02306161,"Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma",Exclusion,"Patients who have received prior chemotherapy or radiation therapy are not eligiblePatients receiving chronic pharmacologic doses of corticosteroids are not eligible; for the purposes of eligibility, chronic exposure is defined as anticipated exposure of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned exposure) must still meet the normal blood glucose requirement; patients receiving chronic inhaled corticosteroids or chronic physiologic replacement doses of corticosteroids are eligible",C16171 = NO AND C15477= NONCI-2014-02403,NCT02428192,A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus,Exclusion/INCLUSION,"EXCLUSIONPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than 3 weeks earlier; patients who have had prior pelvic radiation may be at increased risk for bowel perforation, and therefore may not have residual inflammatory disease of the bowel or residual bowel toxicity based on baseline imaging and clinical assessment; palliative (limited-field) radiation therapy is permitted, if all of the following criteria are met:* Repeat imaging demonstrates no new sites of bone metastases* The lesion being considered for palliative radiation is not a target lesion* Bowel toxicity is not expected from the target field due to increased risk of perforationPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedPatients are excluded if they have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-ligand 2 (L2), anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathwaysPatients who are receiving any other investigational agentsINCLUSIONPatients with a requirement for steroid treatment or other immunosuppressive treatment: patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND (C143250 = NO AND  T-cell co-stimulator = NO))NCI-2014-02405,NCT02438722,"A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) (BI 1200.124)",Inclusion,"Patients must not have received any prior systemic anticancer therapy for advanced or metastatic disease including chemotherapy or EGFR tyrosine kinase inhibitor therapy (including gefitinib, erlotinib, afatinib, or any experimental EGFR tyrosine kinase inhibitors [TKI] agents); prior chemotherapy for non-metastatic disease (i.e. adjuvant therapy or concurrent chemo-radiotherapy) is allowed as long as > 12 months has passed since completion of therapy; adjuvant EGFR-directed therapy is not allowed; local therapy (i.e. palliative radiotherapy) is allowed as long as a period of 7 days has passed since the last dose was received and the patient has recovered from any associated toxicity at the time of registration",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND ((C2167 = NO OR (C2167= YES AND C15675 = NO AND C19151 = NO)))NCI-2014-02410,NCT02323880,"A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors",Exclusion/INCLUSION,"EXCLUSIONConcomitant medications* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid * Investigational drugs: Patients who are currently receiving another investigational drug are not eligible* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligiblePatients who have received a prior solid organ transplantation are not eligibleINCLUSIONPatients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately* Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)* Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair* Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair* Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines* Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1* Corticosteroids: If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid* External beam radiation therapy (XRT): At least 14 days after local palliative XRT (small port); at least 150 days must have elapsed if prior total body irradiation (TBI), craniospinal XRT or if >= 50% radiation of pelvis; at least 42 days must have elapsed if other substantial bone marrow (BM) radiation* Stem cell infusion without TBI: No evidence of active graft vs. host disease and at least 56 days must have elapsed after transplant or stem cell infusion* Patients must not have received prior exposure to selinexor",C130200 = NO AND C16124 = YES AND (C16124 = YES AND C102546= NO)NCI-2014-02413,NCT02063828,Reducing Lung Cancer Survivors' Anxiety (RELAX),Inclusion/EXCLUSION,"INCLUSON 2-24 months post-completion of surgery, radiation therapy and/or chemotherapy with no further planned treatment during the 12-week studyEXCLUSIONRadiation pneumonitis currently being treated with oral steroids",C16169 = YES OR C15477= YES OR C16171 = YES NCI-2014-02424,NCT02498600,"Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Exclusion/INCLUSION,"Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last three years are excluded; patients may have received prior adjuvant chemotherapy and radiotherapy for localized breast cancer, provided that it was completed more than 2 years prior to registration, and the patient remains free of recurrent or metastatic disease and hormonal therapy has been discontinued; patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis or thoracic cavity within the last three years are excluded; prior radiation for localized cancer of the head and neck or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseasePatients who have had prior therapy with nivolumab or with an anti-programmed cell death (PD)-1, anti-PD-ligand (L)1, anti-PD-L2, anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune check point pathwaysThe following medications are contraindicated or must be used with caution* Contraindicated:** Cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8) strong and moderate inhibitors** CYP2C8 inducers** Cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) strong and moderate inhibitors** CYP3A4 inducers** CYP3A4 sensitive substrates* Exclusions: the following supportive care medications will be allowed: dexamethasone, aprepitant, fosaprepitant, and ondansetron; oral pain medications such as hydrocodone, oxycodone taken on an as needed basis are also permitted; transdermal products designed for systemic delivery must be assessed for interaction potential; topical products not designed to provide systemic delivery (including inhaled products, ophthalmologic products and transvaginal preparations) do not need to be considered since they do not have appreciable systemic absorption* Other contraindicated medications (per above) are not allowed unless close monitoring with labs or drug levels with dose adjustments is feasible; patients taking these concurrent medications are ineligible unless they can discontinue or switched to alternative medications prior to initiation of the study drug (at least 5 half-lives)* Use with caution:** CYP2C8 sensitive substrates** CYP2C8 weak inhibitors** CYP3A4 non-sensitive substrates** CYP3A4 weak inhibitors* These agents may be permitted if discontinuation is not feasible and no acceptable alternatives are available as determined by the treating physician; however, caution should be used; consider monitoring with labs or drug levels and dose adjustments of the medicationNo prior carboplatin unless given in neoadjuvant/adjuvant setting for curative intent and more than 6 months have elapsed since last carboplatin dose; in the case of relapsed ovarian cancer, patients are eligible if more than 6 months have elapsed since last carboplatin dosePatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or targeted therapies within 2 weeks prior to entering the study or those who have not recovered (=< grade 1) from adverse events due to agents administered with the exception of any grade of alopeciaINCLUSIONPatients are allowed to have received up to three prior cytotoxic regimens for treatment of their epithelial ovarian, fallopian tube, or primary peritoneal cancer; they must have had one prior platinum-based chemotherapeutic regimen for management of primary disease, possibly including intra-peritoneal therapy, consolidation, biologic/targeted (non-cytotoxic) agents or extended therapy (maintenance/consolidation) administered after surgical or non-surgical assessment; patients are allowed to have received, but are not required to have received, one to two cytotoxic regimens for management of recurrent or persistent disease; (for the purposes of this study poly adenosine diphosphate [ADP] ribose polymerase [PARP] inhibitors given for recurrent or progressive disease will be considered cytotoxic; PARP inhibitors given as maintenance therapy in continuation with management of primary disease will not be considered as a separate cytotoxic regimen); if two cytotoxic regimens had been received for management of recurrent or persistent disease, one of these regimens would have had to contain either a platinum or a taxane agentAppropriate for study entry based on the following diagnostic workup:* History/physical examination within 28 days prior to registration* Imaging of target lesion(s) within 28 days prior to registration* Further protocol-specific assessments:** Recovery from effects of recent surgery, radiotherapy or chemotherapy** Free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI])** Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration** Any other prior therapy directed at the malignant tumor including chemotherapy, targeted agents, immunologic agents, and any investigational agents, must be discontinued at least 4 weeks prior to registration (6 weeks for nitrosoureas or mitomycin C) ** Any prior radiation therapy must be completed at least 4 weeks prior to registration** At least 4 weeks must have elapsed since major surgeryPatients must have at least one â€œtargetâ€ lesion to be used to assess response on this protocol as defined by RECIST 1.1; tumors within a previously irradiated field will be designated as â€œnon-targetâ€ lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy",(C15477= YES OR C16171 = YES OR C16175 = YES OR C16169 = YES) AND (C16124 = YES AND (C143250 = NO AND  T-cell co-stimulator = NO AND C111374 = NO AND CYP3A4 sensitive substrate = NO AND CYP2C8 inducer= NO)NCI-2014-02672,NCT02337517,Pilot Study for the Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD) with GDC-0449 (GDC-0449),Exclusion/INCLUSION,"EXCLUSIONMore than 2 lines of therapy beyond corticosteroids with or without calcineurin inhibitors or sirolimusPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierINCLUSIONPatients with chronic GVHD diagnosed within 3 years after hematopoietic stem cell transplant (HSCT) for any disease, with any graft, and any conditioning regimen with at least one manifestation secondary to fibrosis, including: sclerodermatous skin changes, dry mouth, dry eye, esophageal strictures, or vaginal GVHD",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND C126836 = YESNCI-2014-02674,NCT02339571,Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma,Inclusion,"Patients may have had prior systemic therapy in the adjuvant setting (e.g. interferon, BRAF, or mitogen-activated protein kinase [MEK] agents); patients may have had prior anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) in the adjuvant setting, if at least one year from last dose of treatment has passed prior to beginning treatment; patients may not have had any prior programmed cell death (PD)-1/PD-ligand (PD-L)1 agent in the adjuvant settingPatients must have discontinued chemotherapy, immunotherapy or other investigational agents used in the adjuvant setting >= 4 weeks prior to randomization and recovered from adverse events due to those agents; mitomycin and nitrosoureas must have been discontinued at least 6 weeks prior to entering the study; patients must have discontinued radiation therapy >= 2 weeks prior to entering the study and recovered from any adverse events associated with treatment; prior surgery must be >= 4 weeks from randomization and patients must be fully recovered from post-surgical complicationsPatients must not receive any other investigational agents while on study or within four weeks prior to randomizationPatients are excluded for receiving any non-oncology vaccine therapy used for prevention of infectious diseases for up to four weeks (28 days) prior to or after any dose of ipilimumab; NOTE: Patients are permitted to receive the seasonal influenza vaccine; if seasonal influenza vaccine is considered, killed vaccines should be recommendedPatients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (e.g., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least 2 weeks prior to randomization are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16168 = NO OR C16168 = YES) OR (C16124 = YES AND (C49135 = NO OR C49135 = YES) AND (PD-L1 Inhibitor = NO OR (PD-L1 Inhibitor = YES AND C15675 = NO)) AND (C124946 = NO OR (C124946= YES AND C15675 = NO)))NCI-2015-00030,NCT02360215,A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases,Exclusion,"EXCLUSIONPlanned cytotoxic chemotherapy during the WBRT only; patients may have had prior chemotherapyPrior external beam radiation therapy to the brain or whole brain radiation therapyIntractable seizures while on adequate anticonvulsant therapyâ€”more than 1 seizure per month for the past 2 monthsPrior allergic reaction to memantine (memantine hydrochloride)INCLUSIONPatients may have had prior therapy for brain metastasis, including radiosurgery and surgical resection; patients must have completed prior therapy by at least 14 days prior to Step 2 for surgical resection and 7 days for radiosurgeryBrain metastases outside a 5-mm margin around either hippocampus must be visible on contrast-enhanced magnetic resonance imaging (MRI) performed =< 21 days prior to Step 1 registration; an allowed exception, regarding ability to image brain metastases, would be that patients who had undergone radiosurgery or surgical resection and are planning adjuvant WBRT do not have to have visible disease but do need a pre-surgery MRI or computed tomography (CT) scan demonstrating brain metastases; however, the brain metastases could not have been within 5 mm of either hippocampus",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR (C15477= YES AND C12439 = YES AND C25326 = NO)) AND (C16169 = NO OR C16169 = YES)NCI-2015-00052,NCT02799485,A Phase II Study of sEphB4-HSA in Kaposi Sarcoma,Exclusion/INCLUSION,"EXCLUSIONParticipants who have had anti-neoplastic treatment for KS (including chemotherapy, radiotherapy, local treatment including topical fluorouracil [5-FU], biological therapy or investigational therapy) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study OR those who have not recovered from adverse events due to agents administered more than 4 weeks earlierParticipants on any dose of warfarin or are on full dose anticoagulation with other agents including low molecular weight heparin, antithrombin agents, antiplatelet agents and full dose aspirin within 7 days prior to study enrollment; participants on prophylactic doses of low molecular weight heparin are allowedPrevious local therapy of any KS-indicator lesion unless the lesion has clearly progressed since that local treatment; any prior local treatment to indicator lesions regardless of the elapsed time should not be allowed unless there is evidence of clear-cut progression of said lesionAny steroid treatment except for that required for replacement therapy in adrenal insufficiency, topical or injected testosterone for hypogonadism, or inhaled steroids for the treatment of asthmaINCLUSIONParticipants may be treatment naÃ¯ve, refractory to or intolerant of one or more prior therapies, or treated with prior systemic treatment including but not limited to liposomal doxorubicin",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES)) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES))NCI-2015-00054,NCT02465060,Molecular Analysis for Therapy Choice (MATCH),Inclusion,"Patients must have discontinued steroids >= 1 week prior to registration to Step 0 and remain off steroids thereafter, except as permitted (see below); patients with glioblastoma (GBM) must have been on stable dose of steroids, or be off steroids, for one week prior to registration to treatment (Step 1, 3, 5, 7)* NOTE: The following steroids are permitted (low dose steroid use is defined as prednisone 10 mg daily or less, or bioequivalent dose of other corticosteroid):** Temporary steroid use for computed tomography (CT) imaging in setting of contrast allergy** Low dose steroid use for appetite** Chronic inhaled steroid use** Steroid injections for joint disease** Stable dose of replacement steroid for adrenal insufficiency or low doses for non-malignant disease** Topical steroid** Steroids required to manage toxicity related to study treatment, as described in the subprotocols** Steroids required as pre- or post-chemotherapy medication for acceptable intervening chemotherapy*** NOTE: Steroids must be completed alongside last dose of chemotherapyPatients with brain metastases or primary brain tumors must have completed treatment, surgery or radiation therapy >= 4 weeks prior to start of treatmentAny prior therapy, radiotherapy (except palliative radiation therapy of 30 gray [Gy] or less), or major surgery must have been completed >= 4 weeks prior to start of treatment; all adverse events due to prior therapy have resolved to a grade 1 or better (except alopecia and lymphopenia) by start of treatment; palliative radiation therapy must have been completed at least 2 weeks prior to start of treatment; the radiotherapy must not be to a lesion that is included as measurable disease* NOTE: Prostate cancer patients may continue their luteinizing hormone-releasing hormone (LHRH) agonist* NOTE: Patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results; however, lack of response must be documented prior to registration to Step 1; new non-protocol treatment will NOT be permitted as intervening therapy after registration to Step 0; the decision to stop the intervening non-protocol treatment will be left up to the treating physician if patient has an aMOI; however, patients will need to be off such therapy for at least 4 weeks before receiving any MATCH protocol treatment* NOTE: For patients entering the study via a designated outside laboratory, no intervening systemic non-protocol treatment is permitted after Step 0 registration; all other eligibility requirements still apply to these patients, including the washouts for prior therapy noted above in this section, the time restrictions outlined, and the eligibility criteria for the intended subprotocol",C16124 = NO OR C16124 = YESNCI-2015-00121,NCT03047213,"An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation",Exclusion/INCLUSION,"EXCLUSIONPatients who received radiation therapy within the last 4 weeks; radiation exposure may not exceed 30% of marrow areaSubjects who have initiated treatment with bisphosphonates less than 30 days prior to the first administration of MLN0128 (TAK-228); concurrent bisphosphonate use is only allowed if the bisphosphonate was initiated at least 30 days prior to the first administration of MLN0128 (TAK-228)Concomitant administration of any proton pump inhibitor (PPI) is not permitted during the study; patients receiving PPI therapy before enrollment must stop using the PPI for 7 days before their first dose of study drugsSubjects who are on systemic corticosteroids (intravenous (IV) or oral steroids, excluding inhaled, topical or ophthalmic corticosteroids), or anti-epileptic drugs for treated brain metastasisINCLUSIONPatient must have developed disease progression during or following treatment with at least one platinum- containing regimen (e.g., gemcitabine/cisplatin [GC], methotrexate-vinblastine-doxorubicin-cisplatin [MVAC], carboplatin, gemcitabine [CarboGem]) for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence, or must be unfit or ineligible for cisplatin-based chemotherapy; there is no restriction on the number of prior lines of chemotherapeutics agents received* Patients who progressed within 12 months of treatment with a platinum-containing neoadjuvant or adjuvant regimen are considered second-line patients; therefore, these patients may be also eligible* Patients who are unfit or ineligible for cisplatin-based chemotherapy as defined by any one of the following criteria are eligible for this trial: ** Eastern Cooperative Oncology Group (ECOG) performance score of 2** Creatinine clearance < 60 mL/min ** A hearing loss (measured by audiometry) of 25 dB at two contiguous frequencies ** Grade >= 2 peripheral neuropathy",(C15477= NO OR C15477= YES) AND (C16171 = NO OR C16171 = YES) NCI-2015-00127,NCT02535312,"Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin",Exclusion,Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients who have had targeted therapy will be required to wait 2 weeks due to short half-life of the drugs; treatment with bisphosphonates is permitted,C16171 = YES OR C15477= YESNCI-2015-00130,NCT02359565,"A Safety and Preliminary Efficacy Trial of MK-3475 (Pembrolizumab; Anti-PD-1) in Children with Recurrent, Progressive or Refractory High-Grade Gliomas (HGG) and DIPGs and Hypermutated Brain Tumors",Exclusion/INCLUSION,"EXCLUSIONEXCLUSION CRITERIA FOR HYPERMUTATED BRAIN TUMORS (STRATUM C): Patients who have received previous therapy with an anti-CTLA4, anti-CD137, anti-PD-L1 or anti-PD-1 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)EXCLUSION CRITERIA FOR NB-NGG (STRATUM B): Patients who are receiving any other anti-cancer or investigational drug therapy are ineligibleEXCLUSION CRITERIA FOR DIPG (STRATUM A): Patients who have received the last vaccination of a live vaccine =< 30 days prior to enrollment are ineligible; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella, yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine; seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. Flu-Mist) are live attenuated vaccines, and must meet timeline for live vaccineEXCLUSION CRITERIA FOR NB-NGG (STRATUM B): Patients who have received the last vaccination of a live vaccine =< 30 days prior to enrollment are ineligible; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella, yellow fever, rabies, BCG, and typhoid (oral) vaccine; seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. Flu-Mist) are live attenuated vaccines, and must meet timeline for live vaccineEXCLUSION CRITERIA FOR DIPG (STRATUM A): Patients may not be on immunosuppressive therapy, including corticosteroids (with the exception of physiologic replacement, defined as 0.75 mg/m^2/day) at time of enrollment; however, patients who require intermittent use of bronchodilators or local steroid injections will not be excluded from the studyEXCLUSION CRITERIA FOR NB-NGG (STRATUM B): Patients may not be on immunosuppressive therapy, including corticosteroids (with the exception of physiologic replacement, defined as 0.75 mg/m^2/day) at time of enrollment; however, patients who require intermittent use of bronchodilators or local steroid injections will not be excluded from the studyEXCLUSION CRITERIA FOR NB-NGG (STRATUM B): Patients who have received previous therapy with an anti-CTLA4, anti-CD137, anti-PD-L1 or anti-PD-1 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)INCLUSIONINCLUSION CRITERIA FOR DIPG (STRATUM A - CURRENTLY CLOSED TO ACCRUAL): Patients must have had their last fraction of:* Craniospinal irradiation >= 3 months prior to enrollment* Other substantial bone marrow irradiation >= 6 weeks prior to enrollment* Local palliative radiation therapy (XRT) (small port) >= 2 weeksINCLUSION CRITERIA FOR DIPG (STRATUM A - CURRENTLY CLOSED TO ACCRUAL): Patient must be >= 12 weeks since autologous bone marrow/stem cell transplant prior to enrollmentINCLUSION CRITERIA FOR DIPG (STRATUM A - CURRENTLY CLOSED TO ACCRUAL): Patients must be fully recovered from all acute effects of prior surgical interventionINCLUSION CRITERIA FOR HYPERMUTATED BRAIN TUMORS (STRATUM C): Patients must be off all colony-forming growth factor(s) for at least 1 week prior to registration (i.e. filgrastim; sargramostim; erythropoietin); 2 weeks must have elapsed for long-acting formulationsINCLUSION CRITERIA FOR DIPG (STRATUM A - CURRENTLY CLOSED TO ACCRUAL): Patient must have completed immunotherapy (e.g. tumor vaccines, oncolytic viruses, etc.) at least 42 days prior to enrollmentINCLUSION CRITERIA FOR DIPG (STRATUM A - CURRENTLY CLOSED TO ACCRUAL): Patients must have received their last dose of known myelosuppressive anticancer therapy at least three (3) weeks prior to study enrollment or at least six (6) weeks if prior nitrosoureaINCLUSION CRITERIA FOR DIPG (STRATUM A - CURRENTLY CLOSED TO ACCRUAL): Patients must have received prior radiation therapy and/or chemotherapy and recovered from the acute treatment related toxicities (defined as =< grade 1 if not defined in eligibility criteria) of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study; there is no upper limit to the number of prior therapies that is allowedINCLUSION CRITERIA FOR DIPG (STRATUM A - CURRENTLY CLOSED TO ACCRUAL): Patients must be off all colony-forming growth factor(s) for at least 1 week prior to registration (i.e. filgrastim, sargramostim, erythropoietin); 2 weeks must have elapsed for long-acting formulationsINCLUSION CRITERIA FOR NB-NGG (STRATUM B): Patients must have received prior radiation therapy and/or chemotherapy and recovered from the acute treatment related toxicities (defined as =< grade 1 if not defined in eligibility criteria) of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study; there is no upper limit to the number of prior therapies that is allowedINCLUSION CRITERIA FOR NB-NGG (STRATUM B): Patients must have received their last dose of known myelosuppressive anticancer therapy at least three (3) weeks prior to study enrollment or at least six (6) weeks if prior nitrosoureaINCLUSION CRITERIA FOR NB-NGG (STRATUM B): Biologic or investigational agent (anti-neoplastic): patient must have received their last dose of the investigational or biologic agent >= 7 days prior to study enrollment* For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration must be discussed with and approved by the study chair* Monoclonal antibody treatment and/or agents with prolonged half-lives: at least three half-lives must have elapsed prior to enrollmentINCLUSION CRITERIA FOR NB-NGG (STRATUM B): Patient must have completed immunotherapy (e.g. tumor vaccines, oncolytic viruses, etc.) at least 42 days prior to enrollmentINCLUSION CRITERIA FOR NB-NGG (STRATUM B): Patients must have had their last fraction of:* Craniospinal irradiation >= 3 months prior to enrollment* Other substantial bone marrow irradiation >= 6 weeks prior to enrollment* Local palliative XRT (small port) >= 2 weeksINCLUSION CRITERIA FOR NB-NGG (STRATUM B): Patient must be >= 12 weeks since autologous bone marrow/stem cell transplant prior to enrollmentINCLUSION CRITERIA FOR HYPERMUTATED BRAIN TUMORS (STRATUM C): Patients must have had their last fraction of:* Craniospinal irradiation >= 3 months prior to enrollment* Other substantial bone marrow irradiation >= 6 weeks prior to enrollment* Local palliative radiation therapy (XRT) (small port) >= 2 weeksINCLUSION CRITERIA FOR HYPERMUTATED BRAIN TUMORS (STRATUM C): Patient must have completed immunotherapy (e.g. tumor vaccines, oncolytic viruses, etc.) at least 42 days prior to enrollmentINCLUSION CRITERIA FOR HYPERMUTATED BRAIN TUMORS (STRATUM C): Biologic or investigational agent (anti-neoplastic): patient must have received their last dose of the investigational or biologic agent >= 7 days prior to study enrollment* For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration must be discussed with and approved by the study chair* Monoclonal antibody treatment and/or agents with prolonged half-lives: at least three half-lives must have elapsed prior to enrollmentINCLUSION CRITERIA FOR HYPERMUTATED BRAIN TUMORS (STRATUM C): Patients must have received their last dose of known myelosuppressive anticancer therapy at least three (3) weeks prior to study enrollment or at least six (6) weeks if prior nitrosoureaINCLUSION CRITERIA FOR HYPERMUTATED BRAIN TUMORS (STRATUM C): Patients must have received prior radiotherapy and/or chemotherapy with the following exceptions:* Patients with secondary CNS cancers after a previous medical problem/malignancy if they cannot receive full dose of radiotherapy (> 50 Gy) as long as they meet all other eligibility criteria* Patients with progressive low-grade gliomas and CMMRD or Lynch syndrome* Patients must have recovered from the acute treatment related toxicities (defined as =< grade 1 if not defined in eligibility criteria) of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study; there is no upper limit to the number of prior therapies that is allowed; the required intervals for prior therapy are identical to those noted below except for patients with HGG who have not experienced disease progression",(C16124 = YES AND (C143250 = NO AND  T-cell co-stimulator = NO)) AND (C15477= YES OR C15477= NO) AND (C16169 = NO OR C16169 = YES) AND (C16168 = NO OR C16168 = YES) AND (C16171 = NO OR C16171 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES)) AND (C16124= YES AND (C15187 = NO OR C15187 = YES)) AND (C16124 = YES AND (C15194 = NO OR C15194= YES))NCI-2015-00159,NCT02363283,A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma,Exclusion/INCLUSION,"EXCLUSIONPatients who have previously received CDX-011 (glembatumumab vedotin) or other monomethyl auristatin E (MMAE)-containing agentsPatients who are receiving any other investigational agents; if the patient received a previous investigational or other agent or treatment, a washout period of 4 weeks is requiredINCLUSIONThe study will be limited to patients who are chemotherapy naÃ¯ve; patients may have received prior systemic or liver-directed local therapies for advanced uveal melanoma as long as those treatments do not involve chemotherapy; this includes, but is not limited to: immunotherapy, targeted therapy, transarterial embolization, radiofrequency ablation, or cryoablation; treatment must be completed at least 28 days prior to initiation of study therapy; radiation therapy is also allowed and must be completed at least 28 days prior to initiation of study therapy; lesions treated via radiation or liver-directed therapy may not be used as target lesions unless they demonstrate growth over a minimum of 3 months on subsequent imagingAll prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4 grade =< 1 (except alopecia); certain exceptions apply, such as immunotherapy-induced hypothyroidism or adrenal insufficiency or panhypopituitarism requiring stable doses of hormone replacement or rash from prior therapy",(C16124 = YES AND (C78449 = NO AND C122637 = NO AND (C49135 = NO OR C49135 = YES)) AND C16171 = NO AND (C15477= NO OR C15477= YES) AND (C16168 = NO OR C16168 = YES)NCI-2015-00257,NCT02381548,A Phase 1 Study of AZD1775 in Combination with Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients with Acute Myeloid Leukemia,Exclusion/INCLUSION,"EXCLUSIONMajor surgical procedures =< 28 days before beginning study treatment or minor surgical procedures =< 7 day before beginning study treatment; no waiting required after placement of a vascular access deviceOther investigational agent within 3 weeks prior to initiation of study therapyOngoing or planned treatment with any of the following:* Atorvastatin* Strong inhibitors or inducers of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4); as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product** If any of these agents have been used, patients must be off them for >= 2 weeks before starting study treatmentReceiving any other therapies for cancer treatment (with the exception of gonadotropin-releasing hormone [GnRH] agonists for prostate cancer); Note: hydroxyurea is allowed before initiation of study treatment and for the first 5 days of study treatmentStem cell transplant within previous 3 months prior to initiation of study therapyINCLUSONPatients must have one of the following, histologically or cytologically confirmed:* Acute myeloid leukemia (AML) [non- acute promyelocytic leukemia (APL) AML]** If previously treated:*** AML that is relapsed or refractory to at least one prior line of therapy** If previously untreated, must meet all of the following:*** >= 60 years of age*** Secondary or therapy-related AML*** Does NOT bear favorable cytogenetic and/or molecular features, eg, core-binding factor abnormalities, FLT3 Internal Tandem Duplication (FLT3-ITD) negative/NPM1 mutated, biallelic CCAAT/enhancer binding protein alpha (CEBPA) mutation without FLT3-ITD* Chronic myeloid leukemia blast crisis (CML-BC)** Relapsed or refractory to at least one Bcr-Abl-TKI-containing regimen* Myelodysplastic syndrome (MDS), must meet all of the following:** Higher risk MDS [intermediate-2 or high risk by the original International Prognostic Scoring System (IPSS)]** Relapsed, refractory, or intolerant to at least one prior line of therapy containing hypomethylating agents (deoxyribonucleic acid [DNA] methyltransferase inhibitors)",(C16169 = NO OR C16169 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES))NCI-2015-00258,NCT02381561,Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers,Exclusion/INCLUSION,"EXCLUSIONPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierPatients who are receiving any other investigational agentsINCLUSIONPatients must not have received systemic chemotherapy for at least 4 weeks, and must not have received prior radiation therapy to the tumor site being irradiated on this study",(C16171 = NO OR C16171 = YES) AND (C15477 = NO OR (C15477= YES AND C54225 = YES)NCI-2015-00260,NCT02500797,Randomized Phase II Study of Nivolumab with or without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma,Inclusion,"No systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of registrationPatients should have resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE, version 4.0, grade 1 or lessPatients should have resolution of any toxic effects of prior therapy (except fatigue and alopecia) to NCI CTCAE, version 4.0, grade 1 or less, including immune toxicityPatients must have completed study drug on arm 1 of A091401 (i.e., last dose of nivolumab) =< 12 months of re-registration to crossover dual agent therapyNo treatment with immunotherapy =< 21 days before re-registration; no treatment with biologic therapy, chemotherapy, investigational agent for malignancy, or radiation =< 28 days before re-registration; no treatment with nitrosourea or mitomycin =< 42 days before re-registrationNo systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of re-registration>= 1 prior systemic therapy for sarcoma, including adjuvant systemic therapyNo prior therapy with ipilimumab or nivolumab, or any agent targeting programmed cell death 1 (PD-1), PD-L1 or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)No treatment with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation =< 28 days before study registration; no treatment with nitrosourea or mitomycin =< 42 days before study registration; for GIST, tyrosine kinase inhibitor can be continued for up to 3 days prior to initiation of study treatmentPatients must have completed a minimum of 10 weeks of single agent nivolumab on arm 1 of A091401 to be eligible for re-registration",(C16168 = NO OR C16168 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES)) AND (C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND ((C49135 = NO 0R C49135 = YES) AND PD-L1 Inhibitor = NO AND C124946 = NO AND C128036 = NO))NCI-2015-00323,NCT02516423,Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid versus Zoledronic Acid after Definite Radiation Therapy,Exclusion/INCLUSION,"EXCLUSIONInfection requiring systemic antibiotic therapy or other serious infection within 14 days before registrationINCLUSIONFor all patients:* Radiation dose should range from 4500 cGy to 6000 cGy* No treatment for this disease following radiation therapyFor patients pre-registering after the completion of radiation therapy, documentation of a bone marrow aspirate and biopsy containing < 10% clonal plasma cells prior to start of radiation therapyNo ongoing therapy with corticosteroids greater than 10 mg of prednisone or its equivalent per day; please note: inhaled and topical steroids are permittedNo investigational agent within 21 days prior to registrationPatients cannot be on systemic treatment with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or use Ginkgo biloba or St. Johnâ€™s worth within 14 days of registration",C15477= YES AND (C16124 = YES AND (C49135 = NO OR C49135 = YES))NCI-2015-00324,NCT02521493,Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome,Exclusion/INCLUSION,"EXCLUSIONPrior therapy* Patients =< 30 days from the last dose of cytarabine used for treatment of TMDINCLUSIONChildren who have previously received chemotherapy, radiation therapy or any anti-leukemic therapy are not eligible for this protocol, with the exception of cytarabine for the treatment of TMD",(C16171 = NO OR C16171 = C408) AND C15477 = NO AND (C16124 = YES AND ANTI-LEUKEMIC THERAPY = NO)NCI-2015-00378,NCT02659800,The Effect of IL-7 (CYT107) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide,Inclusion/EXCLUSION,"INCLUSIONPatientsâ€™ post-operative treatment must have included at least 80% of standard radiation and concomitant temozolomide; patients may not have received any other prior chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, tumor infiltrating lymphocytes [TIL], lymphokine-activated killer [LAK] or gene therapy), or hormonal therapy for their brain tumor; prior Gliadel wafers are allowed; glucocorticoid therapy is allowedEXCLUSIONPatients receiving any other investigational agents are ineligible",C16169 = YES AND (C15477= YES AND C1244 = YES) AND (C16171= NO OR C16171 = C1244) AND (C16168 = NO OR (C16168 = YES AND C12439 = NO)) AND (C16124 = YES AND (C15187 = NO OR (C15187 = YES AND C12439 = NO)) AND (C16175 = NO OR (C16175 = YES AND C12439 = NO))NCI-2015-00383,NCT02398773,[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer,Inclusion,"Patient must NOT have a history of > 1 line of administered chemotherapy for metastatic disease and must be off chemotherapy for a minimum of 2 weeks; prior chemotherapy in the adjuvant setting is allowedPatient is not now, and never has received adjuvant endocrine therapy OR patient is currently receiving or has received adjuvant endocrine therapy in the past, AND adjuvant endocrine therapy was initiated > 2 years prior to diagnosis of metastatic disease* Note: patients who developed metastatic disease while still receiving adjuvant endocrine therapy must have a planned change in the type of endocrine agent used for subsequent metastatic disease treatment; patient is not receiving blocking adjuvant therapy (such as toremifene or tamoxifen) OR patient is receiving blocking adjuvant therapy, but will stop this therapy a minimum of 60 days prior to FES-PET/CT while still complying with the study timelinePatient must NOT have received prior endocrine therapy for metastatic disease (i.e., must be first-line endocrine therapy for metastatic disease)",(C16171 = NO OR C16171 = YES) AND (C16175 = NO OR (C16175 = YES AND C19151 = NO))NCI-2015-00456,NCT02407405,Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas,Exclusion,"Prior treatment with selumetinib or another specific MEK 1/2 inhibitorPatients who are receiving any other investigational agents, or have received an investigational agent within the past 30 daysHave had recent major surgery within a minimum of 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular accessHave any unresolved chronic toxicity with CTC AE grade >= 2, from previous anti-NF1 therapy, except for alopecia",(C16124 = YES AND (C66939 = NO AND C69145= NO AND (C49135 = NO OR C49135 = YES)) AND (C16169 = NO OR C16169 = YES) AND (C16171 = NO OR C16171 = YES)NCI-2015-00461,NCT02408861,A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors with Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma,Inclusion/EXCLUSION,"INCLUSIONPrior therapy for metastatic disease permitted; at least 4 weeks must have elapsed since prior chemotherapy or biological therapy, 6 weeks if the regimen included carmustine (BCNU) or mitomycin C; radiotherapy must be completed at least 4 weeks prior to registrationEXCLUSIONParticipants who have received any other investigational agents within the 4 weeks prior to enrollment; concurrent radiation therapy is not permitted, except palliative (limited-field) radiation therapy, if all of the following criteria are met:* Repeat imaging demonstrates no new sites of bone metastases* The lesion being considered for palliative radiation is not a target lesionParticipants should be excluded if they have had prior treatment with an anti-PD-1, anti-programmed cell death ligand 1 (PD-L1), anti-programmed cell death ligand 2 (PD-L2), anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways; prior immune modulating therapy including vaccines may be eligible; prior immune events must be evaluated and the risk for new events which may represent continued sub clinical disease or a new process at previously damaged site or immune potentiation (e.g. ipilimumab followed by IL2 causing bowel perforation, ipilimumab followed by indoleamine 2,3-dioxygenase [IDO] inhibitor resulting in clinical hypophysitis); please keep in mind that inflammatory events may occur weeks to months following the last dose of ipilimumab and possibly nivolumab; assessment of potential effects of prior therapy should include:* Immune status* Organ damage* Risk of autoimmunity* ImmunopotentiationThe participant has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except =< grade 2 alopecia, neuropathy, and other non-clinically significant adverse events (AEs)",(C16171 = NO OR C16171 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES)) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES) AND C143250 = NO AND  T-cell co-stimulator = NO))NCI-2015-00537,NCT02588443,Phase I Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 plus Nab-paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 plus Nab-paclitaxel and Gemcitabine for Patients with Newly Diagnosed Resectable Pancreatic Carcinoma,Exclusion,"Previous treatment with any other compound that targets CD40Concurrent treatment with any anticancer agent outside of this protocolTreatment on another therapeutic clinical trial within 4 weeks of enrollment in this trialOngoing or active infection; treatment with systemic antibiotics or antifungals for ongoing or recurrent infection (topical use of antibiotics or antifungals is allowed)Prior therapy such as chemotherapy or radiation therapy or anti-tumor experimental therapy for pancreatic cancer",(C16124 = YES AND CD40 TARGETING DRUG = NO) AND (C16171 = NO OR (C16171 = YES AND C9005 = NO)) AND (C15477= NO OR (C15477= YES AND C9005 = NO)) AND (C16124 = YES AND (C49135 = NO OR (C49135 = YES AND C9005 = NO)))NCI-2015-00543,NCT02470091,"Phase 2 Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma",Exclusion/INCLUSION,"EXCLUSIONPatients who have previously received mithramycin, strontium-89, samarium-153 or rheniumPatients who have previously received denosumabPatients who are receiving other cancer directed therapy at the time of enrollmentINCLUSIONPatients must have relapsed or become refractory to conventional therapy, with a regimen including some combination of high dose methotrexate, doxorubicin, cisplatin, ifosfamide and etoposide; and have had histologic verification of osteosarcoma at original diagnosis or at the time of recurrence",(C16124 = YES AND (C1567 = NO AND C1220 = NO AND C1656 = NO AND C61313 = NO) AND C16171 = YESNCI-2015-00545,NCT02417701,A Phase 2 Study of MLN0128 (TAK-228) in Patients with Advanced Squamous Cell Lung Cancers Harboring NFE2L2 and KEAP 1 Mutations,Exclusion,"Treatment with strong inhibitors and/or inducers of cytochrome P450 (CYP) 3A4, CYP2C19 or CYP2C19 within 1 week preceding the first dose of study drugPatients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events from prior treatmentsConcomitant administration of any proton pump inhibitor (PPI) is not permitted during the study; patients receiving PPI therapy before enrollment must stop using the PPI for 7 days before their first dose of study drugsPatients who are receiving any other investigational agents",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) NCI-2015-00546,NCT02523014,Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations,Inclusion,"Documentation of disease:* Histologic documentation: histologically proven intracranial meningioma as documented by central pathology review* Molecular documentation: presence of SMO, PTCH1 or NF2 mutation in tumor sample as documented by central laboratory* Progressive OR residual disease, as defined by the following: ** Residual measurable disease: residual measurable disease immediately after surgery without requirement for progression; for grade I disease, progression pre-operatively needs to be documented, with an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area); the change must occur between scans separated by no more than 12 months; residual measurable disease will be defined by bidimensionally measurable lesions with clearly defined margins by MRI scans, with a minimum diameter of 10 mm in both dimensions** Progressive measurable disease: progression defined as an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area); the change must occur between scans separated by no more than 12 months** Post radiation patients: patients with measurable and progressive meningioma who have received radiation are potentially eligible, but need to show evidence of progressive disease after completion of radiation; at least 24 weeks must have elapsed from completion of radiation to registrationPrior treatment * Prior medical therapy is allowed but not required* No limit on number of prior therapies* No chemotherapy, other investigational agents within 28 days of study treatment* No other concurrent investigational agents or other meningioma-directed therapy (chemotherapy, radiation) while on study* For patients treated with external beam radiation, interstitial brachytherapy or radiosurgery, an interval > 24 weeks must have elapsed from completion of radiation therapy to registration* Steroid dosing stable for at least 4 days * Recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or less toxicity from other agents with exception of alopecia and fatigue* No craniotomy within 28 days of registration",(C16169 = NO OR C16169 = YES) AND (C15477= NO OR C15477= YES) AND (C16171 = NO OR C16171 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES))NCI-2015-00547,NCT02595424,Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-small Cell Gastroenteropancreatic  Neuroendocrine Carcinomas,Inclusion,"Patients may not have had any prior systemic treatment for this malignancy (for example chemotherapy or somatostatin analogues); prior palliative radiation is permitted but radiated lesions may not be used for measurementPatients may not have received any of the protocol agents within 5 years prior to randomizationAny prior surgeries must have been completed at least 4 weeks prior to randomization",(C16124 = NO OR (C16124 = YES AND C15698 = YES AND Advanced G3 Non-small Cell Gastroenteropancreatic  Neuroendocrine Carcinoma = NO)) AND (C15477= NO OR C15477= YES) AND (C16169 = NO OR C16169 = YES)NCI-2015-00606,NCT02446600,"A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Inclusion/EXCLUSION,"INCLUSIONToxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE v4.0); patients with long-standing stable grade 2 neuropathy may be considered after discussion with the overall principal investigator (PI), but may not receive carboplatin and paclitaxel as the reference regimen, if randomized to that armPatients must have platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancers; patients with other (clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma) hihg-risk histologies are also eligible, provided that the patient has a known deleterious germline BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory; Note: Due to the long acceptance of germline BRCA testing through Myriad, Myriad testing will be accepted; if testing for germline BRCA is done by other organizations, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) listing the mutation and confirming that the laboratory results showed a recognized germline deleterious BRCA1 or BRCA2 mutation or BRCA rearrangement is required; please collect a copy of Myriad or other BRCA mutational analysis (positive or VUS or negative) reports* Platinum-sensitive disease defined as no clinical or radiographic evidence of disease recurrence for > 6 months (or 182 days) after last receipt of platinum-based therapy* Patients must have had a complete clinical response to their prior line of platinum therapy and cannot have had progression through prior platinum-based therapyPrior therapy:* Prior chemotherapy must have included a first-line platinum-based regimen with or without intravenous consolidation chemotherapy* Patients may have received an unlimited number of platinum-based therapies in the recurrent setting* Patients may have received up to 1 non-platinum-based line of therapy in the recurrent setting; prior hormonal therapy will not be considered to count as this non-platinum-based line* Patients may not have had a prior anti-angiogenic agent in the recurrent setting; prior use of bevacizumab in the upfront or upfront maintenance setting is allowed* Patients may not have previously received a poly adenosine diphosphate (ADP) ribose polymerase (PARP)-inhibitor* Prior hormonal-based therapy for ovarian, primary peritoneal, or fallopian tube cancer is acceptableEXCLUSIONPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of starting treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients may not have had hormonal therapy within 2 weeks prior to entering the study; patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactionsPatients may not have received prior treatment affecting the vascular endothelial growth factor (VEGF) pathway (including, but not limited to thalidomide, sunitinib, pazopanib, sorafenib, and nintedanib); bevacizumab used in the upfront setting in conjunction with chemotherapy and/or as maintenance to treat newly diagnosed disease will be allowedParticipants receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible; strong inhibitors and inducers of UGT/PgP should be used with cautionAny concomitant or prior invasive malignancies with the following curatively treated exceptions:* Treated limited stage basal cell or squamous cell carcinoma of the skin* Carcinoma in situ of the breast or cervix* Primary endometrial cancer meeting the following conditions: stage not greater than IA, grade 1 or 2, no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous/serous, clear cell, or other International Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions* Prior cancer treated with a curative intent with no evidence of recurrent disease 3 years following diagnosis and judged by the investigator to be at low risk of recurrenceIf cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines* Patients with the following risk factors should have a baseline cardiac function assessment:** Prior treatment with anthracyclines** Prior treatment with trastuzumab** Prior central thoracic radiation therapy (RT), including RT to the heart** History of myocardial infarction within 6 to 12 months (patients with history of myocardial infarction within 6 months are excluded from the study)** Prior history of impaired cardiac functionMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranibNo prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT)",(((C16171 = NO OR (C16171 = YES AND C1450 = YES)) AND (C15477= NO OR C15477= YES) AND (C16175 = NO OR C16175 = YES) AND (C16169 = NO OR C16169 = YES) AND (C16175 = NO OR C16175 = YES)) OR (C16124 = YES AND C2039 = YES)) AND (C16124 = YES AND ((C93259 = NO AND C38155 = YES) AND C15369 = NO AND C116470 AND C62554 = NO))NCI-2015-00651,NCT02502266,"A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)",Inclusion/EXCLUSION,"INCLUSIONToxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per CTCAE v 4.0Patients may not have previously received a PARP-inhibitorNo more than 3 prior treatment regimens (including primary therapy; no more than 1 prior non-platinum based therapy in the platinum-resistant/-refractory setting); hormonal therapies used as single agents (i.e. tamoxifen, aromatase inhibitors) will not count towards this line limitEXCLUSIONIf cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines* Patients with the following risk factors should have a baseline cardiac function assessment:** Prior treatment with anthracyclines** Prior treatment with trastuzumab** Prior central thoracic radiation therapy (RT), including RT to the heart** History of myocardial infarction within 6 to 12 months (Patients with history of myocardial infarction within 6 months are excluded from the study)** Prior history of impaired cardiac functionPrior treatment affecting the VEGF/VEGFR pathway or the angiopoietin pathway in the recurrent setting, including but not limited to thalidomide, bevacizumab, sunitinib, sorafenib, pazopanib, cediranib, nintedanib, and trebananib; bevacizumab used in the upfront setting in conjunction with chemotherapy and/or as maintenance to treat newly diagnosed disease will be allowedPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of starting treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients may not have had hormonal therapy within 2 weeks prior to entering the study; patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions",(C16124 = YES AND ((C93259 = NO AND Angiopoietin Pathway Inhibitor = NO AND C62554 = NO AND C38155 = YES) OR C2039 = YES)) AND (C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477 = YES) AND (C16175 = NO OR C16175 = YES)NCI-2015-00668,NCT02443077,A Randomized Double-Blind Phase III Study of Ibrutinib during and following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype,Inclusion,"No major surgery =< 7 days prior to registration and no minor surgery =< 3 days prior to registration (with the exception of intravenous access placement, e.g. Hickman or peripherally inserted central catheter [PICC])Prior use of ibrutinib is allowed unless patient has had disease progression while receiving ibrutinibPatients should not require concurrent therapeutic doses of steroids (> 20 mg of prednisone/day or equivalent) unless they need them for the indications; steroids should be discontinued for 14 days before starting protocol treatmentNo more than 3 prior regimens for large cell component (e.g. one induction and two salvage therapies); monoclonal antibody alone or involved field/involved site radiotherapy do not count as lines of therapy",C16169 = YES OR C16171 = YES OR C15477= YES OR C16168 = YESNCI-2015-00695,NCT02423057,Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients with Advanced Solid Tumors,Exclusion/INCLUSION,"EXCLUSIONPatients who are receiving any other investigational agentsINCLUSIONPatients must have completed any chemotherapy, radiation therapy, or biologic therapy >= 4 weeks or 5 half-lives (whichever is shorter) (6 weeks for nitrosoureas or mitomycin C) prior to entering the study; patients must be >= 2 weeks since any prior administration of a study drug in a phase 0 or equivalent study and be >= 2 weeks since any prior palliative radiation or cyberknife therapy; patients must have recovered to grade 1 from prior toxicity or adverse events; patients with bone metastases or hypercalcemia on intravenous bisphosphonate treatment prior to study entry may continue this treatmentPatients must have histologically documented solid tumors whose disease has progressed on standard therapy or for which there is no available standard therapy",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND ( C15187 = NO OR C15187 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES))NCI-2015-00741,NCT02453620,"A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors",Exclusion,"Patients who have had chemotherapy or other systemic therapy or radiotherapy, or those who have not recovered from adverse events due to prior administered agents as follows:* Chemotherapy < 3 weeks prior to registration* Hormone therapy < 2 weeks prior to registration* Targeted therapy (other than below) < 2 weeks prior to registration (e.g., tyrosine kinase inhibitors)* Trastuzumab < 6 weeks prior to registration* Bevacizumab < 6 weeks prior to registration* Nitrosoureas/mitomycin C < 6 weeks prior to registration* Radiotherapy < 3 weeks prior to registration (NOTE: a previously irradiated lesion may not be used as a target lesion unless there is evidence of post-radiation progression)* Surgery < 3 weeks prior to registration* Other approved or investigational agents < 3 weeks prior to registration unless otherwise noted by the protocol chair* Patients who have received prior epigenetic (e.g., histone deacetylase [HDAC] inhibitors such as entinostat, panobinostat, vorinostat, romidepsin or demethylating agents such as 5-azacitidine or decitabine) immunomodulatory or other checkpoint inhibitors should only be considered after discussion with the protocol chair* Those who have not recovered from acute adverse events to grade < 2 or baseline due to agents administered, with exception of alopecia, unless approved by the protocol chairPatients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permittedPatients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded; these include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis, systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohnâ€™s, ulcerative colitis, autoimmune hepatitis, and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded; patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible; patients with rheumatoid arthritis and other arthropathies, SjÃ¶grenâ€™s syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible",(C16171 = NO OR C16171 = YES) AND (C16175 = NO OR C16175 = YES) AND (C15477= NO OR C15477= YES) AND (C16169 = NO OR C16169 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES))NCI-2015-00744,NCT02564198,"A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors",Exclusion/INCLUSION,"EXCLUSIONPatients who are currently receiving other anti-cancer agents are not eligiblePatients who are chronically receiving aspirin, ibuprofen or other non-steroidal anti-inflammatory drugs are not eligiblePatients who are currently receiving anti-platelet agents are not eligiblePatients who are receiving anti-hypertensive medications for control of blood pressure at the time of enrollment are not eligible for this trialPatients who are currently receiving therapeutic anti-coagulation with heparin, low-molecular weight heparin or Coumadin are not eligible for this trialPatients who have had or are planning to have the following invasive procedures are not eligible:* Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollment* Central line placement or subcutaneous port placement is not considered major surgery; external central lines must be placed at least 3 days prior to enrollment and subcutaneous ports must be placed at least 7 days prior to enrollment* Core biopsy within 7 days prior to enrollment* Fine needle aspirate within 7 days prior to enrollment* Surgical or other wounds must be adequately healed prior to enrollment; Note: for purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapyPatients who have received a prior solid organ transplantation are not eligiblePatients who have an uncontrolled infection are not eligiblePatients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligiblePatients who are currently receiving another investigational drug are not eligibleINCLUSIONPatients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy* Myelosuppressive chemotherapy: at least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)* Hematopoietic growth factors: at least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair* Biologic (anti-neoplastic agent): at least 7 days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair* Immunotherapy: at least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines* Monoclonal antibodies: at least 3 half-lives of the antibody after the last dose of a monoclonal antibody* Radiation therapy (XRT): at least 14 days after local palliative XRT (small port); at least 150 days must have elapsed if prior total body irradiation (TBI), craniospinal XRT or if >= 50% radiation of pelvis; at least 42 days must have elapsed if other substantial bone marrow (BM) radiation* Stem cell infusion without TBI: no evidence of active graft vs host disease and at least 84 days must have elapsed after transplant or stem cell infusion* Patients must not have received prior exposure to ramucirumab",(C16169 = YES OR C16171 = YES OR (C16124 = YES AND C15187 =YES) OR C16168 = YES OR C15477= YES) AND C130200 = NO AND (C16124 = YES AND C70792 = NO)NCI-2015-00835,NCT02466971,"A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer",Exclusion,"Patients who have had a hysterectomy or are planning to have an adjuvant hysterectomy following radiation as part of their cervical cancer treatment are ineligiblePatient has had a prior invasive malignancy diagnosed within the last three years (except [1] non-melanoma skin cancer or [2] prior in situ carcinoma of the cervix); patients are excluded if they have received prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues at the discretion of the treating physicianPatient is receiving another investigational agent for the treatment of cancer",(C16124 = YES AND C15256 = NO) AND (C15477= NO OR C15477= YES) AND (C16171 = NO OR C16171 = YES)?NCI-2015-00866,NCT02474173,"Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer",Exclusion/INCLUSION,"EXCLUSIONPatients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the studyPatients who are receiving any other investigational agents within 4 weeks or 5 half-lives (whichever is later) prior to the first dose of the study regimenPrior radiation therapy within 2 weeks prior to the first dose of the study regimenPatients in whom prior treatment related toxicities have not recovered to grade 1 or less (except for alopecia)Recent initiation of bone modifying therapy with a bisphosphonate or denosumab unless it has been started more than 4 weeks prior to the first dose of the study regimen; patients who are already enrolled in this study can initiate bone modifying therapy after the first set of re-staging scans (>= 8 weeks from cycle 1, day 1)Prior therapy with AT13387 or another HSP90 inhibitorINCLUSIONAny number of prior therapies for metastatic breast cancer is allowed; patients with weakly estrogen receptor positive breast cancer who received any number of endocrine agents for metastatic breast cancer will also be eligiblePrior taxane is allowed (as long as the patient is not experiencing grade > 1 neuropathy and had no history of disease progression on a taxane therapy within 3 months prior to study enrollment)",(C16171 = NO OR C16171 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES)) AND (C16175 = NO OR C16175 = YES) AND ( C15477= NO OR C15477= YES) AND (C16124 = YES AND (C85454 = NO AND HSP90 Inhibitor = NO))NCI-2015-01000,NCT02484430,A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL),Inclusion/EXCLUSION,"INCLUSIONWorld Health Organization (WHO)-defined acute lymphoblastic leukemia and either:* Relapsed after achieving remission* Refractory to therapy* Newly diagnosed and ineligible for intensive chemotherapy inductionNote: patients with T lineage and B lineage ALL are eligible for this trial; likewise, patients with Philadelphia chromosome positive (Ph+) (as long as they are not candidate for other therapies for Ph+) and Ph- ALL are eligibleNo prior therapy with mTOR inhibitors except for rapalog treatment as part of graft-versus-host (GVH) prophylaxis or treatmentEXCLUSIONPatients who are receiving any other investigational agentsPatients who have had chemotherapy or radiotherapy =< 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; treatment with glucocorticoids, hydroxyurea, and tyrosine kinase inhibitors is allowed up to 24 hour prior to initiation of therapy",(C16171 = YES OR C15477= YES) AND (PRIOR = YES AND C2201 = NO)NCI-2015-01001,NCT02484443,"A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma",Inclusion,"Patient must not have received immune suppressants: corticosteroids (for other than allergic reactions and anaphylaxis), cyclosporine or tacrolimus within 7 days of enrollment* Note: the use of topical and/or inhalational steroids is allowedPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study* Myelosuppressive anti-cancer therapy: must not have been received within 2 weeks of study entry (4 weeks if prior nitrosourea)* Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biologic agent* Radiation therapy (RT): >= 2 weeks for local palliative radiation therapy (RT) (small port); >= 6 weeks must have elapsed if prior craniospinal RT or if >= 50% radiation of pelvis; >= 6 weeks must have elapsed if other substantial bone marrow (BM) radiation* Surgery: >= 2 weeks from last major surgery, including pulmonary metastasectomy, with the exclusion of a central line placement and core needle or small open biopsiesPatients must have had at least one episode of disease recurrence in the lungs without limitation on number of episodes of recurrence as long as they meet the following criteria:* Surgical resection of all possible sites of suspected pulmonary metastases in order to achieve a complete remission within 4 weeks prior to study enrollment*** Pathologic confirmation of metastases from at least one of the resected sites** For patients with bilateral pulmonary metastases, resection must be performed from both lungs and the study enrollment must be within 4 weeks from date of the last lung surgery* Note: If surgery related changes such as atelectasis are seen on the post-operative computed tomography (CT) scan, patients will remain eligible to enroll as long as the operating surgeon believes that all sites of metastases were resected; patients with positive microscopic margins will be eligible to enroll",C16171 = YES OR C15477= YES OR (C16124 = YES AND C15187 = YES) OR C16169 = YES NCI-2015-01053,NCT02496663,A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor,Inclusion/EXCLUSION,"INCLUSIONPatients must have recovered from adverse events attributable to previous treatment to =< grade 1, except for alopecia and sensory neuropathy =< grade 2Patients must have completed last chemotherapy >= 3 weeks or radiotherapy >= 2 weeks prior to receiving study drugsAny number of prior therapies is allowedFor the dose expansion portion ONLY, patient must: 1) have progression of disease with erlotinib, gefitinib or afatinib as last previous systemic treatment, 2) tumors must be EGFR-T790M negative confirmed by central testing prior to treatment (If EGFR-T790M status is unknown patients may consent for trial for biopsy and testing for EGFR T790M will be performed as part of initial biopsy for trial; patients who test positive for EGFR T790M by central testing will be ineligible for the dose expansion), 3) be treatment naive to 3rd generation EGFR-TKI (EGFR inhibitor CO-1686 [CO-1686] and AZD9291) and EGFR monoclonal antibodiesProgressive disease on at least one prior EGFR-TKI (previous treatment with 3rd generation EGFR-TKI including AZD9291 allowed for dose escalation only)EXCLUSIONPatients must discontinue previous EGFR-TKI at least 7 days prior to study enrollmentPatients who are receiving any other investigational agentsPatients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) (at least 1 week prior) and potent inducers of CYP3A4 (at least 3 weeks prior); all patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer/inhibitory effects of CYP3A4",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND C2167= YES)NCI-2015-01097,NCT02498613,A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors,Inclusion/EXCLUSION,"INCLUSIONToxicities of prior therapy (except alopecia) should be resolved to =< grade 1 as per National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0; patients with long-standing stable grade 2 neuropathy may be considered after discussion with the study principal investigator (PI)Patients who have the following risk factors are considered to be at increased risk for cardiac toxicities, and must have documented left ventricular ejection fraction (LVEF) by echocardiogram greater than institutionâ€™s lower limit of normal (or 55% if threshold for normal not otherwise specified by institutional guidelines) obtained within 3 months* Prior treatment with anthracyclines* Prior treatment with trastuzumab* A New York Heart Association (NYHA) classification of II controlled with treatment* Prior central thoracic radiation therapy (RT), including RT to the heart* History of myocardial infarction within 12 months (patients with history of myocardial infarction within 6 months are excluded from the study)EXCLUSIONPatients who have had chemotherapy or RT within 3 weeks prior to start of the study agents, or those who have not recovered from adverse events due to agents administered more than 3 weeks earlierPatients who have received prior inhibitor of VEGF signaling and a poly (ADP-ribose) polymerases (PARP) inhibitor administered in combination; unless administered in combination, patients who received a prior PARP inhibitor or a prior VEGF-signaling inhibitor agent are allowed after discussing with the PIParticipants receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible; dihydropyridine calcium-channel blockers are permitted for management of hypertensionCurrent condition requiring concurrent use of drugs or biologics with anti-arrhythmic or pro-arrhythmic potentialA major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib (percutaneous/endobronchial biopsies are allowed)",(C16171 = YES OR C16171 = NO) AND (C15477 = YES OR C15477= NO) AND (C16169 = YES OR C16169 = NO) AND (C16124 = YES AND (C62554 = NO OR C93259 = NO))NCI-2015-01098,NCT02503709,A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients with Advanced Solid Tumors,Exclusion/INCLUSION,"EXCSLUSION Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study; patients who have had prior onalespib or AT7519M as a monotherapy will not be excludedINCLUSIONThere are no limits on prior lines of therapy; however, patients must have recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to entering the study (except alopecia)",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES)NCI-2015-01139,NCT02503722,A Phase 1 Trial of MLN0128 in Combination with AZD9291 in Advanced EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) after Progression on a Previous EGFR Tyrosine Kinase Inhibitor,Inclusion/EXCLUSION,"INCLUSIONDOSE ESCALATION AND DOSE EXPANSION PHASE:* A minimum of 7 days must have elapsed from the last dose of the prior EGFR inhibitor and resolution of any drug-related toxicity to =< grade 2 except for alopecia* Prior chemotherapy, radiation therapy and surgery are permissible as follows:** Chemotherapy- a minimum of 21 days must have elapsed from the last dose and resolution of toxicity excluding =< grade 2 peripheral neuropathy or alopecia** Surgery- a minimum of 21 days must have elapsed following major surgery and complete wound healing must have occurred** Radiation- minimum of 14 days must have elapsed following radiation therapy and resolution of all radiation induced toxicityEXCLUSIONConcurrent anti-cancer therapy",C16171 = YES AND ( C15477= NO OR C15477= YES) AND (C16169 = NO OR  C16169 = YES)NCI-2015-01144,NCT02613364,"A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors",Inclusion/EXCLUSION,"INCLUSIONHave received surgery, chemotherapy, and/or radiation therapyHave completed all surgery, chemotherapy and/or radiation therapy within the last 2-60 monthsEXCLUSIONBe receiving any form of treatment for cancer with the exception of hormonal or biologic therapy",C16169 = YES OR C16171 = YES OR C15477= YES NCI-2015-01178,NCT02308085,"A Study Evaluating the Pregnancy Outcomes and Safety ofInterrupting Endocrine Therapy for Young Women withEndocrine Responsive Breast Cancer Who Desire Pregnancy",Inclusion/EXCLUSION,"INCLUSIONBreast cancer for which patient is receiving endocrine therapy must have been histologically-proven stage I-III, endocrine-responsive (i.e., estrogen and/or progesterone receptor positive, according to local definition of positive, determined using immunohistochemistry [IHC]), and treated with curative intent* Note:** Patients with synchronous bilateral invasive breast cancer (diagnosed histologically within 2 months) are eligible** Patient with invasive breast cancer or synchronous bilateral invasive breast cancer (diagnosed histologically within 2 months) during pregnancy are eligible** Patients with breast cancer 1/2, early onset (BRCA1/2) mutations are eligible** Patients could have received neo/adjuvant chemotherapy, or other systemic therapy (e.g., neo/adjuvant human epidermal growth factor receptor 2 [HER2]-targeted therapy) according to institutional policy and patientâ€™s desireThe adjuvant endocrine therapy must have stopped within 1 month prior to enrollmentHas received adjuvant endocrine therapy (selective estrogen receptor modulator [SERM] alone, gonadotropin-releasing hormone [GnRH] analogue plus SERM or aromatase inhibitors [AI]) for >= 18 months but =< 30 months for early breast cancer* Note: patients who have received neo/adjuvant endocrine treatment within a clinical trial and patients who have received pharmaco-prevention are eligibleEXCLUSIONHistory of hysterectomy, bilateral oophorectomy or ovarian irradiation",(C16171 = YES OR C16171 = NO) AND (C16175 = YES OR C16175 = NO) AND (C16124 = YES AND (C15256 = NO AND C51590 = NO) AND (C15477= NO OR (C15477= YES AND C12404 = NO))NCI-2015-01236,NCT02562716,A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma,Inclusion,"Patients must not have received prior surgery, radiation therapy, chemotherapy, targeted therapy, or any investigational therapy for pancreatic cancer",(C16169 = NO OR C16169 = YES OR C15477= NO OR C15477= YES OR C16171 = NO OR C16171 = YES OR (C16124 = YES AND (C49135 = NO OR C49135 = YES)) AND C9005 = NONCI-2015-01270,NCT02520778,A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-Mutant Non-small Cell Lung Cancer following Resistance to Initial EGFR Kinase Inhibitor,Inclusion/EXCLUSION,"INCLUSIONPatients must have recovered from adverse events attributable to previous treatment to =< grade 1, except for alopecia and sensory neuropathy =< grade 2Progression after prior treatment with an EGFR TKI; in addition to this one prior line of therapy, any additional prior lines of therapy are permitted; prior treatment with a third-generation EGFR TKI is allowed for the dose escalation phase, but is not permitted for the expansion cohortAny number of prior therapies are allowedEXCLUSIONMajor surgery within 21 days of starting protocol treatmentPatients receiving anticoagulation or anti-platelet therapy are excluded; excluded agents include heparin or low molecular weight heparin, warfarin, clopidogrel, ibuprofen and other nonsteroidal anti-inflammatory drug (NSAIDS), tirofiban, and other anticoagulants, drugs, or herbal supplements that affect platelet function; administration of heparin to keep subject's infusion lines patent is allowed; low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter are allowed; aspirin will not be allowed within 7 days prior to the first dose of navitoclax or during navitoclax administration; however, subjects who have previously received aspirin therapy for thrombosis prevention, may resume a low dose (i.e., maximum 100 mg QD) of aspirin if platelet counts are stable (>= 50,000/mm3) through 6 weeks of navitoclax administration; all decisions regarding treatment with aspirin therapy will be determined by the investigator in conjunction with the medical monitor",(C16171 = YES OR C16169 = YES) AND (C16124 = YES AND C2167= YES)NCI-2015-01271,NCT02520791,A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL),Exclusion,"Major surgery within 30 days prior or during the study periodReceipt of live or live attenuated vaccine within 12 weeks prior to enrollmentPatients who have undergone allogeneic stem cell transplantationPatients who have undergone autologous stem cell transplantation within 3 months from study entry",(C16169 = NO OR C16169 = YES) AND (C16168 = NO OR C16168 = YES) AND (C16124 = YES AND ((C16039= NO OR C16039= YES) AND C147925= NO))NCI-2015-01348,NCT02490878,Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases,Inclusion,"No excess risk of bleeding (any of the following):* Bleeding diathesis or coagulopathy* Thrombocytopenia* Major surgical procedure, open biopsy, or significant traumatic injury within the past 28 days or anticipation of need for major surgical procedure during the course of the study* Minor surgical procedures, stereotactic biopsy, fine need aspiration, or core biopsy within the past 7 daysNo bevacizumab =< 3 months of study registrationNo systemic therapy within 2 weeks prior to registration or plan for systemic therapy within the first 8 weeks after study registration",(C16169 = NO OR C16169 = YES) AND (C16171 = NO OR C16171 = YES) AND  C15477= YESNCI-2015-01408,NCT02535325,A Phase I Study of Methoxyamine Combined with Chemo-radiation for Locally Advanced Non-squamous Non-small Cell Lung Cancer,Exclusion,"Patients receiving any medications or substances that are inhibitors or inducers of nonsteroidal anti-inflammatory drugs (NSAIDS), probenecid, salisylates, sulfonamides are ineligible; concomitant drugs that are sensitive cytochrome P450 (CYP450) substrates or strong and moderate CYP450 inducers and inhibitors should be avoided; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal productPatients who have had prior chemotherapy or any other investigational drug within 30 days of registration or prior radiotherapy to the study treatment volume; prior surgery is allowed; there must be at least 6 weeks between mitomycin or nitrosoureas and any new therapyPatients who are receiving any other investigational agents",(C16171 = NO OR C16171 = YES ) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES)) AND (C16169 = NO OR C16169 = YES) AND C15477= NO? NCI-2015-01411,NCT02535338,A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-small Cell Lung Cancer,Inclusion/EXCLUSION,"INCLUSIONPatients must have recovered from adverse events attributable to previous treatment to =< grade 1, except for alopecia and sensory neuropathy =< grade 2FOR PHASE II COHORT A: If patient is on erlotinib at the time of signed consent, erlotinib does NOT need to be discontinued prior to receiving treatment erlotinib and onalespib; last dose of erlotinib must be less than 28 days from when patient signs consentFOR PHASE II COHORT B: (EGFR Exon 20 Insertions): Prior EGFR-TKIs including erlotinib is allowed; if patient is on erlotinib at the time of signed consent, erlotinib does NOT need to be discontinued prior to initiation of erlotinib and onalespibPatients must have completed last chemotherapy >= 3 weeks or radiotherapy >= 2 weeks prior to receiving study drugsEXCLUSIONPatients who are receiving any other investigational agents",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES)NCI-2015-01548,NCT02635009,Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer,Exclusion,"Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields",C15477= NO OR (C15477= YES AND C12418 = NO)NCI-2015-01640,NCT02568553,A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL),Exclusion/INCLUSION,"EXCLUSIONPrior treatment with blinatumomab or CD-directed CAR T-cell therapyPrior treatment with lenalidomide within 8 weeks prior to entering the studyPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierINCLUSIONPatients must have had at least two prior chemotherapeutic or biologic (ie. rituximab alone) regimens and not currently eligible for standard curative options; steroids alone and local radiation do not count as regimensAny prior therapy must have been completed at least 4 weeks prior to entry into the study",(C16124 = YES AND ((C62528 = NO AND (C126102 = NO OR (C126102 = YES AND C78347 = NO)))) AND (C16171 = YES OR C15477= YES)NCI-2015-01642,NCT02567409,A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma,Inclusion,No prior cytotoxic chemotherapy for metastatic disease,C16171 = NO OR (C16171 = YES AND C19151 = NO)NCI-2015-01643,NCT02567422,A Phase I Study of VX-970 in Combination with Cisplatin and XRT in Patients with Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121),Exclusion,"Prior systemic chemotherapy for the current cancer (prior chemotherapy for a different cancer is allowed)Prior receipt of radiotherapy that would result in overlap of the new and old radiation therapy fields",(C16171 = NO OR (C16171 = YES AND PRIOR TREATMENT OF CURRENT CANCER = NO)) AND (C15477= NO OR (C15477= YES AND C12418 = NO))NCI-2015-01644,NCT02567435,"A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) versus VAC/VI plus Temsirolimus (TORI, Torisel, NSC# 683864, IND#122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)",Exclusion,Patients who have received any chemotherapy (excluding steroids) and/or radiation therapy prior to this enrollment,C16171 = NO AND C15477= NONCI-2015-01681,NCT02572453,"Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL",Exclusion/INCLUSION,"EXCLUSIONPatients who are receiving any other investigational agents; all investigational agents other than ibrutinib must have been discontinued at least 4 weeks prior to beginning treatment; prior ibrutinib therapy must have been discontinued at least 2 weeks prior to beginning therapyPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; steroids for symptom palliation are allowed, but must be either discontinued or on stable doses at the time of initiation of protocol therapyINCLUSIONBCL6+ DLBCL: patients must have disease that has relapsed and or is refractory to prior therapy, which must have included an anthracycline, if not contraindicated; patients must have relapsed following or be ineligible for, or refuse, autologous stem cell transplantMCL: patients must have disease that has relapsed and or is refractory to prior therapy, which must have included a multiagent chemotherapy regimen and prior ibrutinib or other BTK inhibitor therapy; patients must have relapsed following or be ineligible for, or refuse, autologous stem cell transplantALK+ ALCL: patients must have disease that has relapsed and or is refractory to prior therapy, which must have included a multiagent chemotherapy regimen including an anthracycline, if not contraindicated, and prior brentuximab; prior crizotinib or other ALK inhibitor therapy, while recommended, is not mandatory; patients must have relapsed following or be ineligible for, or refuse, autologous stem cell transplant",(C16124 = YES AND (C49135 = YES OR C49135 = NO)) AND (C16171 = YES OR C16171 = NO) AND (C15477= NO OR C15477= YES)NCI-2015-01706,NCT02749903,A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers,Inclusion,"No prior therapy with enzalutamide (previous chemotherapy and/or other AR-targeted approaches is allowed)Any number of prior lines of therapyChronic concomitant treatment with strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors is not allowed; patients must discontinue the drug >= 14 days prior to registrationChronic concomitant treatment with strong cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8) inhibitors is not allowed; patients must discontinue the drug >= 14 days prior to registration",(C16124 = YES AND C71744 = NO) AND (C16171 = YES OR C16171 = NO) AND (C16175 = YES OR C16175 = NO)NCI-2015-01707,NCT02761057,"A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)",Inclusion,"Patients may have received prior surgery; at least 28 days must have elapsed since surgery and patient must have recovered from any adverse effects of surgeryPatients may have received up to one prior systemic therapy for advanced or metastatic renal cell carcinoma with the exception of another VEGF inhibitor Food and Drug Administration (FDA)-approved for advanced RCC (i.e., pazopanib, bevacizumab, sorafenib or axitinib); if a patient develops metastatic disease within six months of discontinuation of adjuvant therapy, this will constitute one prior systemic therapy for advanced or metastatic renal cell carcinoma (RCC); if a patient develops metastatic disease and more than six months has elapsed since discontinuation of adjuvant therapy, this will not constitute prior systemic therapy for advanced or metastatic RCC; patients may have also received prior immunotherapy; patients must not have received a MET/hepatocyte growth factor (HGF) inhibitor or sunitinib as prior therapy; at least 14 days must have elapsed since completion of prior systemic therapy; patients must have recovered from all associated toxicities at the time of registrationPatients may have received prior radiation therapy, but must have measurable disease outside the radiation port; at least 14 days must have elapsed since completion of prior radiation therapy; patients must have recovered from all associated toxicities at the time of registration",(C16169 = YES OR C16169 = NO) AND (C16171 = NO OR (C16171 = YES AND C93259 = NO) OR (C16171 = YES AND C93259 = YES AND C9385 = NO)) AND (C15477= YES OR C15477= NO)NCI-2015-01744,NCT02581930,A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance,Exclusion/INCLUSION,"EXCLUSIONSubjects who received a strong cytochrome P450 (CYP) 3A inhibitor within 7 days prior to the first dose of ibrutinib or subjects who require continuous treatment with a strong CYP 450 3A inhibitorPatients who have had chemotherapy or immunotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy within 2 weeks prior to cycle 1 day 1; patients who have had tyrosine kinase inhibitors (such as Brad or MEK inhibitors) within 15 days of cycle 1 day 1Need for daily corticosteroids at high doses (prednisone =< 20 mg daily, or an equivalent) is prohibited from 28 days prior to first dose and during treatment with ibrutinib; brief (up to 7 days) and episodic use of systemic corticosteroids for other general conditions (e.g. pre-medication for radiographic imaging due to intravenous [IV] contrast allergy, chronic obstructive pulmonary disease [COPD] exacerbation, poison ivy, etc.) is allowedPrior exposure to ibrutinib or other ITK inhibitorsReceived anticoagulation therapy with warfarin, or equivalent vitamin K antagonists, within the last 28 days prior to day 1 of ibrutinib; patients with familial coagulopathic diseases (e.g. hemophilia, von Willebrand disease) are also excluded; if applicable, subjects must discontinue fish oil and vitamin E supplements within 7 days prior to initiating ibrutinib therapyINCLUSIONPrior treatment-related toxicity resolved to =< grade 1 or baseline with the exception of alopecia and permanent grade =< 2 toxicities related to prior immune checkpoint inhibitor treatment (e.g. PD-1/PD-L1, CTLA-4, CD40, LAG3) treatment with the review and approval by the lead principal investigator (PI)Prior radiation allowed (no restriction on amount); measurable lesion(s) may not have been previously irradiated",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16168 = NO OR C16168 = YES) AND (C16124 = YES AND (C81934 = NO AND ITK Inhibitor = NO)NCI-2015-01745,NCT02797470,"A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells",Exclusion/INCLUSION,"EXCLUSIONHistory of grade III hemorrhagic cystitis due to prior cyclophosphamide chemotherapyINCLUSIONBiopsy-proven intermediate or high-grade non-Hodgkinâ€™s lymphoma, meeting one of the following criteria (timeline 8 months prior to enrollment):* In partial remission* Relapsed after initial complete remission* Failed induction therapy, but responds to salvage therapy (i.e., chemosensitive disease)* In complete remission with high-risk features as specified by the International Prognostic IndexBiopsy-proven advanced stage follicular lymphoma, that have failed at least two lines of therapy multi-agent chemotherapy, but responds to salvage therapy (i.e., chemosensitive disease) (timeline 8 months prior to enrollment)Biopsy-proven Hodgkinâ€™s lymphoma, meeting one of the following criteria (timeline 8 months prior to enrollment)* In first, or greater relapse after initial complete remission* In partial remission* Failed induction therapy, but responds to salvage therapy (i.e., chemosensitive disease)Biopsy-proven Burkittâ€™s lymphoma, meeting one of the following criteria (timeline 8 months prior to enrollment):* In second complete remission after relapse following initial complete remission* Failed induction therapy, but responds (very good partial remission, complete remission, or near complete remission) to salvage therapy (i.e., chemosensitive disease)",(C16171 = YES OR C16171= NO) AND (C15477= YES OR C15477= NO)NCI-2015-01779,NCT02589522,Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC),Exclusion,"Patients must not have received prior WBRT (previous SRS done at least 4 weeks ago is acceptable)Patients who have had systemic cytotoxic chemotherapy or other targeted agents or any other investigational agents within 4 half-lives (6 weeks for nitrosoureas or mitomycin C) prior to starting study treatment or patients who have not recovered from serious adverse events due to agents administered more than 4 weeks earlier",(C15477= NO OR (C15477= YES AND C12439=NO)) AND (C16171 = NO OR C16171 = YES)NCI-2015-01906,NCT02595866,Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm,Inclusion/EXCLUSION,"INCLUSIONNon-small cell lung cancer (NSCLC)* Metastatic or locally advanced disease that progressed after at least one prior therapy * Note: patients who have actionable molecular targets (e.g., epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK], c-ros oncogene 1[ROS1] mutations) must have received (when indicated) prior appropriate targeted therapy using Food and Drug Administration (FDA)-approved agentsKaposi sarcoma (KS) impacting physical and/or psychological wellbeing and not amenable to local therapy and one or more of the following: * Stable KS by despite 6 or more cycles of liposomal doxorubicin or paclitaxel or other active cytotoxic agents (i.e. etoposide, bleomycin, anthracyclines, vincristine [vincristine sulfate], vinblastine); or* Progressive disease despite 3 or more cycles of liposomal doxorubicin or paclitaxel or other active cytotoxic agents (i.e. etoposide, bleomycin, anthracyclines, vincristine, vinblastine); or* Patient who has received a cumulative lifetime dose of anthracycline of >= 550 mg/m^2; or* Recurrent or progressive KS after completion of prior first line chemotherapy* Intolerant of or refuse further cytotoxic chemotherapyMelanoma* Unresectable or metastatic and disease progression following a B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor if BRAF V600 positive* Note: prior therapy with ipilimumab not requiredResolution of any adverse events (AEs) from prior treatments must be resolved to baseline or grade =< 1 AE if resolvable at enrollment (with the exception of alopecia), neuropathy, and ototoxicity (i.e., AEs that are not expected to improve within the washout period)No prior treatment with anti-PD-1 or anti-PD-L1EXCLUSIONSystemic steroid therapy or steroid therapy that cannot be discontinued with more than 7 consecutive days of steroids within the prior 2 weeks* Note: the use of prednisone or equivalent < 0.125 mg/kg/day (absolute maximum of 15 mg/day) as replacement therapy is permitted; inhaled or topical corticosteroids are permittedPrior organ allograft or allogeneic transplantation, if the transplanted tissue is still in place",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND (C15289 = NO AND PD-L2 INHIBITOR = NO AND PD-L1 Inhibitor = NO)NCI-2015-01907,NCT02595879,Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer,Exclusion,No prior pelvic radiation therapy or chemotherapy,C16171 = NO AND (C15477= NO OR (C15477= YES AND C12767 = NO)NCI-2015-01910,NCT02595892,Phase 2 Study of VX-970 (NSC# 780162) in Combination with Gemcitabine versus Gemcitabine Alone in Subjects with Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer,Inclusion/EXCLUSION,"INCLUSIONPrior therapy: No line limit but no more than 1 prior regimens in the platinum resistant setting; no prior treatment targeting the ATR/checkpoint kinase 1 (CHK1) pathway and no prior gemcitabine as single agent; hormonal therapies immunotherapy, and antiangiogenic therapies (as single agents) do not count as lines; poly (adenosine diphosphate [ADP]-ribose) polymerases (PARP)-inhibitors count as line of therapy; prior carboplatin/gemcitabine is allowed provided that there was no disease progression within 12 months after completion of the carboplatin/gemcitabine regimen; subjects may begin protocol treatment at least 4 weeks or 5 half-lives, whichever is shorter, after their last dose of chemotherapy or hormonal therapy, assuming they are otherwise eligibleAll acute, clinically significant treatment-related toxicity from prior therapy, except for alopecia, must have resolved to grade =< 1 prior to study entryEXCLUSONPatients who have had chemotherapy within 4 weeks or five half-lives, whichever is shorter, (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier",(C16124 = YES AND (ATR/Checkpoint Kinase 1 (CHK1) Pathway Inhibitor = NO AND (C66876 = NO OR (C66876 = YES AND C15756 =NO)))) AND (C16175 = NO OR C16175 = YES) AND (C16171 = NO OR C16171 = YES)NCI-2015-01911,NCT02734537,Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing,Inclusion,"Per the operative report, the gross total resection of the primary tumor with curative intent was completed within 8 weeks prior to randomization",C16169 = YESNCI-2015-01912,NCT02595905,Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer,Inclusion,"Patients must have had =< 1 prior cytotoxic regimen for metastatic diseasePatients must have completed any prior radiation therapy and hormonal therapy at least 14 days prior to registrationPatients must not have received prior cisplatin or poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors; prior carboplatin in the adjuvant/neoadjuvant setting and prior treatment with iniparib is allowed, if completed more than 6 months prior to study entryPatients must not have received any chemotherapy within 14 days prior to registrationPatients must not have received any immunotherapy, biologic or any investigational drug within 28 days prior to registration; patients must not have received bevacizumab within 42 days prior to registrationPatients with known brain metastases must either meet the additional criteria and enroll as part of the brain metastases cohort, or else have clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 14 days of stable neurologic function prior to registration; patients with previously treated progressive brain metastases are not eligible for the standard cohort, but may be considered for the brain metastases cohort","C16171 = YES AND (C15477= NO OR C15477= YES) AND (C16175 = NO OR C16175 = YES) AND (C16124 = YES AND (C376 = NO AND C62554 = NO) AND (C16168 = NO OR C16168 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES)) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES))"NCI-2015-01913,NCT02595918,"A Pilot Study of Neoadjuvant Nivolumab in High-Risk, Non-metastatic, Renal Cell Carcinoma",Exclusion,Prior systemic therapy for renal cell carcinoma,C16171 = NO OR (C16171 = YES AND C9385 = NO)NCI-2015-01915,NCT02595931,Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors,Exclusion/INCLUSION,"EXCLUSIONPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from clinically significant adverse events due to prior agents administered to =< grade 1 or baseline with the exception of alopecia and peripheral neuropathy, unless approved by the protocol chairINCLUSIONNo limit on prior lines of therapy for metastatic disease; prior adjuvant or neoadjuvant chemotherapy does not count as a prior line of therapy as long as completion of the adjuvant or neoadjuvant therapy was more than 1 year prior to patient enrollment",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES)NCI-2015-01916,NCT02595944,Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab after Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers,Inclusion,"Prior to randomization patients with any non-hematologic toxicity from surgery, chemotherapy and radiation therapy must have recovered to grade =< 1 with the exception of alopecia, ototoxicity and neuropathyPatients must have completed and recovered from any adjuvant chemotherapy 2 or more weeks prior to randomization (6 weeks for mitomycin and nitrosoureas; 4 weeks for post-operative radiation therapy)No prior treatment with an immune checkpoint inhibitor (anti-programmed cell death [PD]-1, anti-PD-L1, anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] monoclonal antibody)",(C16169 = NO OR C16169 = YES) AND (C16171 = NO OR C16171 = YES) AND (C15477 = NO OR C15477= YES) AND (C16124 = YES AND C143250 = NO)NCI-2015-01917,NCT02642965,"A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)",Inclusion,"Growth factors:* Patients must not have received growth factors for 7 days prior to CPX-351* Patients must not have received pegfilgrastim for 14 days prior to CPX-351Stem cell transplant (SCT): no evidence of active graft vs. host disease for at least 4 weeks; for allogeneic SCT patients, >= 3 months must have elapsed since transplant* Must have received no more than 1 prior autologous or allogeneic stem cell transplant.* Patients must be off all systemic immunosuppressive therapy for at least 2 weeks, excluding hydrocortisone for physiologic cortisol replacementRadiation therapy (RT): >= 2 weeks for local palliative RT (small port); >= 6 months must have elapsed if prior craniospinal RT or if >= 50% radiation of pelvis; >= 6 weeks must have elapsed if other substantial bone marrow (BM) radiation; Note: patients must have received =< than 13.6 Gray (Gy) prior radiation to the mediastinumMyelosuppressive chemotherapy: must not have received myelosuppressive chemotherapy within 3 weeks of entry onto this study (excluding hydroxyurea)* Cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of CPX-351Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, stem cell transplant or radiotherapy prior to entering this study; all prior treatment-related toxicities must have resolved to =< grade 2 prior to enrollmentTo be eligible for the phase 2 efficacy phase:* Relapse patients:** Patients must be in first marrow relapse, and ** Patients must not have received prior re-induction therapy; donor lymphocyte infusion (DLI) is considered a re-induction attemptTo be eligible for the dose-finding phase: (the dose-finding phase completed in 12/2016) * Relapsed patients** Patients must be in first relapse, and** Patients must not have received prior re-induction therapy* Refractory patients** Patients must not have received more than one attempt at remission induction, which may consist of up to two different therapy courses; Children Oncology Group (COG) AAML1031 de novo therapy including induction I and induction II is an example* Treatment-related AML (t-AML)** Patients must be previously untreated for secondary AML",C15477= YES OR C16171 = YES OR C16168 = YES OR C147925= YES OR (C16124 = YES AND C16039 = YES )NCI-2015-01918,NCT02750826,Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer,Inclusion,"No prior bariatric surgery or planning to undergo this procedure within the next 2 years after study registrationPatients must have had a bilateral mammogram within 12 months prior to registration, unless the initial surgery was a total mastectomy, in which case only a mammogram of the remaining breast is required; (subjects with bilateral total mastectomies do not require imaging)All adjuvant or neoadjuvant chemotherapy, radiation, and surgery completed at least 21 days prior to registration* All triple negative patients must receive chemotherapy of the treating physicianâ€™s choice* ER/PR+ patients must receive chemotherapy (of the treating physicianâ€™s choice) unless Oncotype Dx or another genomic predictor score indicates that they are at low or intermediate risk of disease recurrence with endocrine therapy alone* Patients may have breast reconstruction during protocol participation, but definitive breast cancer surgery must be completed at least 21 days prior to registration** Concomitant biologic therapy, hormonal therapy, and bisphosphonates are acceptableAll subjects (both adjuvant and neoadjuvant) must have sentinel lymph node biopsy and/or axillary lymph node dissection* Sentinel lymph node biopsy alone is allowed in the following instances:** Sentinel lymph node biopsy is negative: pN0** Sentinel lymph node biopsy is positive for isolated tumor cells only: pN0 (i+)** Clinically node negative, T1-2 tumors with sentinel lymph node biopsy positive in =< 2 lymph nodes without matted nodes and undergoing breast conserving surgery and tangential whole breast irradiation, or undergoing mastectomy and chest wall irradiation** For patients who had a positive node prior to neoadjuvant chemotherapy, sentinel node alone is allowed after neoadjuvant therapy if:*** Sentinel node biopsy is negative after chemotherapy and either at least 2 sentinel nodes were removed or a clip was placed in the involved node prior to treatment*** =< 2 lymph nodes are positive for cancer and the patient is participating in A011202HIV seropositive participants must be on antiretroviral therapy (ART) with the following criteria:* A complete ART regimen that does not include the study drug as one of a minimum of 3 active drugs, which may include an integrase inhibitor or efavirenz in combination with nucleoside reverse-transcriptase inhibitors (NRTIs)* The ART regimen must not include protease inhibitor (PIs); participants must not have received a PI-based regimen for at least 4 weeks prior to enrollment* Participants must either have an undetectable HIV plasma ribonucleic acid (RNA), or if plasma RNA detectable, must be on the same stable regimen for a minimum of 12 weeks prior to study enrollment* No minimum cluster of differentiation (CD)4 count, but maximum HIV plasma RNA of 1,000 copies/mL",(C16169 = NO OR (C16169 = YES AND C84399 = NO)) AND (C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES)NCI-2015-01919,NCT02717455,Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma,Inclusion/EXCLUSION,"INCLUSIONNON-PROGRESSED DIPG (STRATUM 2): Patients must have recovered from the acute treatment-related toxicities (defined as =< grade 1) of radiotherapy prior to entering this studyNON-PROGRESSED DIPG (STRATUM 2): Patients must have had their last fraction of focal irradiation to the primary site > 14 days prior to enrollment; patients must not have received local palliative irradiation or craniospinal irradiationNON-PROGRESSED DIPG (STRATUM 2): Patients must be off all colony-forming growth factor(s) for at least 7 days prior to enrollment (i.e. filgrastim, sargramostim or erythropoietin); 14 days must have elapsed if patients received PEG formulationsRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients must be off all colony-forming growth factor(s) for at least 7 days prior to enrollment (i.e. filgrastim, sargramostim or erythropoietin); 14 days must have elapsed if patients received poly(ethylene glycol) (PEG) formulationsRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Biologic or investigational agent (anti-neoplastic): patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent >= 7 days prior to study enrollment * For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur, and discussed with the principal investigatorRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients must have received their last dose of known myelosuppressive anticancer therapy or immunotherapy at least 21 days prior to enrollment (42 days if prior nitrosourea)RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients must have received a minimum of 54 Gy focal irradiation administered over approximately 42 days prior to enrollment; patients must have recovered from the acute treatment-related toxicities (defined as =< grade 1) of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this studyEXCLUSIONRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients have had prior bone marrow transplantRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients have had valproic acid within 28 days prior to enrollmentRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients have had prior histone deacetylase (HDAC), deacetylase (DAC), heat shock protein 90 (HSP90) inhibitors for the treatment of their DIPG",(C15477= NO OR C15477= YES) AND (C16124 = YES AND (C1946 = NO OR (C1946 = YES AND C94764 = NO) AND (Deacetylase Inhibitor = NO OR (Deacetylase Inhibitor = YES AND C94764 = NO) AND (HSP90 INHIBITOR = NO OR (HSP90 INHIBITOR = YES AND C94764 = NO) AND (C49135 = NO OR C49135 = YES)) AND (C16124 = YES (C15187 = NO OR C15187 = YES)) AND (C16168 = NO OR C16168 = YES)NCI-2015-01929,NCT02601209,A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma,Inclusion,"Chronic concomitant treatment with proton pump inhibitors must discontinue the drug for 7 days prior to registration on the studyPrior treatment with pazopanib or any phosphoinositide 3-kinase (PI3K), mTOR, protein kinase B (AKT), or dual PI3K/mTOR complex (CREB regulated transcription coactivator [TORC]1/TORC2) inhibitors will be prohibitedChronic concomitant treatment with strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors must discontinue the drug for 14 days prior to registration on the studyPatients should have resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, grade 1 or lessProgression on at least one prior systemic chemotherapy for advanced, unresectable or metastatic disease; prior adjuvant or neoadjuvant therapy is not included as prior systemic chemotherapy unless treatment occurred within the 6 months prior to study enrollmentThere is no limit to the number of prior lines of treatment a patient has received",(C16124 = YES AND (C74547 = NO AND Phosphoinositide 3-kinase (PI3K) Inhibitor = NO AND C2201 = NO AND Protein Kinase B (AKT) Inhibitor = NO AND Dual PI3K/mTOR Complex (CREB Regulated Transcription Coactivator [TORC]1/TORC2) Inhibitor) = NO)) AND C16171 = YESNCI-2015-02064,NCT02627443,"Phase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine with or without VX-970 in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer",Exclusion,"Prior exposure to gemcitabinePatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier, excluding alopecia; patients with treatment related effects, such as peripheral neuropathy, that are grade 1 or less are eligible",(C16124 = YES AND C66876 = NO) AND (C16171 = YES OR C15477= YES)NCI-2015-02125,NCT02631733,A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors,Exclusion,"Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients must have completed prior biological therapies and/or targeted therapies >= 2 weeks prior to study enrollment; patients who have had radiation to the pelvis or other bone marrow-bearing sites will be considered on a case by case basis and may be excluded if the bone marrow reserve is not considered adequate (i.e. radiation to > 25% of bone marrow)INCLUSIONPrior poly ADP ribose polymerase (PARP) inhibitor therapy is allowed; patients with ovarian cancer and a BRCA mutation should have had prior treatment with olaparib per guidelines for standard of care treatment",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES))NCI-2015-02126,NCT02631746,Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma,Exclusion/INCLUSION,"EXCLUSIONPrior allogeneic transplantationGrade 2 or greater toxicity from prior therapyPrior treatment with anti-PD-1, anti-programmed death-ligand (PD-L)1, anti-PD-L2 antibodyPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierINCLUSIONPatients with acute or lymphoma forms must have received at least one cycle of combination chemotherapy (with or without mogamulizumab) or interferon (with or without zidovudine and/or arsenic); individuals with chronic or smoldering acute T-cell lymphoma (ATL) are not required to have had prior treatment or could have received any number of previous courses of therapy",C147925= NO AND (C16124 = YES AND (PD-L1 Inhibitor = NO AND C124946 = NO AND PD-L2 INHIBITOR = NO)) AND (C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES)NCI-2015-02248,NCT02890355,Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer,Inclusion,"Prior systemic therapy and chemoradiotherapy for treatment of resectable, borderline resectable or locally advanced unresectable disease is allowed and does not count toward prior therapy for metastatic diseasePatients must have had one and only one prior regimen of systemic therapy for metastatic disease unless the patient meets the criteria belowPatients must not have received prior PARP inhibitor therapy including, but not limited to ABT-888, olaparib, rucaparib, and talazoparib (BMN637)Patients must not have received prior irinotecan-based chemotherapy (e.g. irinotecan hydrochloride, leucovorin calcium, fluorouracil, and oxaliplatin [FOLFIRINOX] or FOLFIRI)Patients must have completed systemic therapy at least 14 days prior to registration, any surgical procedure must have been performed at least 14 days prior to registration, and radiation therapy must be completed at least 7 days prior to registration; patients must have recovered from major side effects of prior therapies or procedures in the opinion of the local site investigator prior to registration",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND (C62554 = NO AND C62040 = NO)) AND (C16169 = NO OR C16169 = YES)NCI-2015-02250,NCT02642042,A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease following One or Two Prior Systemic Therapies,Inclusion,"PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have documented progressive cancer following at least one but no more than two prior regimens of systemic therapy for lung cancer, one of which must have been platinum based combination chemotherapy; treatment with an immune therapy or targeted therapy for advanced disease will be considered a separate regimen and will count toward the prior regimens; maintenance therapy will not be counted as a separate regimen; adjuvant chemotherapy or chemotherapy administered as part of concurrent chemotherapy and radiation therapy for the treatment of lung cancer will not count as a prior regimen of systemic therapy as long as recurrence of patientâ€™s lung cancer occurred more than 12 months after the last day of chemotherapyPRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have received any chemotherapy, biologic agent, or any investigational agent within 14 days prior to registration. Patients must have recovered from any adverse events to Common Terminology Criteria for Adverse Events (CTCAE) grade 0-1 prior to registrationPRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have received prior docetaxel; patients must not have received therapy with a drug known to be either a mitogen-activated protein kinase (MEK) inhibitor or a phosphatidylinositol 3 kinase (PI3K)/v-akt murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of rapamycin (mTOR) pathway inhibitorPRIOR/CONCURRENT THERAPY CRITERIA: Prior treatment with an anti-PD-1 or anti-PDL1 is not requiredPRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have had a major surgery within 28 days prior to registration; patients must have recovered from any adverse effects of prior surgery to the satisfaction of the treating physician; biopsies and central IV access placement are not considered major surgeryPRIOR/CONCURRENT THERAPY CRITERIA: Patients may have had prior radiation therapy as long as it has not affected greater than 25% of the bone marrow and at least one measurable lesion is outside the area of prior radiation; at least 7 days must have elapsed since last radiation treatment; patients must have recovered from any adverse events from prior radiation therapy to =< CTCAE grade 1PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have recovered from any adverse effects from prior therapy (except alopecia) to =< CTCAE grade 1 prior to registrationPatients must not have had prior treatment with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathwaysPatients must not have received systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to sub-study registration; inhaled or topical steroids, and adrenal replacement doses =< 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease",(C16171 = YES AND C1450 = YES AND C191 = YES) AND (C16124 AND (C15187 = NO OR C15187 = YES) AND (C16124 = YES AND ((C49135 = NO OR C49135 = YES) AND C1526 = NO AND C69145 = NO AND Phosphatidylinositol 3 kinase (PI3K)/v-akt murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of rapamycin (mTOR) pathway inhibitor = NO) AND (C16169 = NO OR C16169 = YES) AND (C15477= NO OR (C15477= YES AND C54225 = YES)) AND (C16124 = YES AND (C143250 = NO AND T-cell co-stimulator = NO))NCI-2016-00071,NCT03077451,A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma,Exclusion/INCLUSION,"EXCLUSIONParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study enrollment or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to study enrollmentINCLUSIONParticipant may be either previously untreated for KS or refractory to or intolerant of any one or more prior KS therapies",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES)NCI-2016-00150,NCT02724579,A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients,Exclusion,Patients must not have received any prior tumor-directed therapy other than surgical intervention and corticosteroids,"(C16169 = NO OR C16169 = YES)NOT CLEAR IF BY ""TUMOR-DIRECTED"" THEY MEAN THE C25471 TUMOR OR ANY CANCER?"NCI-2016-00195,NCT02689453,A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL),Exclusion/INCLUSION,"EXCLUSIONPatients who have received any systemic corticosteroid therapy within 4 weeks prior to the start of therapy, with the exception of physiological replacement doses of cortisone acetate or equivalentINCLUSIONPatients must have recovered to less than grade 1 Common Terminology Criteria for Adverse Events (CTCAEv4) from toxicity of prior chemotherapy or biologic therapy and must not have had major surgery, chemotherapy, radiation or biologic therapy within 4 weeks prior to beginning treatment",(C16171 = YES) OR (C16124 = YES AND C15187 = YES)NCI-2016-00203,NCT02713386,"A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Exclusion,"Patients who have received prior chemotherapy for any abdominal or pelvic tumor within the last three years are excluded; patients may have received prior adjuvant chemotherapy and radiotherapy for localized breast cancer, provided that it was completed more than 2 years prior to registration, the patient remains free of recurrent or metastatic disease and hormonal therapy has been discontinuedPatients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis or thoracic cavity within the last three years are excluded; prior radiation for localized cancer of the head and neck or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic diseaseReceipt of an investigational study drug for any indication within 30 days or 5 half-lives (whichever is longer) prior to day 1 of protocol therapy",(C16171 = NO OR C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16175 = NO OR C16175 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES))NCI-2016-00222,NCT02921256,A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer,Exclusion,"Prior treatment with an investigational compound being tested in this study (e.g., poly ADP ribose polymerase [PARP] inhibitor)",(C16124 = YES AND (C1794 = NO AND C505= NO AND C607= NO AND C1181 = NO AND C60768 = NO))NCI-2016-00232,NCT02717507,Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial,Inclusion,Patient must have completed cancer treatment >= 2 years prior to study enrollment,C16124 = YESNCI-2016-00233,NCT02927249,A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial,Inclusion,"Prior adjuvant treatment with chemotherapy and/or endocrine therapy, as determined by the treating physician, is allowed; the last dose of chemotherapy or radiation therapy must be at least 30 days prior to study registration; concurrent hormonal therapy will be allowed",(C16171 = NO OR C16171 = YES) AND (C16175 = NO OR C16175 = YES) AND (C15477= NO OR C15477= YES)NCI-2016-00264,NCT02728596,A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia-Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER),Inclusion,"Patients must be registered prior to their first cycle of systemic therapy (chemotherapy, immunotherapy, biologic therapy, or combination regimens) their current disease and stage (or disease setting); patient must not have had any systemic therapy in the 180 days just prior to registration",C16124 = NO OR C16124 = YESNCI-2016-00325,NCT02728258,"A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations",Exclusion/INCLUSION,"EXCLUSIONPatients who have had prior therapy with any phosphatidylinositol 3 kinase (PI3K)/v-akt murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of rapamycin (mTor) pathway inhibitorUnresolved toxicity higher than CTCAE grade 1 attributed to any prior therapy/procedure, excluding alopeciaINCLUSIONPatients may have received prior radiation therapy for treatment of endometrial cancer; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, intravaginal brachytherapy and/or palliative radiation therapy; all radiation therapy must be completed at least 4 weeks prior to registrationPatients may have received prior hormonal therapy for treatment of endometrial carcinoma; all hormonal therapy must be discontinued at least 4 weeks prior to registrationPatients may have received prior therapy (including chemotherapy, biologic/targeted therapy and immunotherapy) for treatment of endometrial cancer; all therapy must be discontinued at least 4 weeks prior to registration; any investigational agent must be discontinued at least 30 days prior to registrationPatients must have had at least one prior chemotherapeutic regimen for management of endometrial carcinoma; initial treatment may include chemotherapy, chemotherapy and radiation therapy, or consolidation/maintenance therapy; chemotherapy administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a systemic chemotherapy regimen* Patients are allowed to receive, but not required to receive, up to a total of 3 lines of chemotherapy",(PRIOR = YES AND phosphatidylinositol 3 kinase (PI3K)/v-akt murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of rapamycin (mTor) pathway inhibitor = NO) AND C15477= YES AND (C16175 = NO OR C16175 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES) AND (C16168 = NO OR C16168 = YES)NCI-2016-00326,NCT03055013,A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC),Inclusion,"No ongoing condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications; no treatment with other immunosuppressive agents within 14 days prior to the first dose of study drug; topical, ocular, intra-articular, intranasal, inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.; a brief (less than 3 weeks) course of corticosteroids (any amount) for prophylaxis (for example: contrast dye allergy) or for treatment of non-autoimmune conditions (for example: delayed-type hypersensitivity reaction caused by a contact allergen) is permitted if > 14 days since last dosePatient must have no prior history of RCC that was resected with curative intent within the past 5 yearsNo concurrent or prior systemic or local anti-cancer therapy for RCC is permitted; examples of these prohibited therapies include:* Radical or partial nephrectomy for prior RCC* Metastectomy for RCC* Radiation therapy to the renal bed or any distant metastatic sites* Antineoplastic systemic therapies for RCC: i.e., chemotherapy, hormonal therapy, immunotherapy, or standard or investigational agents for treatment of RCC* Prior treatment with an anti-programmed cell death 1 (PD-1), anti-programmed cell death-ligand 1 (PD-L1), anti-PD-L2, anti-cluster of differentiation (CD)137, or anti-cytotoxic T-lymphocyte protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways",(C16171 = NO OR (C16171 = YES AND C9385 = NO)) AND (C15477= NO OR (C15477= YES AND C9385 = NO)) AND (C49135 = NO OR (C49135 = YES AND C9385 = NO)) AND (C16169 = NO OR (C16169 = YES AND C9385 = NO)) AND (C16168 = NO OR (C16168 = YES AND C9385 = NO)) AND (C16175 = NO OR (C16175 = YES AND C9385 = NO))NCI-2016-00355,NCT02723864,"Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination with Cisplatin in Patients with Refractory Solid Tumors",Inclusion/EXCLUSION,"INCLUSIONPatients must have completed any chemotherapy, radiation therapy, surgery, or biologic therapy >= 3 weeks (or >= 5 half-lives, whichever is shorter) prior to entering the study; patients must be >= 2 weeks since any prior administration of a study drug in an exploratory investigational new drug (IND)/phase 0 study and >= 1 week since any palliative radiation therapy; patients must have recovered to eligibility levels from prior toxicity or adverse eventsEXCLUSIONPatients who have had prior platinum-based therapy who have > grade 1 neurotoxicity or ototoxicity at the time of enrollment will not be permitted on study",(C16171 = NO OR (C16171 = YES) AND (C15477= NO OR C15477= YES) AND (C16169 = NO OR C16169 = YES) AND (C16124 = YES AND (C15187 = NO OR C15187 = YES)) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES))NCI-2016-00451,NCT03091660,A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer,Inclusion,"Patients must not have received prior intravesical BCGPatients must have had all grossly visible papillary tumors removed within 30 days prior to registration or cystoscopy confirming no grossly visible papillary tumors within 30 days prior to registration",(C16124 = YES AND ((C298 = NO OR (C298 = YES AND C13415= NO))) AND (C16169 = NO OR C16169 = YES)NCI-2016-00456,NCT02839343,Preoperative Extended Chemotherapy vs. Chemotherapy plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas,Inclusion,"Chronic concomitant treatment with strong inhibitors of cytochrome p450, family 3, subfamily a, polypeptide 4 gene (CYP3A4) is not allowed on this study; patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the studyChronic concomitant treatment with strong CYP3A4 inducers is not allowed; patients must discontinue the drug 14 days prior to the start of study treatmentNo prior chemotherapy or radiation for pancreatic cancer",(C16171 = NO OR (C16171 = YES AND C9005 = NO)) AND (C15477= NO OR (C15477 = YES AND C9005 = NO))NCI-2016-00643,NCT02808650,"A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors",Exclusion/INCLUSION,"EXCLUSIONStrong CYP1A2 inhibitors: Patients must not have received strong CYP1A2 inhibitors (ciprofloxacin, fluvoxamine, zafirlukast) for at least 7 days prior to enrollment and must not receive them for the duration of the studyPatients who have received a prior solid organ transplantation are not eligibleCorticosteroids: Patients receiving corticosteroids must have been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid EXCLUSIONPatients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the defined eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately* Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment** >= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)* Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days must have elapsed from last dose of agent; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment* Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1* Corticosteroids: If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid * Hematopoietic growth factors: >= 14 days must have elapsed since the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator* Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days must have elapsed since the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)* Stem cell infusions (with or without total body irradiation [TBI]):** Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days must have elapsed after infusion, and no evidence of graft-versus-host disease (GVHD)** Autologous stem cell infusion including boost infusion: >= 42 days must have elapsed after completion* Cellular therapy: >= 42 days must have elapsed since the completion of any type of cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.)* X ray (XRT)/external beam irradiation including protons: >= 14 days must have elapsed after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial bone marrow (BM) radiation* Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131 iodine metaiodobenzylguanidine [131I-MIBG]): >= 42 days must have elapsed since systemically administered radiopharmaceutical therapy* Patients must not have received prior exposure to LY2606368",C130200 = NO AND (C16171 = NO OR C16171 = YES) AND (C16168 = NO OR C16168 = YES) AND (C15477= NO OR C15477= YES) AND (C16124 = YES AND C91392 = NO)NCI-2016-00666,NCT02775851,A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM),Inclusion,"Patients must not have received live vaccines within 42 days prior to registration; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, Bacillus Calmetteâ€“Guerin (BCG), and typhoid (oral) vaccine; seasonal influenza vaccines for injection are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are not allowedPatients may have received prior surgery; all adverse events associated with prior surgery must have resolved to =< grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE] 4.0) prior to registrationPatients must not have received prior systemic treatment for this melanomaPatients must not have received radiation therapy, non-cytotoxic agents or investigational agents or systemic corticosteroids within 14 days prior to registration",(C16169 = NO OR C16169 = YES) AND C16124 C15698 for C25471 Cancer = NO AND (C15477= NO OR (C15477= YES AND C54225 = YES)) AND (C16171 = NO OR C16171 = YES) AND (C16124 = YES AND (C49135 = NO OR C49135 = YES))NCI-2016-00667,NCT02775812,"A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)",Exclusion/INCLUSION,"EXCLUSIONPrior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fieldsPrior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy, or immune therapy for the study cancer; note: prior cytotoxic chemotherapy or biologic/targeted therapy for a different cancer is allowable; however, a prior anti-programmed cell death (PD)-1, anti-PD-L1, or anti-programmed cell death 1 ligand 2 (PD-L2) agent is not permittedINCLUSION Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx squamous cell carcinoma (SCC) within 63 days prior to registration; note: patients may have a biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection; the gross total resection has to be done within 63 days prior to registration; if, however, patients have ablative resection but demonstrate rapid gross recurrence or are determined to have gross persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible","(C15477 = NO OR C15477 = YES AND C54225 = YES) AND (C16171 = NO OR (C16171 = YES AND Prior Systemic Therapy for Current Cancer = NO)) AND (C16124 = YES AND (C15187 = NO OR (C15187 = YES AND Prior Systemic Therapy for Current Cancer = NO))) AND (C16168 = NO OR (C16168 = YES AND C124946 = NO AND PD-L1 Inhibitor = NO AND PD-L2 INHIBITOR = NO)) AND (C16169 =  NO OR C16169 = YES)                         I INCLUDED PRIOR SURGERY = NO SO THAT IT INCLUDES NON-HIGH RISK SCCs"NCI-2016-00708,NCT02780804,"A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma",Inclusion/ EXCLUSION,"INCLUSIONPatients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the defined eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately* Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment** Solid tumor patients: >= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)** Lymphoma patients: a waiting period prior to enrollment is not required for patients receiving standard cytotoxic maintenance chemotherapy (i.e. corticosteroid, vincristine, thioguanine[6MP], and/or methotrexate)** >=14 days must have elapsed after the completion of other cytotoxic therapy, with the exception of hydroxyurea, for patients not receiving standard maintenance therapy; additionally, patients must have fully recovered from all acute toxic effects of prior therapy; Note: cytoreduction with hydroxyurea must be discontinued >= 24 hours prior to the start of protocol therapy* Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days must have elapsed from the last dose of agent; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment* Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1* Hematopoietic growth factors: >= 14 days must have elapsed from the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator* Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days must have elapsed from the last dose of interleukins, interferon or cytokines (other than hematopoietic growth factors)* Stem cell infusions (with or without traumatic brain injury [TBI]):** Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days must have elapsed from infusion and no evidence of graft versus host disease (GVHD)** Autologous stem cell infusion including boost infusion: >= 42 days must have elapsed from infusion* Cellular therapy: >= 42 days must have elapsed from last dose of any type of cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.)* External beam radiation (XRT)/External beam irradiation including protons: >= 14 days must have elapsed after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to 50% of the pelvis; >= 42 days if other substantial bone marrow (BM) radiation* Radiopharmaceutical therapy (e.g., radiolabeled antibody, iobenguane I-131 [131I-MIBG]): >= 42 days must have elapsed from the last dose of systemically administered radiopharmaceutical therapy* Histone deacetylase (HDAC) inhibitors: Patients must not have received prior therapy with entinostat; patients who have received therapy with other HDAC inhibitors are eligibleEXCLUSIONPatients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroidPatients who have received a prior solid organ transplantation are not eligible",(C16171 = NO OR C16171 = YES) AND (C16168 = NO OR C16168 = YES)  AND (C15477= NO OR C15477= YES) AND C130200 = NO AND (C16124 = YES AND C1863 = NO)NCI-2016-00787,NCT03030417,A Phase I Study of Indenoisoquinoline LMP744 in Adults with Relapsed Solid Tumors and Lymphomas,Inclusion,"Prior therapy with topoisomerase I inhibitors is allowedPatients must have recovered to grade 1 or baseline from adverse events (AEs) and/or toxicity of prior chemotherapy or biologic therapy; they must not have had chemotherapy, biologic therapy, or definitive radiotherapy within 4 weeks (6 weeks for nitrosoureas and mitomycin C) or 5 half-lives, whichever is shorter, prior to entering the study; palliative-intent radiotherapy (30 Gy or less) must be completed at least 2 weeks prior to start of treatment, and may not be to a lesion that is included as measurable disease; patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (where a sub-therapeutic dose of drug is administered) at the principal investigator's (PIâ€™s) discretion, and should have recovered to grade 1 or baseline from any toxicities",C16171 = YES OR (C16124 = YES AND C15187 = YES)  OR C15477= YES OR (C16124 = YES AND C49135 = YES),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,